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The Presidential Commission for the Study of Bioethical Issues (the Commission) 
is an advisory panel of the nation’s leaders in medicine, science, ethics, religion, 
law, and engineering. The Commission advises the President on bioethical issues 
arising from advances in biomedicine and related areas of science and technology. 
the Commission seeks to identify and promote policies and practices that 
ensure scientific research, health care delivery, and technological innovation are 
conducted in a socially and ethically responsible manner.
for more information about the Commission, please see www.bioethics.gov.
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vPresidential Commission for the Study of Bioethical Issues
President Barack Obama
The White House
1600 Pennsylvania Avenue, NW
Washington, DC 20500
Dear Mr. President:
On behalf of the Presidential Commission for the Study of Bioethical Issues, we present to you  
this report, “Moral Science: Protecting Participants in Human Subjects Research.”
In response to your request of November 24, 2010, the Commission oversaw a thorough review  
of current regulations and international standards to assess whether they adequately protect human 
participants in federally funded research, no matter where it occurs.
The Commission held four multi-day, public meetings. Speakers addressed a range of U.S. and 
international policies and norms, and provided perspectives from a wide array of professional  
and institutional organizations. At your request, we sought the advice of international experts and 
appointed the International Research Panel, a subcommittee of the Commission. Finally, the  
Commission solicited information from the public and it received over three hundred comments.
The Commission concludes that current regulations, which apply to a diverse and wide-ranging 
portfolio of research, generally appear to protect people from avoidable harm or unethical treatment. 
However, because of the currently limited ability of some governmental agencies to identify basic 
information about all of their human subjects research, the Commission cannot say that all federally 
funded research provides optimal protections against avoidable harms and unethical treatment. 
Many of our most important advances derive from research that involves human participants.  
It is essential, therefore, that critical research of this sort adheres to the highest ethical practices to 
ensure, as best as possible, that those who volunteer to participate in studies for the benefit of others 
are protected. Thus, the Commission offers 14 recommendations to improve the current system.
The Commission Members are honored by the trust you have placed in us and we are grateful  
for the opportunity to serve you and the nation in this way.
Sincerely,
Amy Gutmann, Ph.D. James Wagner, Ph.D.
Chair Vice-Chair
1425 New york Avenue, NW, Suite C-100, Washington, DC 20005
Phone 202-233-3960  fax 202-233-3990 www.bioethics.gov
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Human research serves to ensure the safety of new medicines, establish tolerable exposure levels for environmental and workplace hazards, 
and determine the effectiveness of new interventions in public health, educa-
tion, and countless other fields. Without volunteers, these studies would be 
impossible to conduct. Recognizing society’s responsibility to protect human 
subjects of research from avoidable harm and unethical treatment, President 
Barack Obama asked the Presidential Commission for the Study of Bioethical 
Issues (the Commission) to conduct a thorough review of current regulations 
and international standards to assess whether they adequately protect human 
subjects in federally supported scientific studies, no matter where they occur. 
The Commission’s review confirmed that the federal government supports 
a diverse and wide-ranging portfolio of research, which includes activities 
funded directly, or by award or sub-award, throughout the world. Support 
for medical and public health research predominates, but the federal govern-
ment also supports a large volume of human subjects research in other fields, 
including social and behavioral sciences and education. 
Sound scientific experimentation is rooted in uncertainty and volunteers 
cannot be immunized from all physical or psychological risks. However, in 
order for research with human beings to be ethical, human subjects must 
be volunteers who give their informed consent, who are treated fairly and 
respectfully, who are subjected only to reasonable risks from which propor-
tionate humanitarian benefit can be obtained, and who are not treated as 
mere means to the ends of others. (Some carefully specified and regulated 
exceptions to informed consent are based on the incapacity of some subjects 
or the very low risk of the experiments, provided that all the other condi-
tions—including fair and respectful treatment—hold.)1
In the absence of these ethical constraints, tragic results may follow. 
Many prior abuses of human subjects are now carefully documented, and 
some informed the development of today’s federal human subjects protec-
tion system. Eighteen federal departments and agencies require adherence 
to a uniform regulatory f loor for human subjects research, known as the 
“Common Rule,” which generally requires informed consent, independent 
ethical review, and the minimization of avoidable risks. These standards apply 
to all research funded by these departments and agencies, regardless of where 
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it occurs. The food and Drug Administration applies essentially the same 
standards to all research conducted in support of seeking u.S. marketing 
approval for drugs, devices, and biologics; regardless of the source of funding. 
These rules reflect widely accepted principles of ethics. These principles are 
rooted in longstanding values that find expression in many sources of moral 
philosophy; theological traditions; and codes, regulations, and rules. They are 
the bulwark of ethically sound science, or “moral science,” as the Commission 
terms it. Each generation may re-examine how these principles are contextu-
ally applied and understood. And, their application or implementation may 
vary depending on the level of risk that a subject faces. Medical research that 
poses risk of physical injury rightly raises more concerns than does routine 
social survey research, for example. Nonetheless, the same ethical principles 
govern all of these activities, and serve as enduring guideposts that must not 
be ignored. 
the public has a right to expect researchers to abide by rules that satisfy 
these principles. Researchers themselves benefit from public confidence when 
they conform to these rules; and with public esteem they earn the ability to 
conduct potentially important research with public support. Without such 
earned confidence, research participation may be threatened and critical 
research jeopardized. More than these measurable effects, society risks irre-
trievably losing sight of what is inherently owed to fellow human beings and 
those who deserve special protection by virtue of their willingness to partic-
ipate in experiments designed to benefit others and advance scientific and 
social progress. 
from time to time society revisits the rules applied to research with human 
subjects and the implementation of guiding ethical principles. The need for 
reassessment may arise from challenges presented by novel scientific advances, 
a perceived mismatch between ethical principles and their implementation, or 
revelations of abuse. When President Obama charged the Commission with 
undertaking this review of contemporary human subjects protection stan-
dards, he recognized the sacred trust and responsibility that we as a society 
have to ensure that human research subjects are protected from harm and 
unethical treatment.2 the immediate catalyst to action came from newly 
discovered evidence of unethical activities by u.S. scientists in Guatemala 
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in the late 1940s. The Commission’s findings and ethical assessment of those 
events, documented in its report “Ethically Impossible” STD Research in Guate-
mala 1946 to 1948, illustrate how the quest for scientific knowledge without 
regard to relevant ethical standards can blind researchers to the humanity of 
the people they enlist into research.3
for this review, the first of its kind by a national bioethics commission in 
a decade, the President asked the Commission to complete its work in nine 
months. Recognizing the increasing involvement of foreign sites and partners 
in human subjects research, the Commission organized a panel of interna-
tional experts, the International Research Panel (the Panel), consisting of 
experts in bioethics and biomedical research from 10 countries: Argentina, 
Belgium, Brazil, China, Egypt, Guatemala, India, Russia, uganda, and the 
united States.4 The Panel, led by Commission Chair Amy Gutmann, held 
three day-long meetings to discuss research standards and practices around 
the globe. In their discussions, Panel members drew upon their individual 
expertise and decades of experience conducting research and developing 
policy to protect human subjects. 
In attempting to assess the current depth and breadth of the federally funded 
human research enterprise, the Commission quickly learned there is no ready 
source that comprehensively describes its basic characteristics, such as level 
of funding, or number of studies, subjects, or geographic locations. Instead, 
what exists are isolated pockets of information and some descriptive summa-
ries. to better understand, and enable the public to know the scope and 
volume of “scientific studies supported by, the federal Government,” the 
Commission therefore asked each Common Rule agency to provide limited, 
project-specific information on human subjects research supported in fiscal 
year 2010, and to identify trends, if possible, the same information back 
through fiscal year 2006. 
The Commission collected basic, project-level data about human subjects 
research, including study title, number and location of sites, number of 
subjects, and funding information. these data were compiled into the 
Commission’s “Research Project Database,” and analyzed as part of its 
Human Subjects Research Landscape Project (see further discussion below 
and Appendices I and II). Among other things, the Commission learned that 
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the federal government supported more than 55,000 human subjects research 
projects around the globe in fiscal year 2010, mostly in medical and health-
related research, but also in other fields such as education and engineering. 
The Commission also learned that many federal departments and agencies 
have no ready means to identify basic information about the research they 
support (e.g., location of study sites) or link funding information with study-
level data. 
the Commission convened an Empirical Advisory Group, comprised of 
experts in bioethics, statistics, clinical trial management, and qualitative 
research, to assist in analysis and interpretation of the Human Subjects 
Research Landscape Project and suggest future empirical work that could be 
conducted to evaluate the current human subjects protection system.
In sum, the Commission concludes that current regulations generally appear 
to protect people from avoidable harm or unethical treatment, insofar as is 
feasible given limited resources,5 no matter where u.S.-supported research 
occurs. This conclusion is fully consistent with, and also qualified by, the 
large yet incomplete set of information made available to the Commission in 
the time available to carry out its charge. Specifically, the Commission found:
The current U.S. system provides substantial protections for the health, 
rights, and welfare of research subjects and, in general, serves to “protect 
people from harm or unethical treatment” when they volunteer to partici-
pate as subjects in scientific studies supported by the federal government. 
However, because of the currently limited ability of some governmental 
agencies to identify basic information about all of their human subjects 
research, the Commission cannot conclude that all federally funded 
research provides optimal protections against avoidable harms and uneth-
ical treatment. The Commission finds significant room for improvement 
in several areas where, for example, immediate changes can be made to 
increase accountability and thereby reduce the likelihood of harm or 
unethical treatment. 
In reaching this conclusion, the Commission believes that the ethical prin-
ciples for human subjects research should not—indeed must not—vary 
depending on the source of funding or location of the research.6 While the 
specific methods of implementing the ethical principles of human subjects 
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research are likely to differ, the principles should not. Ethical principles 
provide the foundation for the rules and regulations that govern human 
subjects research as well as lay the groundwork upon which everyone who 
conducts human subjects research must stand. 
There is no way to eradicate all risk of harm, particularly in some types of 
medical and translational research, but the Commission found several 
important areas where improvement or refinement of the current system 
is both possible and desirable. It offers guidance and ref lection in eight 
specific areas, all ripe for action or advancement now. Chief among these, 
the Commission finds that accountability can and should be refined through 
improving access to basic information about the scope and volume of human 
subjects research funded by the government. It also draws a bright line 
affirming the view of most bioethicists and others, including the majority of 
nations supporting human subjects research around the globe, that human 
subjects should not individually bear the costs of care required to treat 
harms resulting directly from that research. The Commission also calls on 
the federal government to respect the equivalent protections offered by inter-
national partners and exercise its longstanding authority to recognize these 
protections when available. 
The Commission’s review of the current system comes while the government is 
already considering systematic reform through revision of the Common Rule. 
Some of the proposed reforms offer useful means to improve upon current 
practices. Although the Commission was not asked to undertake a compre-
hensive assessment of the proposed reforms, it did examine the published 
ideas and offers several overarching comments to further these reform goals. 
Improving Accountability
Science requires substantial societal investment, putting it in competition 
with other important activities that also contribute to the public good. The 
public therefore has the right to accountability in the use and management 
of resources allocated to the pursuit of scientific knowledge for the common 
good. The need for accountability is all the more heightened when publicly 
funded research also depends on the participation of human subjects. In 
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carrying out President Obama’s charge to assess the degree to which current 
federally funded research protects human subjects from harm or unethical 
treatment, the Commission encountered a significant challenge in ascer-
taining federal investment in human subjects research. Internal department or 
agency-specific systems to track human subjects research are generally avail-
able, although they vary widely in the basic information they maintain and 
differ considerably in the information they can readily retrieve or make avail-
able publicly or online. to accurately track and assess the volume and scope 
of human subjects research and to determine whether protections are in place, 
there must be better data and more ready availability of information.
Recommendation 1: Improve Accountability through Public Access
To enhance public access to basic information about federal government-
funded human subjects research, each department or agency that supports 
human subjects research should make publicly available a core set of data 
elements for their research programs—title, investigator, location, and 
funding—through their own systems or a trans-agency system. The Office 
for Human Research Protections or another designated central organizing 
agency should support and administer a central web-based portal linking to 
each departmental or agency system. This should not preclude the prospec-
tive development of a unified federal database that may ultimately be more 
cost-effective and efficient.
The Commission also encourages additional research into the effectiveness 
of human subjects protection standards to obtain empirical data through 
which to assess such protections. Such data could, for example, illuminate 
issues pertinent to research site selection or assist in promoting the effec-
tiveness of community engagement—both topics the Commission believes 
could use improvement.
Recommendation 2: Improve Accountability through Expanded Research
To evaluate the effectiveness of procedural standards embedded in current 
human subjects protection regulations, the federal government should 
support the development of systematic approaches to assess the effective-
ness of human subjects protections and should expand support for research 
related to ethical and social consideration of human subjects protection.
MOR AL SCIENCE  Protecting Participants in Human Subjects Research
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Treating and Compensating for Research-Related Injury
Those who sponsor or engage in human subjects research have an ethical obli-
gation to protect those who volunteer as research subjects. Almost all other 
developed nations have instituted policies to require treatment, or compensa-
tion for treatment, for injuries suffered by research subjects. The Panel advised 
the Commission to recommend that the united States establish a system to 
assure compensation for the medical care of human subjects harmed in the 
course of biomedical research. However, the Commission believes that before 
altering the current approach to compensation for injuries sustained during 
federally funded research, the nature and scope of harms that remain unad-
dressed must be assessed. 
Recommendation 3: Treating and Compensating for Research-Related Injury
Because subjects harmed in the course of human research should not indi-
vidually bear the costs of care required to treat harms resulting directly 
from that research, the federal government, through the Office of Science 
and Technology Policy or the Department of Health and Human Services, 
should move expeditiously to study the issue of research-related injuries 
to determine if there is a need for a national system of compensation or 
treatment for research-related injuries. If so, the Department of Health 
and Human Services, as the primary funder of biomedical research, should 
conduct a pilot study to evaluate possible program mechanisms.
the Commission stresses that it is important to recognize the limits of 
current models for providing compensation, like the National Vaccine Injury 
Compensation program, and also the various means by which the govern-
ment may satisfy the ethical obligation to compensate individuals who suffer 
research-related injuries in a federally funded study. While there are systems 
already in place for some government research, the Commission recom-
mends a study to evaluate future options and outlines many questions to be 
considered. It also recognizes that several national bodies have made similar 
recommendations in the past. Given the seriousness of the ethical concern, 
and these past efforts, the Commission encourages the government to follow 
up publicly with its response.
EXECutIVE SuMMARy
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Recommendation 4: Treating and Compensating for Research-Related 
Injury Follow Up
The Commission recognizes that previous presidentially appointed bioethics 
commissions and other duly appointed advisory bodies have made similar 
recommendations regarding compensation or treatment for research-related 
injuries; yet no clear response by the federal government has been issued. 
Therefore, the federal government, through the Office of Science and Tech-
nology Policy or the Department of Health and Human Services, should 
publicly release reasons for changing or maintaining the status quo.
Creating a Culture of Responsibility: Human Research Protections as 
Professional Standards
The Commission heard from a wide range of research professionals that the 
procedural requirements of human subjects regulations are often viewed as 
unwelcome bureaucratic obstacles to conducting research. The density of some 
of these requirements can obscure their justification and routinized inter-
pretation can create distance between the underlying ethical principles and 
how they are viewed and implemented by institutional review boards and the 
research community. The Commission too recognizes that there is often a 
fundamental distinction between ethical principles (and the personal respon-
sibilities that must be exercised to effect them), and procedural or policy 
strategies to apply and implement these principles. While tension between 
principles and procedures is, in some ways, perennial, the Commission 
believes that specific steps can be taken now to deflect the tilt that some see 
favoring process over principle. two of these recommendations are directed to 
government specifically, and a third more generally relates to education and 
the duty to all engaged in the research enterprise.
Recommendation 5: Make the Ethical Underpinnings of Regulations 
More Explicit
To promote a better understanding of the context and rationale for applicable 
regulatory requirements, the Department of Health and Human Services or 
the Office of Science and Technology Policy should ensure that the ethical 
underpinnings of regulations are made explicit. This goal is also instrumental 
to the current effort to enhance protections while reducing burden through 
reform of the Common Rule and related Food and Drug Administration 
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regulations. (See Promoting Current Federal Reform Efforts below.) Following 
the principle of regulatory parsimony, regulatory provisions should be ratio-
nalized so that fundamental, core ethical standards are clearly articulated.
Recommendation 6: Amend the Common Rule to Address Investigator 
Responsibilities
The Common Rule should be revised to include a section directly addressing 
the responsibilities of investigators. Doing so would bring it into harmony 
with the Food and Drug Administration regulations for clinical research 
and international standards that make the obligations of individual 
researchers more explicit, and contribute to building a stronger culture of 
responsibility among investigators. 
Recommendation 7: Expand Ethics Discourse and Education
To ensure the ethical design and conduct of human subjects research, 
universities, professional societies, licensing bodies, and journals should 
adopt more effective ways of integrating a lively understanding of personal 
responsibility into professional research practice. Rigorous courses in 
bioethics and human subjects research at the undergraduate as well as 
graduate and professional levels should be developed and expanded to 
include ongoing engagement and case reviews for investigators at all levels 
of experience.
Respecting Equivalent Protections
Research supported by the federal government is subject to the same regu-
latory requirements domestically as well as internationally. Research 
collaborators and partners in other countries who are funded or supported 
by Common Rule agencies file an assurance that they will comply with these 
requirements, regardless of overlapping or more protective standards that may 
exist in the country where the research is conducted. At the same time, u.S. 
regulations governing the protection of human research subjects delineated 
in the Common Rule have long permitted u.S. departments and agencies 
supporting or conducting research to recognize and accept procedures from 
foreign countries that may differ from those delineated in u.S. regulations 
as long as they provide “protections that are at least equivalent” to those in 
the Common Rule. yet u.S. departments and agencies have rarely, if ever, 
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exercised the authority to accept any foreign country’s procedures as equiv-
alent. Instead they sometimes insist that all u.S. procedural details must 
be met, in all cases, regardless of the effectiveness or similarity of foreign 
requirements. This insistence on both the spirit and letter of u.S. regula-
tory constraint fails to recognize or respect that many nations today have 
systems to protect human subjects that are as good, or perhaps more stringent, 
than our own. Despite numerous efforts to clarify or resolve the meaning 
and interpretation of “equivalent protections,” no comprehensive policy has 
emerged for determining when equivalent protections exist.
Recommendation 8: Respect Equivalent Protections
The federal government, through the Office for Human Research Protections, 
should adopt or revise the 2003 Health and Human Services Equivalent 
Protections Working Group’s articulation of the protections afforded by 
the specific procedural requirements of the Common Rule. It should use 
these requirements to develop a process for evaluating requests from foreign 
governments and other non-U.S. institutions to determine if their laws, 
regulations, and procedures can be recognized as providing equivalent 
protections to research subjects. 
Promoting Community Engagement
The Panel directed the Commission’s attention to the value of community 
engagement and demonstration of respect for cultural differences that are 
compatible with the ethical conduct of human subjects research. These values 
are applicable to research conducted both domestically and abroad. Effec-
tive community engagement provides an additional layer of safeguards by 
providing the community with opportunities to thoroughly weigh and accept 
or reject the risks and benefits of research activities, discover possible impli-
cations of research that might have unintended consequences to the host 
community, and independently debate the effectiveness of research protec-
tions. Interactive and ongoing dialogue between communities and research 
teams allows for the integration of community norms, beliefs, customs, and 
cultural sensitivities into research activities. The guidelines enumerated in 
the Joint united Nations Programme on HIV/AIDS and the AVAC Good 
Participatory Practice Guidelines, for example, provide a standardized frame-
work for implementing community engagement activities across a wide range 
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of research. The Commission believes these, and related documents, should be 
evaluated and guidance provided by the government on effective community 
engagement strategies for all human subjects research.
Recommendation 9: Promote Community Engagement
The federal government, through the Office for Human Research Protections 
and authorized research funders, should support further evaluation and 
specification of the Joint United Nations Programme on HIV/AIDS and 
the AVAC Good Participatory Practice Guidelines with the aim of providing 
a standardized framework for those community engagement practices that 
would further the protection and ethical treatment of human subjects in all 
areas of research. Research should be conducted to prospectively evaluate 
the effectiveness of this framework and strengthen it after it is developed.
Justifying Site Selection
Careful selection of sites for research is important for two sets of reasons. 
first, the ethical criteria for how subjects must be treated narrows the selec-
tion of sites to those that allow for the ethical treatment of subjects. Second, 
as the Belmont Report states, “selection of research subjects needs to be scru-
tinized in order to determine whether some classes are being systematically 
selected because of their easy availability, their compromised position, or their 
manipulability, rather than for reasons directly related to the problem being 
studied.” Thus, careful examination of site selection is extremely important 
and critical to ensuring that research is done ethically and participants are 
protected from harm or unethical treatment. Some domestic and interna-
tional settings present challenges that increase concern about exploitation 
of human subjects. One proposed strategy for minimizing the potential of 
exploitation when research is done in low-income communities—whether 
domestic or international—is to ensure that the proposed study is responsive 
to the medical, as well as other, needs of the local community or communi-
ties. The ethical requirement of responsiveness to local communities needs to 
be further developed and implemented for responsiveness to become a clearly 
justified criterion for site selection.
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Recommendation 10: Ensure Capacity to Protect Human Subjects
Funders of research should determine that researchers and the sites that 
they propose to select for their research have the capacity—or can achieve 
the capacity contemporaneously with the conduct of the research—to 
support protection of all human subjects. 
Recommendation 11: Evaluate Responsiveness to Local Needs as a Condition 
for Ethical Site Selection
The federal government, through the Off ice for Human Research 
Protections and federal funding agencies, should develop and evaluate 
justifications and operational criteria for ethical site selection, taking into 
consideration the extent to which site selection can and should respond to 
the needs of a broader community or communities. The Office for Human 
Research Protections should produce, and other agencies should consider 
developing, guidance for investigators.
Ensuring Ethical Study Design
Study design, particularly in clinical research, is another area where concerns 
about exploitation have arisen in the past. The Commission reviewed issues 
surrounding use of placebo and other comparator arms in randomized clinical 
trials conducted in locations that do not have access to the highest standard 
of care. It found consensus around a “middle ground” to guide researchers 
designing clinical trials that expose subjects to interventions or conditions 
that may not be viewed as the best available standard of care but nonethe-
less provide potential for benefit to the local population. The Commission’s 
proposed framework, rooted in the thinking that has developed in the litera-
ture over several decades, provides a pathway to ensuring that research subjects’ 
interests are protected.
Recommendation 12: Ensure Ethical Study Design for Control Trials
When assessing how to reconcile the requirements of rigorous study design 
with the interests of research subjects, a nuanced approach is recommended 
that permits subjects to receive a placebo or an active agent that other-
wise might not represent the “best-proven” approach when the site selected 
is ethically justifiable and the following conditions are met: a) the “best-
proven” intervention is not known to be the best for a particular population 
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due to local infrastructural, behavioral, genetic, or other relevant circum-
stances; and b) the scientific rationale and the ethical justification for the 
study design have undergone careful review to ensure all of the following: 
i) use of placebo or other comparators is of limited duration; ii) subjects are 
carefully monitored; iii) rescue measures are in place should serious symp-
toms develop; and iv) there are established withdrawal criteria in place for 
subjects who experience adverse events. 
Promoting Current Federal Reform Efforts
The Commission commends efforts already underway to reform federal policy 
for the protection of human subjects and recommends that these efforts 
be advanced. In particular, the Commission endorses the following proposals 
presented in the Advance Notice of Public Rulemaking issued in July 2011 
by the Office of the Secretary of the Department of Health and Human 
Services (HHS) in coordination with the Office of Science and technology 
Policy (OStP). 
Recommendation 13: Promoting Current Federal Reform Efforts
The Commission supports the federal government’s proposed reforms to:
a) Restructure research oversight to appropriately calibrate the level and 
intensity of the review activities with the level of risk to human subjects;
b) Eliminate continuing review for certain lower-risk studies and regularly 
update the list of research categories that may undergo expedited review;
c) Reduce unnecessary, duplicative, or redundant institutional review board 
review in multi-site studies. Regardless of the process used to review and 
approve studies, institutions should retain responsibility for ensuring that 
human subjects are protected at their location as protection of human 
subjects includes much more than institutional review board review. 
The use of a single institutional review board of record should be made 
the regulatory default unless institutions or investigators have sufficient 
justification to act otherwise;
d) Make available standardized consent form templates with clear language 
understandable to subjects;
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e) Harmonize the Common Rule and existing regulations of the Food and 
Drug Administration, and require that all federal agencies conducting 
human subjects research adopt human subjects regulations that are 
consistent with the ethical requirements of the Common Rule; and
f) Work toward developing an interoperable or compatible data collection 
system for adverse event reporting across the federal government. 
Following Up
the Commission recognizes that several of these recommendations have 
been made by presidentially appointed bioethics commissions and other 
duly appointed government advisory bodies in the past, and it found no 
clear response by the federal government to many of them. for example, a 
number of commissions, including the National Commission for the Protec-
tion of Human Subjects of Biomedical and Behavioral Research, the National 
Bioethics Advisory Commission, the Presidential Commission for the Study 
of Ethical Problems in Medicine and Biomedical and Behavioral Research, 
and the President’s Advisory Committee on Human Radiation Experiments, 
made recommendations endorsing compensation for subjects for injuries 
arising from research.7 Both National Bioethics Advisory Commission and 
Advisory Committee on Human Radiation Experiments recommended recog-
nition of equivalent protections.8 In addition, National Bioethics Advisory 
Commission addressed many of the same issues raised in the recommenda-
tions in this report, such as community engagement, ethics training, and 
the importance of an expanded research agenda addressing human research-
related issues.9
Recommendation 14: Responding to Recommendations
The Commission recommends that the Office of Science and Technology 
Policy or another appropriate entity or entities within the government 
respond with changes to the status quo or, if no changes are proposed, 
reasons for maintaining the status quo with regard to the recommenda-
tions below. Possible departments or agencies to lead the efforts include 
the Department of Health and Human Services, the Office for Human 
Research Protections, and the National Institutes of Health, as well as other 
funders and regulators. 
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Table ES.1 Recommendation Follow-up Summary
REcommEndaTion 
numbER†
SummaRy oFFicE
1 Increase accountability through online access to basic 
human subjects research data.
OHRP/all departments and 
agencies that support human 
subjects research
2 Support the development of systematic approaches to 
assess the effectiveness of human subjects protections 
and expand support for research related to ethical and 
social consideration of human subjects protection.
OHRP/all departments and 
agencies that support human 
subjects research
3 Study research-related injuries to determine if there 
is a need for a national system of compensation or 
treatment for research-related injuries because subjects 
harmed in the course of human research should not 
individually bear the costs of care required to treat 
harms resulting directly from that research.
OSTP/HHS
4 Publicly release reasons for changing or maintaining 
the status quo regarding compensation or treatment for 
research-related injuries.
OSTP/HHS
5 Explicate the ethical underpinnings for human subjects 
protection requirements. 
HHS/OSTP
6 Add responsibilities of investigators to the Common Rule. HHS/OSTP
8 Adopt or revise the 2003 Department of Health and 
Human Services Equivalent Protections Working 
Group’s analysis and develop a process for evaluating 
requests from foreign governments and other non-U.S. 
institutions for determinations of equivalent protections.
OHRP
9 Support further evaluation of the UNAIDS/AVAC 
Guidelines to provide a standardized framework for 
community engagement practices across research fields.
OHRP
11 Support research to develop and evaluate justifications 
and operational criteria for ethical site selection.
OHRP/all departments and 
agencies that support human 
subjects research
13 Develop proposed regulations to reform the current 
Common Rule. 
OSTP/OHRP
14 Follow up. OSTP/other appropriate entity
† Listed here are recommendations directed to the federal government only.
A response need not be unduly lengthy or be provided by a single depart-
ment, agency, or division, but the public should know whether the federal 
government intends to move forward, and if so in what way, with any or all of 
these recommendations. (See table ES.1 for a summary of recommendations 
directed towards the federal government.)
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Introduction
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Research is not only important as a means of advancing knowledge; it is also a core component of America’s growth and prosperity in human 
health, energy, defense, education, and countless other components of daily 
life. Social progress depends on new discoveries and new ways of thinking 
about old problems. yet, as the philosopher Hans Jonas observed, “society 
would indeed be threatened by the erosion of those moral values whose loss, 
possibly caused by too ruthless a pursuit of scientific progress, would make its 
most dazzling triumphs not worth having.”10
The relationship between scientific progress and morality is not a new concern 
in the united States. Writing nearly 200 years before Jonas, and in the midst 
of the hard work of building the new nation, Benjamin franklin reflected 
that “[t]he rapid progress true science now makes, occasions my regretting 
sometimes that I was born so soon.” He continued:
“It is impossible to imagine the height to which may be carried, in 
a thousand years, the power of man over matter . . . . Agriculture 
may diminish its labor and double its produce; all diseases may by 
sure means be prevented or cured, not excepting even that of old 
age, and our lives lengthened at pleasure even beyond the ante-
diluvian standard. O that moral science were in as fair a way of 
improvement, that men would cease to be wolves to one another, 
and that human beings would at length learn what they now 
improperly call humanity!”11
Surely franklin would not be wholly satisfied in how far our society or the 
world has progressed in conquering “wolfish humanity,” and neither should 
society. yet franklin and the other American founders believed that the 
values of individual freedom of speech, conscience, and inquiry—along 
with a dedication to pursuing the common good—held great promise for a 
republic dedicated to progress in both science and morality, and that science 
and morality inform one another by challenging dogmatism in either realm. 
What franklin called “moral science” is what we would today call “ethics.”12 
franklin clearly intended that “moral science” (ethics) should inform empir-
ical science. Thus, using a contemporary play on franklin’s phrase, one can 
say that the challenge of “moral science” (i.e., pursuing science in a morally 
justified manner) is one that every generation must take up again.13
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There is no more acute instance of this challenge than research involving 
human subjects, upon which knowledge and discovery often depend. Human 
research subjects, in most cases, must be informed volunteers who are willing 
to allow their bodies or personal information to be used by researchers to 
craft new hypotheses, infer plausible explanations and predictions, and test 
theories.14 Pursuit of these goals sometimes offers no direct prospect of benefit 
to the human research subject. Early stage translational research serves to 
test physiological effects or biological functions of new drugs and medical 
interventions but is not necessarily designed to benefit subjects. Sometimes 
research subjects experience serious adverse health effects as a result of partici-
pation in trials.15 Research in other fields, including housing, social work, and 
criminology, typically poses fewer physical risks, but may pose substantial 
social, psychological, and economic risks for human subjects. Such research 
also aims to improve the lives of later generations without offering any direct 
or measurable benefit to those who participate as research subjects. 
Regardless of whether research offers the prospect of direct benefit to human 
subjects, long-standing ethical principles constrain the unfettered pursuit of 
knowledge. for research with human subjects to be ethical, volunteers must 
be treated fairly and with respect, subjected only to reasonable risks from 
which proportionate humanitarian benefit can be obtained, and not treated 
as mere means to the ends of others. Experimentation is rooted in uncertainty, 
and human subjects cannot be immunized from all physical risks. None-
theless, these stated boundaries dictate that anticipated and avoidable harms 
must be eliminated, informed consent must be obtained in most cases, and 
the burdens and benefits of research must be equitably shared.
from time to time, society has been reminded of the need to revisit the rules 
applied to research with human subjects. The need for reassessment might 
arise from challenges emerging from novel scientific advances or from a 
perceived mismatch between ethical principles and how they are implemented 
in practice. Revelations of abuses also have been a driving force in reconsid-
eration of the policies and procedures for protecting the subjects of research.
In the past few years, several factors have converged to compel a contemporary 
review of human subjects protection policies and practices. The Presidential 
Commission for the Study of Bioethical Issues (the Commission) initiated this 
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review in response to a charge from President Obama to undertake “a thorough 
review of [current] human subjects protection to determine if federal regula-
tions and international standards adequately guard the health and well-being 
of participants in scientific studies supported by the federal Government.”16
This request came paired with the President’s charge to conduct an investi-
gation of new revelations about medical research supported by the united 
States and conducted in Guatemala between 1946 and 1948. Some of that 
research involved the deliber ate exposure of people to sexually transmitted 
diseases (StDs) without their consent. Subjects, including soldiers, prisoners, 
psychiatric patients in a state-run institution, and commercial sex workers, 
were exposed to syphilis, gonorrhea, and chancroid. Serology diagnostic 
testing involved the previous four groups as well as children, u.S. Servicemen 
stationed in Guatemala, and leprosarium patients. In October 2010, Presi-
dent Obama expressed “deep regret” to the President of Guatemala for this 
research, and affirmed the federal government’s “unwavering commitment to 
ensure that all human medical studies conducted today meet exacting” stan-
dards for the protection of human subjects.17
The results of the Commission’s investigation into the Guatemala experi-
ments were released in September 2011 in its report, “Ethically Impossible” 
STD Research in Guatemala from 1946 to 1948, the findings of which are 
summarized below.18 That report provided a histor ical account and ethical 
assessment of the Guatemala experiments. It uncovered and contextualized as 
much as could be known about experiments that took place nearly 65 years 
ago. It also aimed to inform current and continuing efforts to protect the 
rights and welfare of the subjects of u.S.-sponsored or -conducted research. In 
“Ethically Impossible,” the Commission recognized that u.S. and international 
policies and practices governing human subjects research have evolved in the 
time since the Guatemala experiments from an informal set of principles, 
based primarily on medical ethics and the doctor-patient relationship, to a 
highly structured oversight system codified in regulation and statute. 
However, the uncovering of the 1940s StD studies in Guatemala prompted 
President Obama to ask whether such unethical research could be conducted 
in today’s research environment using u.S. federal funds. When the President 
asked the Commission to undertake this review of human subjects protection 
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Regarding the changing 
geography of clinical research, 
“[w]e are seeing a massive shift 
in the conduct of research.…
[W]hat we are seeing is a large 
shift in economics and finance 
occurring at a setting in which 
the marketing of medical 
products has become global  
in every respect.” 
Dr. Robert M. Califf, Vice Chancellor  
for Clinical Research, Duke University 
Professor of Medicine, Duke University 
Medical Center, Director, Duke 
Translational Medicine Institute,  
speaking to the Commission on  
March 1, 2011.
standards, he recognized, as do we all, the sacred trust and responsibility that 
society has to ensure that human research subjects are protected from harm 
and unethical treatment.19
The Need to Assess the Contemporary Environment
Since the 1940s, the research enterprise and the system of protection for 
human subjects have continuously evolved. Abuses uncovered in the 1960s 
and 1970s led to the development of the current u.S. regulations for the 
protection of human subjects. these regulations combine with long-
standing professional norms and obligations to map the ethical boundaries 
for research today. for federally funded research, the rules have remained 
largely unchanged since at least 1991. for some agencies, the regulations are 
even older. for example, explicit Department of Health and Human Services 
(HHS; then the Department of Health, Education, and Welfare) policy 
requirements began in 1953 with the opening of the National Institutes of 
Health (NIH) Clinical Center (the agency’s internal research hospital).20 
They expanded with statutory requirements for informed consent in food and 
Drug Administration (fDA) regulated clinical trials and other HHS policy 
requirements in the 1960s, and were further modified with the regulations for 
government-sponsored medical research promulgated in 1972.21
The decades that have elapsed since the first 
national bioethics commission began an 
evaluation of u.S. human subjects protec-
tions in 1974 have seen dramatic changes in 
the research enterprise and further develop-
ment of our system for protecting human 
subjects.22 Research beyond public health and 
medicine, in social science and related fields, 
can involve thousands of research subjects 
through increasingly accessible survey tools 
and methodologies that expand experimental 
rigor.23 Much like the globalization of busi-
ness and other sectors of our economy and 
culture, research with human subjects is now 
a global enterprise (see figure 1.1). 
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Figure 1.1: National Institutes of Health. Map of All Studies in ClinicalTrials.gov. (n.d.). Retrieved from  
http://www.clinicaltrials.gov/ct2/search/map/click?map.x=322&map.y=305 (accessed December 5, 2011).
In the health sector, large-scale, multi-site, and multi-national clinical trials 
and management by contract research organizations (third parties to whom 
research sponsors outsource many of the administrative needs for research) 
are just two markers of this increasingly decentralized enterprise. Biomed-
ical research is rapidly and inexorably 
expanding internationally.24 It increasingly 
addresses diseases more prevalent in other, 
sometimes developing, nations. treat-
ment naïve subjects (those not yet exposed 
to myriad pharmaceutical interventions), 
larger study populations, and the need to 
perform research in certain countries for 
both marketing and scientific purposes, 
further explain decisions to locate research 
in international settings.25 With the excep-
tion of the goals of product marketing, 
these factors are relevant to both publicly 
and privately funded research activities. 
“Looking at the change in global 
clinical trials, I think many people 
have rightly said that pendulum is 
swinging from where the majority 
of clinical trials were done in 
North America and Western 
Europe, to the point now where 
they are being done all over, to 
the point where they are going 
to be done in other parts of the 
world….” 
Dr. Murray M. Lumpkin, Deputy 
Commissioner for International Programs, 
FDA, speaking to the Commission on 
May18, 2011.
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Research Across Borders
Recognizing the increasing involvement of foreign sites and partners in 
human subjects research, the Commission organized the International 
Research Panel (Panel), consisting of experts in bioethics and biomedical 
research hailing from 10 countries: Argentina, Belgium, Brazil, China, 
Egypt, Guatemala, India, Russia, uganda, and the united States.26 The Panel, 
chaired by Commission Chair Amy Gutmann, met on three day-long occa-
sions to discuss research standards and practices around the globe. In their 
discussions, Panel members drew upon their individual expertise and decades 
of experience conducting research and developing policy to protect human 
subjects.
The Panel presented its findings and recommendations, which focused on 
biomedical research, to the Commission in its report, Research Across Borders: 
Proceedings of the International Research Panel of the Presidential Commission 
for the Study of Bioethical Issues.27 The Panel reached consensus on several 
issues. The united States and many other nations, the members agreed, have 
made significant progress in developing measures to protect human subjects 
in research over the last 50 years. Still, the rules, standards, and practices 
inside and outside the united States continue to vary greatly.28 The Commis-
sion’s research on international standards confirmed these findings.
The Panel concluded that researchers must demonstrate respect for human 
subjects and their communities in all phases of study design and imple-
mentation, and wherever research occurs. Recognizing different cultural 
standards and practices through community engagement that are compat-
ible with the ethical treatment of human subjects is an important way of 
demonstrating respect across national boundaries, just as it is an important 
way of demonstrating respect within a diverse society. The Panel also stressed 
the importance of ongoing international dialogue between the united States 
and international bodies. As many within the united States and international 
partners have said before, the Panel agreed that u.S. and foreign investigators 
would benefit from clarification of the u.S. regulatory exception for foreign 
“protections that are at least equivalent to those” in the united States (“equiv-
alent protections” found at 45 C.f.R. § 46.101(h)), and how it can be applied.
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the Panel proposed increased account-
ability by expanding access to public 
information about research.29 “Greater 
efforts are needed,” the Panel concluded, 
“to enhance transparency, monitor 
ongoing research, and hold researchers 
and institutions responsible and account-
able for violations of applicable rules, 
standards, and practices.” Specifically, 
the Panel suggested that the govern-
ment require all greater than minimal 
risk research to be registered and results 
reported in a system such as Clinical-
trials.gov (a federally sponsored on-line 
registry of most clinical trials conducted 
in or outside of the united States).30
the Panel also highlighted one of the 
widest disparities between the united 
States and other nations—many other 
countries provide greater protection for 
human subjects by ensuring treatment 
for research-related injuries or compen-
sation for the costs of research-related 
treatment. the Panel noted that most 
other developed countries require spon-
sors, investigators, or others engaged 
in research to provide such treatment 
or reimbursement free of charge to the 
subject. The Commission’s research reached similar conclusions (see Appendix 
IV). In light of these facts, and the strong ethical case for such protection, the 
Panel recommended that the federal government explore whether revision of 
its rules is needed to ensure compensation for the medical costs of research-
related injuries.31
inTERnaTional collaboRaTion: 
RV144 TRial 
Working with the Thai Ministry of 
Public Health (MOPH), U.S. and Thai 
researchers tested an HIV vaccine 
(RV144) that showed a 31.2% 
efficacy rate in preventing HIV 
transmission in a study sponsored 
by the U.S. Army and primarily 
funded by NIH.
The Panel considered this case 
study in its proceedings and focused 
its attention on the collaboration 
between the two countries. Of note, 
the vaccine developers guaranteed 
from the outset that, if the vaccine 
proved effective, Thailand would get 
it at a discount, as well as rights to 
manufacture it locally. In addition, 
naming a Thai MOPH official as one 
of the principal investigators in the 
study assured the Thai government 
that its interests would be honored.
Source: Presidential Commission for the 
Study of Bioethical Issues. (September 2011). 
Research Across Borders: Proceedings of 
the International Research Panel of the 
Presidential Commission for the Study of 
Bioethical Issues, pp. 50-53. Washington, 
DC: Presidential Commission for the Study 
of Bioethical Issues; AVAC (2010). AVAC 
Report 2010: Turning the Page, p. 25. AVAC. 
Retrieved from http://www.avac.org/ht/a/
GetDocumentAction/i/28305. 
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finally, the Panel echoed a view voiced by many of the guest speakers and 
individuals who provided written comments to the Commission. Reflecting 
what might be called “process fatigue,” the group endorsed ongoing efforts 
to harmonize and clarify existing rules to better protect human subjects over 
creating new rules.32
the Panel’s findings and recommendations gave the Commission impor-
tant insight into the practice of human subjects research internationally and 
appreciation of the capacity of the current system to protect human subjects 
from harm and unethical treatment domestically as well as internationally. 
furthermore, the Panel reinforced a conclusion the Commission reached in 
its own research—namely, that the ethical principles constraining pursuit 
of knowledge with human subjects apply regardless of where research takes 
place or who funds it.33 Procedural differences can, and sometimes should, 
affect the implementation of these principles, but the fundamental ethical 
foundations and boundaries of ethically sound research apply to all domestic, 
international, public, and private research.
Contemporaneous Reviews of the Human Subjects Protection System
Shortly after the Commission began its work in this area, the Office of the 
Secretary of HHS, in coordination with the White House Office of Science 
and technology Policy (OStP) issued an Advance Notice of Proposed Rule-
making, signaling the intent to consider comments on how to modernize 
the u.S. regulations governing human subjects research to make them more 
effective. This ANPRM, issued July 26, 2011, notes that the current HHS 
regulations34 also signed onto by 17 other federal departments and agencies 
(i.e. the Common Rule), were developed more than 20 years ago, “when 
research was predominantly conducted at universities, colleges, and medical 
institutions, and each study generally took place at only a single site.”35
In addition to changes over time in who is conducting research and where, 
the ANPRM also notes other trends in an evolving research enterprise, 
such as the expansion of health services research, research in the social and 
behavioral sciences, and research involving databases, the Internet, biological 
specimens, and genomics. The ANPRM sought comments on “how to better 
protect human subjects who are involved in research, while facilitating valu-
able research and reducing burden, delay, and ambiguity for investigators.”36
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thus, in undertaking its review in response to the President’s charge, the 
Commission also considered aspects of the ANPRM for which it could make 
an informed contribution and reviewed ongoing efforts to modernize and 
clarify existing rules.
About this Report
President Obama gave the Commission nine months to thoroughly inves-
tigate the activities in Guatemala and, following the appointment of the 
Panel in March 2011, nine months to complete this contemporary review. 
The Commission held four multi-day, public meetings to address the Presi-
dent’s requests. Meeting speakers addressed a range of u.S. and international 
policies, rules, regulations, and publicly enunciated principles, providing 
perspectives from a wide array of professional and institutional organizations. 
The Commission also participated in deliberative discussion with members 
and the audience. It received more than 300 comments on this work.37
In the course of its review, the Commission studied human subjects research 
protections around the globe. A brief summary of some of those standards is 
made readily available through the website of the Office for Human Research 
Protections. The Commission also asked federal departments and agencies 
for information about their policies and practices to protect human research 
subjects.38 Department and agency liaisons provided extensive information 
concerning relevant policies used during the planning, execution, and over-
sight of research. They also provided valuable practical insight into how each 
department or agency supports and conducts research, as well as the efforts 
they take to ensure that human subjects are protected.
the Commission’s deliberations took into account the work of numerous 
preceding bodies. The 1995 Final Report of the Advisory Committee on Human 
Radiation Experiments offered 18 detailed and thoughtful recommendations 
regarding past abuses and remedies for participants injured in government-
sponsored scientific studies as well as empirically based ways to improve 
protection for human subjects in current and future studies. These included 
specific recommendations for ongoing debate through public fora.39 Many of 
these recommendations have since been implemented, and all of them raised 
important considerations to guide the Commission in its work.
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In 2001, the National Bioethics Advisory Commission issued a comprehen-
sive report on the existing system to protect human research subjects that 
included more than 30 specific recommendations; it also issued a report on 
research in international settings with 28 recommendations.40 In 2003, the 
Institute of Medicine (IOM) issued Responsible Research: A Systems Approach 
to Protecting Research Participants, with recommendations to extend the over-
sight system to all research, regardless of funding source or research setting.41 
Additional IOM recommendations focused on the duties and functions of 
Institutional Review Boards, conflict of interest rules, the informed consent 
process, compensation for research-related injuries, levels of ethics review, 
and the need for quality improvement. foreshadowing a perspective that the 
Commission heard repeatedly in this investigation, and voiced previously in 
the context of synthetic biology, IOM Chair Daniel federman wrote, “[w]e 
do not, however, urge a permanent accretion of new regulations and bureau-
cracy.”42 Rather, federman urged periodic reexamination of the problems and 
challenges facing the oversight system to better appreciate its appropriateness 
in “minimiz[ing] harm while enabling the benefits of progress to emerge.”43 
Also during the last decade, the Secretary’s Advisory Committee on Human 
Research Protections (SACHRP), which advises the Secretary of HHS, has 
provided extensive guidance to the government on human subjects research 
protections and practices, including but not limited to recommendations 
regarding current rules for research involving children, prisoners, and other 
vulnerable populations; informed consent practices; community engagement; 
regulatory burden; and the need for harmonization of human subjects regula-
tions.44 Collectively, all of this work assisted the Commission.
In Chapter 2, the Commission provides its response to the question of 
whether current protections are adequate to protect subjects from harm or 
unethical treatment. Chapter 3 includes further findings and recommenda-
tions. Additional background material appears in the appendices.
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CHAPtER 2 
Assessing the Current System
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President Obama charged the Commission to determine whether “current rules for research participants protect people from harm or unethical 
treatment, domestically as well as internationally” and to undertake “a thor-
ough review of human subjects protection to determine if federal regulations 
and international standards adequately guard the health and well-being of 
participants in scientific studies supported by the federal government.”45 In 
making this request the President sought assurance that the rules governing 
federal research today adequately guard against the abuses perpetrated by the 
u.S. Public Health Service in Guatemala in the 1940s. The President also 
asked for assurance that current rules protect people from harm or unethical 
treatment, no matter where in the world u.S.-supported research occurs.
In its previous report, “Ethically Impossible” STD Research in Guatemala from 
1946 to 1948, the Commission detailed how researchers in the 1940s failed to 
protect subjects from harm and unethical treatment in research supported by 
the Public Health Service and the government of Guatemala.46 In that case, 
investigators enrolled people in studies that involved intentional exposure to 
StDs without informing them of risks or seeking their consent. The study 
design, and the investigators’ actions in executing it, relied on flawed meth-
odology and failed to minimize risks or maximize benefits for the majority 
of subjects and the community. Investigators intentionally hid information 
from the subjects, the public, and others who might have questioned their 
methods or aims. 
In 1946, when the research in Guatemala began, no federal laws, regula-
tions, guidelines, or explicit international standards protected human subjects 
from these abuses. However, professional standards for physicians that had 
been promulgated by the American Medical Association, and the researchers’ 
own conduct in a previous u.S.-based StD trial that they had conducted in 
1943 and 1944, demonstrated their awareness that participants should not be 
exposed to undue risk and should be informed volunteers. Given these facts, 
the Commission concluded that many of the investigators and others in the 
chain of command supporting the research failed to protect subjects from 
harm and unethical treatment and did not abide by ethical constraints that 
they knew applied to their work. 
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Since the 1940s, however, major changes in the oversight and practice 
of research with human subjects have created a vastly different world for 
researchers and subjects alike. federal laws, regulations, and guidelines; 
numerous transnational standards; and many similar laws and guidelines in 
other countries, enumerate and impose specific provisions to protect human 
subjects. today’s federal rules reflect the now widely and long-recognized view 
that researchers must demonstrate respect for all human research subjects, 
including minimizing the risks and maximizing the benefits of research before 
it begins and respecting each person’s right to give his or her informed consent 
or its moral equivalent. These norms also are reflected in the terms of interna-
tional human rights treaties, such as the International Covenant on Civil and 
Political Rights, to which the united States is a signatory.47 Americans, like 
many people and nations, hold these norms to be fundamental moral duties 
owed to every person, each of whom is entitled to respect by virtue of their 
unique status as moral agents. 
federal statutes and regulations require informed consent from volun-
teers, independent ethical review, equitable subject selection, confirmation 
of scientific validity, and minimization of risks to subjects, among other 
essential limits.48 The Common Rule extends these requirements to most 
federally funded scientific studies regardless of where they occur.49 In addi-
tion, fDA regulations for protecting human subjects apply to all clinical 
research on drugs, including biologics, and devices, regardless of the source 
of funding (i.e. public or private sources).50 (See figure 2.1.) The history of 
Figure 2.1: Federal Protection of Human Subjects in Research
FDA
Applies to privately 
and federally 
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Common Rule
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departments and 
agencies.
FDA-regulated research supported by 
Common Rule agencies
SCIENTIFIC STUDIES WITH HUMANS:
FEDERAL PROTECTION OF HUMAN SUBJECTS IN RESEARCH
Not federally 
funded and 
not subject to 
FDA rules
Federally funded 
and not subject 
to FDA rules or 
the Common Rule
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these rules, which have evolved over several decades, is well documented. 
together, they extend to most, although not all, research conducted in the 
united States and nearly all research funded with public monies outside of 
the country.51
Regulatory standards are not the sole or sufficient means to ensure that human 
subjects are protected from harm or unethical treatment. There are long and 
distinguished philosophical traditions, traceable in Western traditions, for 
example, to Aristotle’s moral psychology and to a Kantian ethics of acting 
out of moral duty, that emphasize the need to cultivate individual moral char-
acter.52 for research, this focus on virtuous character translates into a focus on 
the internal ethical motivation of individual investigators, not only the rules 
and regulations that externally motivate investigators toward compliance. 
Although there are disagreements about how much reliance should be placed 
on the virtuous researcher, and although there are notorious instances in 
which virtue alone has not sufficed as a bulwark of research protections, it is 
undeniable that any compliance regimen is more effective and efficient when 
researchers have internalized a strong sense of personal responsibility as part 
of their professional calling. A strong sense of personal responsibility that 
supports research ethics may emerge from the individual’s own moral sensi-
bility, but it also can and should be cultivated through an education that 
effectively emphasizes the importance of ethics and a keen sense of social 
responsibility in professional life.
Professional standards for research today, as the Commission details in 
Chapter 3, are available but limited. Existing guidelines are found in the 
codes of conduct of numerous professional societies, universities, and 
pharmaceutical companies.53 Embedded in these codes are the principles of 
respect for persons, beneficence, and justice, as demonstrated by the inclusion 
of safeguards such as standards for risk balancing, disclosure of investigator 
funding source, and independent review of payments to human subjects and 
investigators. Provisions calling for registration of clinical trials and publica-
tion of study results provide for greater transparency. Review requirements 
also seek to ensure scientific rigor and subject safety in trial design.54 The 
Pharmaceutical Researchers and Manufacturers Association (PhRMA) and 
many of its affiliates promote general professional standards of conduct.55 
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AstraZeneca is one organization that explicitly characterizes the conduct of 
research ethics as a professional standard.56 Various federal agencies provide 
protections in addition to those in the Common Rule or fDA rules. These 
include conflict of interest regulations to guide investigators in disclosure 
practices and privacy rules that ensure researchers comply with confidenti-
ality requirements of the Health Insurance Portability and Accountability Act 
(HIPAA) Privacy Rule.57
With well-recognized rules (including regulations and professional standards) 
for consent, prospective review, scientific validity, and minimization of risks 
now in place, there is a starting point to answer the question of whether 
research subjects are adequately protected from harm and unethical treat-
ment. However, having adequate rules in place does not, in and of itself, 
ensure that those rules are well implemented or, that they therefore provide 
adequate protection for human subjects. A far more extensive analysis than 
is possible now would assess whether these rules are sufficiently understood 
and implemented given the scope and volume of human subjects research 
supported or conducted by the federal government today. 
The Scope and Volume of Federal Human Subjects Research
faced with the need to assess all scientific studies with humans supported 
by the government, the Commission found that the scope and volume of 
federally supported scientific studies involving human subjects is broad and 
not easily identified. Available information about u.S.-funded research is 
sporadic, with no single listing of human subjects research available inside 
or outside of the government. Public information on research in medicine 
and health is generally more accessible than information on research in other 
sectors, such as education, justice, or engineering. But, overall, systemic infor-
mation is very limited. 
Given these limitations, the Commission sought to collect basic, project-
level data about human subjects research, including study title, number and 
location of sites, number of subjects, and funding information directly from 
each Common Rule department and agency.58 These data were compiled into 
its Research Project Database, and analyzed as part of its Human Subjects 
Research Landscape Project (see further discussion in Chapter 3 and Appen-
dices I and II). 
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the Commission’s data collection efforts show that federally supported 
human subjects research is occurring around the globe and with an enormous 
investment by the federal government.59 Over 55,000 human subjects research 
projects (awards and individual studies) were supported in fiscal year 2010, 
mostly in medical and health-related research, but also in other fields such as 
education and engineering. The Commission’s direct request for information 
from Common Rule departments and agencies revealed that some lack the 
means to readily identify what human subjects research they support. for 
example, some lack a straightforward way, such as the ability to sort relevant 
records in internal systems, to identify human subjects research projects. 
Short of reaching down into the operating components of departments and 
agencies and to individual program officers, which several agencies did to 
support the Commission’s efforts, many agencies have no means to identify 
even basic information about agency-supported human subjects research.60 
With over six months to gather and submit project data, some departments 
and agencies were unable to respond fully to the Commission’s request.
these systemic problems notwithstanding, the Commission found that 
the federal government supported approximately 55,386 human subjects 
research projects in fiscal year 2010. HHS supported almost half of all proj-
ects, approximately 26,651, with NIH supporting the largest percentage of 
HHS research by far, approximately 23,891 projects, or 89.6 percent of HHS 
studies and 43 percent of all federal studies. (See figures 2.2, 2.3, and tables 
2.1 and I.4.) Data from earlier years, though less complete, show that the 
total number of human subjects projects is rising but the distribution among 
departments and agencies is fairly steady. HHS is the largest supporter of 
research with human subjects and, within it, NIH is the primary funder. (See 
tables 2.1, I.4, I.9, and I.10.)
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Figure 2.2 
Figure 2.3
Human Subjects Projects by Department/Agency, FY10†
† “Projects” include awards and individual studies. The CIA did not submit project-level data to the Commission’s database because 
these data are confidential (although not classified). Departments/agencies that appear italicized reported that they were unable to 
provide complete data. See Appendix II for additional details. 
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Table 2.1 Human Subjects Projects over Time†
dEPaRTmEnT/
agEncy 
Fy06 Fy07 Fy08 Fy09 Fy10 mEan
HHS 25,275 25,700 25,168 26,512 26,651 25,861
VA 16,763 16,731 16,706 16,383 15,415 16,400
DOD 6,518 6,557 6,886 6,279 7,084 6,665
NSF 1,820 2,271 2,627 2,988 3,051 2,551
ED 222 1,145 1,199 1,296 1,969 1,166
DOE 407 368 371 348 363 371
USDA 118 122 220 201 272 187
DOJ 120 118 86 140 216 136
NASA 83 104 121 133 136 115
USAID 159 157 106 64 62 110
DOT 26 26 35 47 56 38
EPA 36 41 43 21 46 37
DOC 21 26 34 27 23 26
DHS‡ N/R 22 30 24 10 22
SSA 15 18 17 14 13 15
HUD 7 11 7 18 18 12
CPSC 1 1 2 1 1 1
CIA§ N/R N/R N/R N/R N/R N/R
Total 51,591 53,418 53,658 54,496 55,386
† “Projects” include awards and individual studies. “N/R” means that the data were not reported to the Commission.
Departments/agencies that appear italicized reported that they were unable to provide complete data. See Appendix 
II for additional details.
‡ DHS reported that there “are no earlier data” than FY07.
§ The CIA did not submit project-level data to the Commission’s database because these data are confidential  
(although not classified). 
It is no surprise that HHS, and NIH within it, supports the largest volume of 
human subjects research. Research with humans is critical to advancing many 
fields and chief among these is medicine and health. NIH has led develop-
ment of human subjects protection standards for more than 50 years since the 
opening of its Clinical Center in 1953.61
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L e s s  we l l  k nown i s  in forma-
tion about the volume of research 
supported outside of HHS. the 
top f ive supporters of research 
with human subjects in fisca l 
yea r  2010,  ba sed on projec t s 
reported, were HHS, followed by 
the Department of Veterans Affairs 
(15,415), Department of Defense 
(7,084), National Science founda-
tion (3,051), and Department of 
Education (1,969). (See table 2.1.) 
Research funded in these depart-
ments and agencies includes some 
medical/health-related research, 
but also largely includes research 
in other fields, like education and 
engineering. 
Substantial human subjects research 
programs are also in place at the 
Department of Justice, the Depart-
ment of Agriculture, and the Department of Energy. Here again, some of 
the research includes health-related activities, for example, measuring health 
effects of new technologies, but much relates to program and policy eval-
uation.62 (See table 2.2.) Although it is difficult to precisely quantify the 
proportion of health-related research, by relying on the mission of the depart-
ments and agencies—an imperfect but preliminary measure—approximately 
42,066 projects were medical or health-related, and 13,320 projects were in 
other fields, including education and engineering.
Social, bEHaVioRal, and Economic 
SciEncE RESEaRcH mETHodS
Laboratory Experiments – measure effects  
of social or physical manipulation in a 
controlled setting
Field Experiments – measure effects of 
social or physical manipulation in a real 
world setting
Observations of Natural Behavior – 
document descriptions of real world 
behavior
Interviews – 1) Unstructured: gather open 
ended, qualitative data; 2) Semistructured: 
gather qualitative data on a specific topic;  
3) Structured: gather quantitative data on  
a specific topic
Secondary Data Analyses – analyze 
existing data for another research purpose
Source: Coleman, C. et al. (2005) The Ethics and 
Regulation of Research with Human Subjects. Newark, 
NJ: LexisNexis.
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Table 2.2 Examples of non-clinical Human Subjects Research
Department of Housing  
and Urban Development 
(HUD)
Observational Studies Illuminate Environmental Effects on Health
A HUD-supported observational study examined whether a neighborhood’s 
environment influences the health of its inhabitants. Researchers randomly assigned 
some participants living in public housing to receive vouchers to move to lower 
poverty areas, and found that moving to an area with lower poverty has a modest, but 
potentially significant, impact on the incidence of obesity and diabetes in residents.
Department of Energy 
(DOE)
International Research Improves Radiation Protection Standards
Through the Radiation Effects Research Foundation (RERF), which is co-sponsored by 
the U.S. and Japanese governments, the DOE studies the long-term health impacts 
resulting from radiation exposure from the atomic bombs detonated in Hiroshima 
and Nagasaki in 1945. The RERF research, which has yielded improved radiation 
protection standards that are now employed worldwide.
Department of Justice 
(DOJ)
New Technologies Improve Safety By Preventing Injury
DOJ supported a study to monitor the use of conducted energy devices or CEDs (e.g., 
Taser stun guns). Comparing safety outcomes of law enforcement agencies that 
deployed CEDs to those of agencies that did not, researchers found that the former 
had improved safety outcomes compared to the latter.
Sources: Ludwig, J., et al., (2011). Neighborhoods, obesity, and diabetes – A randomized social experiment. The 
New England Journal of Medicine 365(16),1509-1519; Radiation Effects Research Foundation: A Cooperative Japan-
US Research Organization. (2007). [Foundation website]. Retrieved from http://www.rerf.or.jp/index_e.html; Police 
Executive Research Forum. (September 2009). Comparing safety outcomes in police use-of-force cases for law 
enforcement agencies that have deployed Conducted Energy Devices and a matched comparison group that have not: A 
quasi-experimental evaluation. Report submitted to the National Institute of Justice. Washington, D.C.: Police Executive 
Research Forum. Retrieved from http://www.policeforum.org/library/use-of-force/CED%20outcomes.pdf.
the Commission found, for some departments and agencies, that it was 
difficult to obtain comprehensive, country-specific data on where research 
is occurring. Some agencies limit support to domestic research and some 
lack authority to operate internationally. for example, the Department of 
transportation and HHS’s Indian Health Service, with 56 and 251 projects 
respectively reported for fiscal year 2010, limited their support to studies 
in the united States. (See tables I.7 and I.8.) for these funders, all research 
occurred in the united States. By contrast, some departments and agencies 
did not identify specific countries in which research occurs. for example, 
readily available records were sometimes limited to saying whether work is 
“foreign” or “domestic,” and some departments or agencies did not report 
where work is occurring with certainty. (See figure 2.4. and tables I.7 and 
I.8.) However, for those that did report country-specific information, the 
Commission found that u.S.-government research was occurring in at least 
117 countries around the globe in fiscal year 2010 and on each inhabited 
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continent. About 4.6 percent of the 55,386 fiscal year 2010 government-
supported projects included at least one international component (site or data 
collection); 65.1 percent were entirely domestic; and 30.3 percent did not 
report a site country. (See table I.7.) In HHS, approximately 7.7 percent of 
the 26,651 fiscal year 2010 projects included at least one international 
component (site or data collection); 88.3 percent were entirely domestic. (See 
table I.8.)
Figure 2.4
When considering responsibility for research, an important distinction exists 
between the government’s support for intramural human subjects research 
(i.e., conducted directly by governmental personnel and at governmental facil-
ities) and extramural human subjects research (i.e., conducted by academic 
investigators or others supported through agency grant, contract, or other 
mechanism). (See tables I.2, I.3, I.5, and I.6.) Generally, departments and 
agencies have a far more direct line of authority and responsibility for the 
conduct of intramural research. It is, in a sense, “their” work. Extramural 
† “Projects” include awards and individual studies. The CIA did not submit project-level data to the Commission’s database because 
these data are confidential (although not classified), but did indicate to the Commission that all of its human subjects research 
takes place in the United States. See Appendix II for additional details. 
‡ Over 90 percent of “unknown” studies were reported by the VA, which explained that normally its human subjects research takes 
place in the United States.
Human Subjects Projects by Location, FY10†
Unknown‡
16,785
Domestic
36,046
Domestic and Foreign
1,624
Foreign
931
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research, by contrast, is conducted by individuals outside of the govern-
ment, although they are funded by the government and, for contract-funded 
research, operate at the behest and with specific guidance from the govern-
ment. the proportion of intramural and extramural projects across the 
Common Rule departments and agencies varies greatly. But, generally, based 
on total number of projects, the government’s extramural research portfolio, 
comprising around 54 percent of the government’s total research efforts, is 
more extensive than its intramural portfolio. In fiscal year 2010, the federal 
government directed extramural awards to approximately 3,100 institutions, 
about 200 of which are located outside the united States. (See table I.13.) 
funding to these approximately 3,100 institutions totaled about $16.7 billion. 
(See table I.9.) 
Current Rules
Knowing the scope and volume of research is a prerequisite for assessing 
whether the current system is adequate for protecting human subjects from 
harm or unethical treatment, but another critical determinant is whether the 
investigators and researchers conducting this research understand and abide 
by the ethical rules and constraints applicable to their work. 
the Common Rule agencies have various civil methods to enforce their 
regulations. (See table 2.3.) Within HHS, the Office for Human Research 
Protections (OHRP) evaluates complaints and conducts compliance oversight 
site visits and not-for-cause surveillance evaluations of institutions. OHRP 
does not conduct investigations of noncompliance regarding research solely 
conducted or supported by agencies other than HHS. Those other agencies are 
responsible for directly investigating allegations of noncompliance in research 
they support. 
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Table 2.3 Examples of agency Enforcement authorities
agEncy lEad EnFoRcEmEnT auTHoRiTy
Health and Human Services Office for Human Research Protections
Central Intelligence Agency Human Subject Research Panel
Department of Defense Director, Defense Research and Engineering
Department of Veterans Affairs Research Compliance Officers; Office of Research Oversight
National Aeronautics and Space Administration Chief Health and Medical Officer
Sources: Department of Health and Human Services, Office of the Assistant Secretary for Health, Office for Human 
Research Protections.  Program Description; Letter from V. Sue Bromley, Associate Deputy Director, CIA, to Amy 
Gutmann, Chair, Presidential Commission for the Study of Bioethical Issues. (May 16, 2011); DOD Directive 3216.02, 
Protection of Human Subjects and Adherence to Ethical Standards in DOD-Supported Research, sec. 4.10, March 25, 
2002; VHA Handbook 1058.01: Research Compliance Reporting Requirements, para. 6; VHA Directive 1058, The Office 
of Research Oversight. www1.va.gov/vhapublications/ViewPublication.asp?pub_ID=1825. NASA. (2007).NASA Policy 
Directive: Protection of Human Research Subjects. June 14. Retrieved from http://nodis3.gsfc.nasa.gov/npg_img/N_
PD_7100_008E_/N_PD_7100_008E__main.pdf.
Recent reviews of OHRP’s enforcement actions show that noncompliance 
often involves violations related to the IRB initial review process and IRB 
approval of informed consent documents.63 The identified violations were 
overwhelmingly procedural, with a much smaller percentage of the violations 
reflecting substantive concerns such as a failure to obtain informed consent 
(8 percent of violations).64 These data offer a snapshot of the ways that institu-
tions have failed to comply with regulations. Given the volume of research 
HHS supports, these results suggest that there is room for improvement, but 
that the incidence of serious harm or unethical treatment is fairly low.
Once a database of federally sponsored human subjects research is readily 
available, there are various methods that could be useful to assess investi-
gators’ specific understanding of ethical requirements and practices on the 
ground. for example, a project-by-project assessment could be undertaken 
using a sample of recent federally supported projects in order to determine 
how individuals and organizations conducting human subjects research 
currently apply federal regulations and international standards. Such an 
assessment could identify the practical ethical challenges facing researchers 
and the organizations that oversee them. Document review of agency IRB 
records, structured interviews with research team members and other stake-
holders, as well as site visits, could bring far more specific information than is 
now readily available. Given limited information and time, the Commission 
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did not undertake these actions, but it encourages future reviewers and 
policymakers to consider them.
Conclusion
Existing evidence suggests both that the rules governing federal research 
today adequately guard against abuses analogous to those perpetrated in 
Guatemala in the 1940s and that current regulations generally appear to 
protect people from avoidable harm or unethical treatment, insofar as is 
feasible given limited resources, no matter where u.S.-supported research 
occurs. This conclusion, set forth more fully below, is both consistent with 
and also qualified by the large, yet incomplete, set of information made avail-
able to the Commission in the time available to carry out its charge. 
The Commission concludes, however, that improvement of the current system 
is both possible and desirable. In Chapter 3, the Commission describes those 
areas where improvements are warranted at this time. With these improve-
ments, or response from policymakers to explain to the public as to why they 
are not justified, the abuses of the past can be left firmly in the past. There 
is no way to eradicate all risk of harm, particularly in some types of medical 
and translational research, but the current system, with the improvements 
suggested here, can become one in which we can all be more confident. 
In sum, the Commission finds:
The current U.S. system provides substantial protections for the health, 
rights, and welfare of research subjects and, in general, serves to “protect 
people from harm or unethical treatment” when they volunteer to partici-
pate as subjects in scientific studies supported by the federal government. 
However, because of the currently limited ability of some governmental 
agencies to identify basic information about all of their human subjects 
research, the Commission cannot say that all federally funded research 
provides optimal protections against avoidable harms and unethical treatment. 
The Commission finds significant room for improvement in several areas 
where, for example, immediate changes can be made to increase account-
ability and thereby reduce the likelihood of harm or unethical treatment. 
43
CHAPtER 3 
further Analysis and Recommendations
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I n several important ways, the current regulatory and professional system for the protection of human research subjects can and should be strength-
ened. Ethical standards, at least as ref lected in current regulations, are 
sometimes seen as a barrier or burden rather than as an integral part of 
the web of respectful human relationships.65 Society as a whole often lacks 
adequate information with which to hold researchers and research funders 
accountable for the work that they do. And, despite the fact that science itself 
is founded on the expansion and exchange of human knowledge, there are 
insufficient data available to assess the soundness of current human subject 
protections or their accessibility and responsiveness to stakeholders and the 
general public. 
The Commission identified several areas for improvement, including:
1) increasing accountability; 
2) helping those who are harmed as a result of research participation;
3) respecting equivalent protections of international partners;
4) promoting a culture of responsibility;
5) evaluating site selection and the justification for chosen study designs; and 
6) engaging communities at all levels of research.
Some of these recommendations include specific suggestions for government 
action and others are directed more broadly to the community of research 
investigators, scientists, and others involved in protecting human subjects 
from harm and unethical treatment. The Commission also offers endorse-
ment and comments on several of the proposed reforms published by HHS 
and OStP in the ANPRM to reform the Common Rule issued in July 2011.66
The Commission’s attempts to understand the full range of human subjects 
research conducted or supported by the federal government highlighted the 
difficulty of performing such an inquiry. Thus, recommendations are offered 
on increasing accountability of research programs. Review of existing regu-
lations, guidelines, and professional standards; combined with testimony 
received about the challenges of linking procedural requirements to ethical 
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principles; underscored the need to focus on a variety of means to further 
cultivate and reinforce a culture of responsibility among researchers.
In examining the current system to ensure that subjects are protected from 
harm or unethical treatment, the Commission also identified a set of important 
ethical questions about study design and site selection that remain unsettled, 
yet possible to address in the context of particular research endeavors. Ethical 
considerations for the choice of study design include a range of issues, such 
as ascertaining to whom the benefits of the trial accrue, and determining 
whether the interests of the subjects and their communities are properly 
weighed and balanced in relation to the distribution of risks and benefits. 
Study design and methods cannot be justified by the importance of research 
alone. Certain study designs—such as comparing placebos to experimental 
interventions through a controlled trial—raise ethical concerns when existing 
alternative treatments can be effective in the communities where the research is 
intended to occur, unless a strictly defined set of conditions can be met under 
which comparison is justified. Engaging with relevant communities prior to 
beginning research may be one important step for researchers to show respect 
and sensitivity to cultural norms relevant to protecting human subjects. 
The globalization of biomedical and behavioral research has at times outpaced 
the thoughtfulness with which decisions can or should be made about the 
selection of research sites, a decision that should never be simply a matter 
of efficiency or expediency. Ethical concerns inherent in moving research 
across international borders need further careful specification. Many issues 
are unlikely to be unique to international research; they also arise domesti-
cally when, for example, research is undertaken in resource-poor or culturally 
distinct settings. It is recognized that taking research to specific sites that 
are less expensive because of lower costs associated with care or recruitment, 
or because of the relative ease of identifying populations with the condition 
under study who might be treatment naïve does not necessarily mean the 
research is ethically unacceptable. But when the circumstances of selecting 
research sites suggest the possibility or appearance of exploitation and failure 
to respect individual human dignity or appropriate community interests, site 
selection—both domestic and international—needs to be examined more 
carefully than it has been at times in the past.67
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finally, it has long been agreed, as a matter of principle, that respectful treat-
ment of those who volunteer as research subjects should include medical 
treatment for injury, however rare, without charge to subjects. While people 
may disagree on the extent to which medical expenses should be paid and 
by whom, the notion that research subjects should not be made worse off as 
a result of volunteering to advance science and society is generally uncon-
troversial. The just distribution of burdens suggests that individuals should 
not be forced to bear the costs of injuries they suffer to advance collective 
well-being. But here, as in much of life, the devil lies in the details. the 
Commission recognizes that there are variable policies and practices in place 
now to insulate subjects from bearing medical treatment costs and believes 
that the federal government should undertake further study to determine 
whether, and if so how, a government-wide policy could be developed.
The recommendations in this report are intended to enhance and strengthen 
the current system. they include some overarching issues applicable to 
research in any sector and several other issues that, while focused largely 
on details of health research, have important implications for how human 
subjects are protected. The Commission’s recommendations, if implemented, 
will help to ensure that the well-being and rights of research subjects are 
protected, promote professionalism, better integrate ethical responsibilities 
among researchers, and serve to increase society’s confidence that research 
volunteers are not subjected to avoidable harm or unethical treatment. In 
short, these recommendations offer tools to aid the practice of ethically sound 
research. There of course can be no guarantor of perfection or final word in 
this complex realm. Just as the President asked the Commission to examine 
our country’s understanding and application of fundamental ethical princi-
ples for the protection of human subjects in research today, future generations 
will need to re-evaluate their contemporary application of these principles in 
the context of their own time. 
Commission Recommendations
1. Improving Accountability
The need for greater accountability among all federal supporters of research 
emerged as a crucial, and imminently remediable, issue among the Commis-
sion’s overarching concerns. Contemporary tools for public access to 
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information offer mechanisms to enhance accountability. Expanded support 
for research into the methods and processes of human subjects protection 
offers the opportunity to further assure that human subjects are protected 
from harm or unethical treatment.
Science requires substantial societal investment, putting it in competition 
with other important activities that may contribute to the public good. There-
fore, and especially for publicly funded research, the public has the right to 
accountability in the use and management of the resources allocated to the 
pursuit of scientific knowledge for the common good. Moreover, public scru-
tiny can offer the opportunity for responsible officials and scientists to gain a 
better understanding of the values and preferences of the public whose good 
they ultimately serve. As subject matter experts may sometimes fail to appre-
ciate all implications of their work, substantive contributions by others, not 
directly engaged, may provide unexpected and positive contributions. 
However, the rationale for accountability is not merely one rooted in the 
contingencies of public funding. Modern science is grounded in the enlight-
enment values of democratic participation and public demonstration, so that 
access to insights about the nature of the universe is not limited to only a 
small fraction of society. Over the last 200 years—and especially in recent 
decades—science has developed into an increasingly collaborative activity 
among teams that are often geographically distant, each taking responsibility 
for an aspect of a complex body of work. Peer review, which is an integral 
and longstanding practice in decisions about both funding and publication of 
research, is another element that crucially contributes to accountability and 
exemplifies the fact that science is a communal activity. Making research more 
transparent can help to improve its quality, reduce the chances for unneces-
sary duplication, and inform determinations of scientific merit and reasonable 
risk in human subjects research. Systems for making research information 
publicly available should take into account privacy and intellectual property 
concerns, and conform to applicable statutory and regulatory constraints. 
Scientif ic and lay communities have increasingly advocated for public 
access to information about federally sponsored biomedical research activi-
ties. Insufficient access to research information allows studies and results to 
be hidden and can result in injuries to human subjects, wasted resources, 
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and unethical exposure to 
unnecessary risk.68 federal 
law since 1997 has required 
publ ic and onl ine access 
to limited, basic informa-
t ion about c l inica l  t r ia l s 
involving drugs for serious or 
life-threatening conditions, 
whether publicly or privately 
funded.69 Congress expanded 
these requirements in 2007 
to cover most clinical trials of 
drugs and devices and public 
access to basic results of these 
trials through the government 
website, Clinicaltrials.gov.70 
The International federation 
of Pharmaceutical Manufac-
turers Associations and the 
State of Maine promulgated 
policies mandating public 
access to cer ta in cl inica l 
tria l information, and the 
World Health Organization 
developed a voluntary inter-
national clinical trial registry 
platform in which many countries participate.71 Several countries maintain 
their own national registries a well.72
The Declaration of Helsinki now states that “[e]very clinical trial must be 
registered in a publicly accessible database before recruitment of the first 
subject.”73 federal law has also mandated online public access to basic infor-
mation about federally funded grant and contract research. for example, 
uSASpending.gov was implemented by the federal funding Accountability 
and transparency Act to create a publicly accessible, online database of all 
federal contracts and grants over $25,000; cataloguing details such as the 
ExamPlES oF clinical TRial REgiSTRiES  
aRound THE WoRld
australia and new Zealand –  
http://www.anzctr.org.au/
brazil – http://www.ensaiosclinicos.gov.br/
china – http://www.chictr.org/en/
cuba – http://registroclinico.sld.cu/
European union –  
https://www.clinicaltrialsregister.eu/
germany –  
https://drks-neu.uniklinik-freiburg.de/drks_web/
india – http://www.ctri.in/
iran – http://www.irct.ir/
international Standard Randomised controlled 
Trial number Register – http://www.isrctn.org/
Japan – http://rctportal.niph.go.jp/en/index
netherlands –  
http://www.trialregister.nl/trialreg/index.asp
Pan africa – http://www.pactr.org/
South Korea – http://ncrc.cdc.go.kr/cris/index.jsp
Sri lanka – http://www.slctr.lk/
Source: World Health Organization. (n.d.). Members of the WHO 
Registry Network. Retrieved from http://www.who.int/ictrp/
network/primary/en/index.html.
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funding agency, the recipient, project site, and a description of the project’s 
subject matter.74 Recovery.gov is a similar site that allows the public to track 
use of funding made available specifically under the American Recovery and 
Reinvestment Act.75
Despite these several and promising recent developments in making 
information about research publicly available, more can be done. Only 
“applicable” clinical trials must be registered in Clinicaltrials.gov, yet 
human subjects research encompasses a much broader range of study types. 
Biomedical research alone comprises first-in-human and other early phase 
trials, natural history studies, and physiological studies that are not among 
those required to be registered. Research with human subjects also includes, 
for example, social, behavioral, and economic research conducted by federal 
departments and agencies such as the Department of Education, the National 
Science foundation, and the Department of Justice. Indeed, the National 
Science foundation and Department of 
Education were among the top five federal 
supporters of human subjects research (by 
number of projects) in fiscal year 2010. 
(See table I.1.) And, databases such as 
uSASpending.gov and Recovery.gov track 
federal grants and contracts generally, not 
those related to research—much less human 
subjects research—specifically.
Other notable efforts to enhance account-
ability and access to information about 
human subjects research are also underway. 
for example, “Health Research Web,” initi-
ated by the Council on Health Research 
for Development, an international non-
governmental organization whose primary 
objective is to strengthen research for 
health and innovation, compiles informa-
tion on studies taking place around the 
world, as well as information about IRBs 
and research ethics committees, countries’ 
clinicalTRialS.goV
ClinicalTrials.gov contains 
information about nearly all 
federally and privately funded 
clinical trials investigating new 
drugs or devices, except phase I 
drug and device trials and  
certain types of post-market 
surveillance. Registration of 
covered studies in ClinicalTrials.
gov is mandated by statute.
Publicly available data at 
ClinicalTrials.gov includes: 
the trial’s sponsor; the title, 
description, and design of the 
study; locations where the 
study is conducted; and contact 
information for the trial facility. 
Clinicaltrials.gov does not collect 
funding information.
Source: Food and Drug Administration 
Amendments Act § 801, 42 U.S.C. § 282 
(j) (2007).
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governance policies, and other useful data.76 In 2008, Congress required that 
NIH-funded investigators submit their publications to PubMed Central, an 
electronic publicly accessible database.77 And, in accordance with the America 
Competes Act, OStP, in late 2011, requested public input on recommen-
dations on approaches for “encouraging broad public access to unclassified 
digital data that result from federally funded scientific research” and “broad 
public access to the peer-reviewed scholarly publications that result from 
federally funded scientific research.”78
Department- or agency-specific systems to track human subjects research are 
also available, though they vary widely. Some are centralized, publicly avail-
able databases. for example, the Department of Energy’s Human Subjects 
Research Database provides a wide range of protocol-level information 
about Department of Energy-supported human subjects research, including 
funding for and number of subjects involved in specific studies.79 NIH main-
tains RePORtER, a database listing information about all NIH grants and 
contracts such as funding amount, funding organization and location, and 
project abstract.80 Other departments and agencies lack such systems. for 
example, as part of its review, the Commission learned that some agencies are 
unable to link information about human subjects research projects to funding 
information in any systematic way. Other agencies maintain numerous 
internal databases, but cannot relate or de-duplicate among them.
Comparability of existing agency-specific databases is also limited. The data 
elements contained in each database reflect individual agency priorities and 
resources. for example, NIH’s RePORtER database, provides online access 
to award-level rather than project-level data, and includes information on all 
research—not just human subjects research. Therefore it can be difficult to 
readily distinguish information on specific human subjects studies.
In an effort to collect information on the scope, volume, and type of research 
funded by the federal government, the Commission requested from depart-
ments and agencies limited, project-specific information; such as study title, 
performance country (or countries), number of subjects (if available), and 
funding information; that it deemed necessary to assess the adequacy of 
protections in scientific studies supported by the federal government. for its 
Human Subjects Research Landscape Project, the Commission asked each 
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department and agency covered by the Common Rule to provide data that 
they maintain and have readily available. Some elements were particularly 
difficult for many agencies to report, such as a study’s number of subjects 
and whether the study was exempt from IRB review.81 Each department and 
agency asked for data provided some information about its human subjects 
research portfolio to the Commission. Some were able to respond fully (or 
almost fully) with each of these variables, while others provided more limited 
information. (See Appendices I and II.)
As technical computing and data sharing capabilities have evolved, and the 
public is increasingly able to access information about the research that it 
supports, accountability in research can be increased. While access to infor-
mation alone does not ensure that human subjects will be protected from 
harm or unethical treatment, making information related to human subjects 
research readily available across department and agency supporters will 
contribute to the protection of human subjects by enabling further scrutiny 
and accountability. Knowing where research occurs will enable interested 
members of the public to raise appropriate questions on, for example, site 
selection or research design. It will enable accrediting organizations and 
oversight officials to readily identify basic details about research within their 
jurisdiction.82 And it will enable funders to more easily monitor their own 
portfolio to identify what work they do with human subjects and where more 
resources or attention may be needed. 
The Panel also recommended that information on all research that is more 
than minimal risk be made publicly available through an online tool.83 Given 
the existing requirements already in place for online access to information 
about many clinical trials posing more than minimal risk, the Commis-
sion does not single out this kind of research for special treatment. Rather, 
it recommends that a core, minimal data set on all federally funded research 
with human subjects should be made publicly available. 
Existing systems—both agency-specific and government-wide—provide a 
foundation from which agencies can develop and improve their own systems 
to be utilized as publicly available databases. It may be particularly important 
that departments and agencies collect sufficiently detailed data for individual 
projects to be identified and categorized. Aggregate data do not provide 
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information that would enable members of the public, including fellow 
researchers, to identify individual projects, understand where research may 
be duplicative (therefore imposing unnecessary risks on human subjects), or 
assess if research subjects are adequately protected. A core set of data elements 
about each project is necessary to provide a baseline description of federally 
supported human subjects research and changes over time, and to allow for 
compilation across departments and agencies. This core set of data elements 
should include at least: 1) title, 2) principal investigator and institutional affil-
iation, 3) location of research activities, and 4) funding source and funding 
amount.84 Where possible, the nature of the research study or abstract of 
the study and number of participants should also be included. for clinical 
research, an “NCt” number, assigned to projects registered in Clinicaltrials.
gov, if available, should be included to facilitate accountability by linking to 
other readily available information already maintained by the government. 
The Commission considered whether a new, central, government-wide data-
base of this information should be developed. Because of cost and capital 
investments required, the Commission recommends instead that each 
department and agency should make core data publicly available either by 
developing or improving upon its own systems to make information publicly 
available or release information through a trans-agency system. for agencies 
without existing systems today, data could be submitted to Clinicaltrials.
gov or another existing online registry, provided the core data elements are 
available.85 The Commission endorses registration and reporting results of all 
human clinical research including early phase studies and all privately funded 
research. Certainly it will be easier if the public can access as much informa-
tion as possible through an existing and widely recognized mechanism such 
as Clinicaltrials.gov. Moreover, information submitters may find it easier to 
rely on this existing system rather than having to prepare information for 
multiple databases. 
Creation of a central government web-based portal rather than a single 
government-wide database would enable department- or agency-level systems 
to be centrally accessible, leverage department- or agency-specific systems 
already in place, permit variability among agencies (e.g., differences in 
mission, research types, and recordkeeping practices), and provide oppor-
tunities for innovation and flexibility. A central web portal linking to each 
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department or agency’s system should be created and administered by OHRP 
or another designated agency. OHRP “provides leadership in the protection of 
the rights, welfare, and wellbeing of subjects involved in research conducted 
or supported by the u.S. Department of Health and Human Services,”86 and 
also occupies a prominent role in human subjects protection government-
wide.87 Thus, maintenance of a central web portal for research information 
access is consonant with OHRP’s mission. As above, however, recommen-
dation of a portal mechanism is not intended to preclude the prospective 
development of a unified federal database if it is ultimately more cost-effective 
and efficient to do so and it is not intended to discourage use of available 
mechanisms that may make it easier for the public to obtain information 
efficiently. 
Accordingly, the Commission recommends: 
Recommendation 1: Improve Accountability through Public Access
To enhance public access to basic information about federal government-
funded human subjects research, each department or agency that supports 
human subjects research should make publicly available a core set of data 
elements for their research programs—title, investigator, location, and 
funding—through their own systems or a trans-agency system. The Office 
for Human Research Protections or another designated central organizing 
agency should support and administer a central web-based portal linking to 
each departmental or agency system. This should not preclude the prospec-
tive development of a unified federal database that may ultimately be more 
cost-effective and efficient.
In addition to making core information available and more transparent for 
public scrutiny, the Commission finds that data are essential to determining 
whether current policies are meeting their intended goals. Contemporary 
federal policies regarding human subjects protection are generally based on 
sound ethical principles and many include procedural mechanisms that are 
intended to satisfy them. Determining the extent to which these procedures 
actually serve to protect human subjects depends, at least in part, upon empir-
ical evidence. today, there are limited data that demonstrate the effectiveness of 
particular procedures and no agreed upon metrics by which to measure them.88
MOR AL SCIENCE  Protecting Participants in Human Subjects Research
54
Empirical and conceptual bioethics research synergistically play impor-
tant roles in protecting human subjects. The need for empirical research in 
bioethics is well established. Descriptive data can inform and test normative 
work in bioethics.89 It amplifies the force of conceptual bioethics activity, such 
as the development and delineation of ethical principles, by enabling such 
work to more closely map onto real-world situations and provide concrete 
solutions and recommendations. “[E]mpiric bioethics research serves [at least] 
three essential functions . . . : 1) debunking widely held but erroneous views; 
2) assessing the importance of ethical concerns; and 3) facilitating the realiza-
tion of certain ethical values.”90 The latter functions can help determine the 
extent to which contemporary research policies manifest abstract values and 
ethical principles as well as tangible human subject potections. 
Recognizing the value of empirical research to advancing human subjects 
protection, Dr. francis Collins, NIH Director, detailed for the Commis-
sion his agency’s expanding research agenda in this area. Remarking that 
NIH Institutes and Centers have devoted roughly $50 million per year 
to research in bioethics, according to the most recent survey, Dr. Collins 
noted that the largest program, garnering $18 million per year, resides in 
the National Human Genome Research 
Institute, as its Ethical, Legal, and Social 
Implicat ions Program. this program 
has been investigating the implications 
of genetic and genomic research for the 
last 17 years. During the two-year period 
following passage of the American Recovery 
and Reinvestment Act, NIH funded 21 
bioethics Challenge Grants, which are note-
worthy for the short time period and the 
especially competitive funding and review 
process. Set aside in the budget of the Office 
of the Director is $5 million for institutes 
that propose projects that fit the bioethics 
research and training agenda. A bioethics 
taskforce, comprised of representatives from 
25 Institutes and Centers, has reviewed the 
“The near-term priorities have 
certainly emphasized the 
importance for mission-related 
bioethics initiatives and training 
initiatives. The longer-term  
goal is to try to do more to 
integrate bioethics into the 
full spectrum of biomedical 
research. Not having this as  
a separate discipline but one 
that is fully connected with  
what is going on in the 
laboratories and the clinics.”
Dr. Francis Collins, Director, NIH, 
(2011). Bioethics Research at the NIH. 
Presentation to PCSBI, February 28, 
2011. Available at: http://bioethics.gov/
cms/node/187. 
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results of NIH investment in bioethics research and is now entering a second 
phase and developing a strategic plan for the future of bioethics research at 
NIH. This strategic plan is certain to include initiatives to “integrate bioethics 
into the full spectrum of biomedical research,” making it part and parcel of 
the scientific process instead of a separate discipline.91 
Still, there remains a dearth of knowledge about the actual efficacy of 
human subjects protections. Given this, the Commission recommends that 
the federal government support an expanded operational research agenda to 
study the effectiveness of human subjects protections. Research and evalu-
ation designed to identify and measure protections afforded by Common 
Rule procedures could also inform understanding and implementation of 
the Common Rule’s equivalent protections provision, evaluate the effective-
ness of implementing guidelines for community engagement, and assist in 
clarifying the justifications underlying research-site selection, all of which are 
areas the Commission believes can be improved (see Respecting Equivalent 
Protections, Promoting Community Engagement, and Justifying Site Selection, 
below). Accordingly, the Commission recommends that the federal govern-
ment continue to support and consider expanding its support for systematic 
assessment of current human subjects protection standards.
Recommendation 2: Improve Accountability through Expanded Research
To evaluate the effectiveness of procedural standards embedded in current 
human subjects protection regulations, the federal government should 
support the development of systematic approaches to assess the effective-
ness of human subjects protections and should expand support for research 
related to ethical and social consideration of human subjects protection.
taken together, these recommendations aim to make more data publicly 
available in a coordinated way, enable periodic independent evaluation of the 
scope and volume of federal human subjects research, and support ongoing 
empirical study of human subjects protection standards. With them, the 
public will be better informed about federal research with human subjects, 
domestically as well as internationally, and will have greater opportunity to 
hold researchers and other officials engaged in the research process account-
able for the work that they do. 
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2. Treating and Compensating for Research-Related Injury
Ethical Justification for Compensation
those who sponsor or engage in human subjects research have an ethical 
obligation to protect people who volunteer as research subjects. Just as health 
services researchers speak of both primary and secondary forms of prevention, 
the Commission understands the duty to provide “protection” to encompass 
two important kinds of duties—primary and secondary protection.92
Lifeguards, for instance, have a duty to protect swimmers in both a primary 
and a secondary sense. They are obliged to protect swimmers from drowning 
risks, and to rescue those who begin to drown. Similarly, researchers should 
protect subjects from exposure to undue risk and limit or reverse the harm 
subjects may experience as a result of their participation in the research by 
assuring the provision of appropriate medical care.
The duty to protect only concerns risks that can be avoided or remedied. One 
can only protect against risks that can be reasonably foreseen and avoided or 
risks due to states of affairs that can be identified and modified. Some risks 
cannot be avoided, and there can be no duty to protect against such risks in a 
primary sense. Some harms cannot be remedied, and there can be no duty to 
protect against such harms in a secondary sense.
In thinking about whether there is an ethical justification for providing treat-
ment or some form of compensation for the medical costs of research-related 
injuries, two important facts about the risks of research must be considered: 
•	 first, for the most part, the benefits of such research redound to the common 
good, while the risks are almost entirely borne by the subjects.93
•	 Second, some risks of human subjects research are unavoidable and often not 
readily foreseeable. This unforeseeable nature of some of the risk is part of the 
ethical justification for undertaking human subjects research in the first place.
Many have argued that there is a duty to provide medical care for subjects 
harmed by their participation in research.94 This Commission is not the first to 
study the question of compensation for injuries incurred in the course of research 
participation. The Presidential Commission for the Study of Ethical Problems in 
Medicine and Biomedical and Behavioral Research in 1982 and NBAC in 2001 
explored this issue and called on the government to study the feasibility and 
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need for requiring treatment or compensation for medical costs in the united 
States.95 The Institute of Medicine in 2002, also recommended that “organiza-
tions conducting research should compensate any research participant who is 
injured as a direct result of participating in research, without regard to fault.”
Over the last several decades, almost all other developed nations, and many 
transnational standard-setting bodies, have instituted policies to require 
researchers or sponsors to provide treatment or compensation for treatment 
for research subjects’ injuries.96 (See table 3.1.) the Commission’s Panel 
recommended to the Commission that the united States should establish a 
system to assure compensation for the medical care of subjects harmed in the 
course of biomedical research.97
Table 3.1 international Requirements for Treatment of Research-Related injury
counTRy Policy
Belgium Requires subjects receive treatment for injury and compensation for death.
Denmark Establishes fund ensuring treatment for injury and additional compensation for 
pain and suffering, spouse or partner, loss of earnings, loss of earning capacity, 
loss of dependency for children, and injury to a person’s feelings or reputation.
Finland Establishes fund ensuring subjects receive treatment for injury and additional 
compensation for pain and suffering, disability, and economic loss.
Uganda Requires that subjects receive treatment for injury and compensation for any 
resultant impairment, disability, or handicap.
Brazil Requires that subjects receive comprehensive medical care for injury to the 
physical, psychic, moral, intellectual, social, cultural, or spiritual dimensions of 
the human subject.
guidancE documEnT REcommEndaTion
CIOMS, International Ethical 
Guidelines for Biomedical Research 
Involving Human Subjects
Recommends that subjects receive both treatment for injury, recommends 
compensation for resulting disabilities.
International Conference on 
Harmonisation, Guideline for Good 
Clinical Practice
Recommends that subjects receive treatment for injury, and recommends 
compensation for resulting injuries in accordance with applicable regulatory 
requirements.
Institute of Medicine, Responsible 
Research: A Systems Approach to 
Protecting Research Participants
Recommends that subjects receive compensation that includes at least the cost 
of medical care and rehabilitation.
Sources: Belgium: Annex No. 1 Law of May 7, 2004 Concerning Experiments on the Human Person. Denmark: The Danish 
Liability for Damages Act (2005, amended 2006 and 2007). Finland: Pharmaceutical Injuries Insurance: General Terms 
and Conditions (2007). Uganda: Ugandan National Council for Science and Technology. (2007). National Guidelines 
for Research Involving Humans as Research Participant. Kampala: UNCST. Retrieved from http://www.uncst.go.ug/
dmdocumentsGuideline,%20Human%20Subjects%20 Guidelines%20Marc.pdf; Hungary: Act XCV of 2005 on Medicinal 
Products for Human Use and on the Amendment of Other Regulations Related to Medicinal Products. (2005). Brazil: Rules 
on Research Involving Human Subjects. (2003). Council for International Organizations and Medical Sciences and World 
Health Organization. (2002). International Ethical Guidelines for Biomedical Research involving Human Subjects. Geneva: 
World Health Organization. ICH/GCP: International Conference on Harmonisation. (1996). Guideline for good clinical 
practice E6(R1). June 10. Retrieved from http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/
Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf; Institute of Medicine. (2002). Responsible Research: A Systems Approach 
to Protecting Research Participants. Washington, D.C.: National Academies Press.
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The primary argument in favor of providing care or costs for care of research-
related injuries involves the principles of justice and fairness. Those who agree 
to take part in human subjects research accept the risks of this research, and 
place their bodies and sometimes even their lives on the line. for taking on 
the unavoidable risks of bodily injury that are inherent in such research, 
subjects often receive little or no monetary benefit and often no promise of 
any direct therapeutic benefit, particularly in early phases of clinical research. 
Society benefits from research subjects’ acceptance of these risks, so it seems 
fair that they are protected from some of the ameliorable harms that they 
may sustain as a result of their participation. This is sometimes described as 
an argument against “free-riders.”98 Those who benefit have an obligation in 
fairness toward those who experience harms. 
unintended harm is inevitable in the course of human subjects research. 
Human subjects who are harmed as a consequence of participation in research 
should not individually bear the costs of medical care for such harms. This 
is true whether the harm results from a foreseen risk about which they are 
informed as part of the informed consent 
process or from a wholly unforeseen risk. 
treatment or compensation for the cost 
of medical care is appropriate as an act of 
benevolent regard for individuals’ will-
ingness to participate in an enterprise of 
important benefit to the public.
the primary argument against this view 
has been the assertion that there is a freely 
undertaken assumption of risk on the part 
of subjects volunteering for human research. 
If they understand the risks and benefits 
and still freely consent to participate, so the 
argument goes, then they have no claim, 
in justice, for compensation for any harms 
that befall them as a result of their partici-
pation in the research. this argument is 
steeped in legal history and expressed in 
the doctrine of volenti non fit injuria (those 
“I think compensation is the great 
leveler, and … I think if the 
victim is harmed through no fault 
of his or her and through no fault 
of the researcher, I think there 
has got to be [compensation].”
Mr. Feinberg drew a contrast 
with the current tort system, 
noting that a compensation 
program, if implemented, should 
be an “efficient streamlined 
system that can reach resolution 
in months, not years,” noting 
that the current system is  
“often not very efficient.” 
Kenneth R. Feinberg, J.D., Administrator 
of the Gulf Coast Claims Facility and 
Special Master of the September 11 
Victim Compensation Fund. (2011). 
Presentation to the PCSBI, November 17. 
Available at: http://bioethics.gov/cms/
meeting-seven.
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who consent cannot claim injury).99 Because 
society permits research subjects to consent 
freely and accept the risks of research, then 
it is claimed that society should permit 
subjects to consent freely and accept the 
risk of doing so without expectation of free 
medical care or compensation for any harm 
caused by their participation.100
there are several arguments against the 
view that a human subject’s free and 
informed consent to participate in research 
qualifies as assumption of all risks related 
to research participation. This conclusion 
rests on a fallacious conf lation of avoid-
able and unavoidable risks. Society does not 
permit subjects to consent to any and all 
research risks, but requires instead a prior 
determination by an IRB that foreseeable 
risks are minimized or eliminated.101 IRBs 
carry out this duty of primary protection 
by prohibiting research that involves undue 
risk, regardless of whether an individual 
may freely consent to accept those risks. 
IRBs permit subjects to consent and accept 
unavoidable risks when the benefits of the research outweigh the perceived 
risks of harm. But many research risks are not reasonably foreseeable or 
cannot be avoided; this is one of the very reasons why research is conducted. 
While the nature of research at times requires the acceptance of unavoid-
able physical and psychological risks, to which society permits subjects to 
freely expose themselves, this fact does not mandate that society must permit 
subjects also to accept avoidable risks before, during, or after research. Among 
the risks that can be avoided is the cost of medical treatment for unavoid-
able injuries. Protecting human subjects from bearing the costs of medical 
treatment for illness or injury from participation, that is identifiable and 
ameliorable through medical care, comes under the category of secondary 
protection and the duty to assist such subjects arises again.102
“We need human subjects for  
the simple reason you can’t  
try new therapies on lots of 
people that you haven’t tested. 
So we have to have human 
subjects. And there’s going to 
be an unavoidable, ineliminable 
burden that this places on some 
human beings. . . . [W]e have to 
be very careful that we spread 
this risk fairly[.]” But, “doing 
it without a safety net is not 
required. You can do the science 
and provide a safety net. . . .  
[T]here’s no excuse for imposing 
that on subjects whereas there 
is a perfectly good excuse for 
imposing the burden of being a 
research subject, namely you 
can’t do research without it.”
Daniel Wikler, Ph.D., Mary B. Saltonstall 
Professor of Population Ethics, 
Professor of Ethics and Population 
Health, Department of Global Health and 
Population, Harvard University. (2011). 
Compensation for Research-Related 
Injury. Presentation to the PCSBI, 
November 17, 2011. Available at:  
http://bioethics.gov/cms/node/391.
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A just society can protect persons from undue risks. A society that values 
individual freedom and autonomy can consistently determine that some 
arrangements are inherently unfair and unjust. It can also determine that 
some parties are particularly vulnerable and not in the best position to make 
individual determinations that would protect them from undue risk. Society 
makes such a determination in preventing subjects from enrolling in clinical 
trials that are too risky, and charges IRBs with making that determination on 
a routine basis. If research subjects are entitled to such primary protection, 
they should also be extended secondary protection if they are harmed as a 
result of their participation.
The paradigmatic example of this sort of research circumstance is the typical 
Phase I trial of a new but traditional cytotoxic oncologic agent that holds 
promise in animal studies but has not yet been tried in human beings. The 
purpose of such a study is to determine toxicity and tolerability in human 
beings. the subjects enrolling in such trials are typically patients with 
advanced malignancies for which all standard therapeutic options have failed. 
Such studies pose risk and hold very little promise of therapeutic benefit 
for those who volunteer as subjects. The risks are largely unforeseeable and 
unavoidable. These subjects are vulnerable, often desperate, holding out hope 
for individual benefit even though informed that the probability of individual 
benefit is small. Even if an individual’s own motives are not altogether altru-
istic, the results of such trials nonetheless redound to the common good. Even 
negative trials contribute to our common scientific understanding. to say to 
such persons that they are volunteering for the common good but that they 
must bear full financial responsibility for medical care needed to treat any 
harms that ensue as a direct result of their participation seems grossly unfair.
Nor does the argument for compensation depend on the untenable assump-
tion that research is conducted always and only to benefit the general public. 
The argument instead is that voluntary acceptance of risk by human subjects, 
which advances the interest of the biomedical research enterprise, warrants 
benevolent and just responses. Even when the motives of the investigators and 
sponsors are not solely to advance the common good, the fact remains that 
the research enterprise does redound to the common good regardless of the 
motives of the investigators. Moreover, human subjects are explicitly recruited 
to volunteer for research, even in the for-profit sector, under the assumption 
that their efforts are at least partly intended to advance the common good. 
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Still another objection to compensating research subjects might be that 
the presumption that subjects are volunteers is naïve: some research today, 
it may be claimed, comes closer to the market conditions of laborers and 
employers freely contracting, with both primarily motivated by personal 
gain. This is the model of the research subject as “wage-earner,”103 which 
some commentators have explicitly endorsed.104 Adopting the wage-earner 
model full-throttle, however, actually enhances the case for compensation 
on the basis of justice, rather than undermining it. If research subjects are 
employees, and employees in a dangerous job, then how can they be justly 
excluded from a form of worker’s compensation that is available to other 
employees in other industries? Clearly any harm caused to their health by 
virtue of their participation in the research would be “work-related” injuries 
that ought to entitle them to compensation.
Whichever model one chooses for understanding the relationship between 
human research subjects, investigators, and sponsors, justice argues for 
a system that assures that research subjects who suffer medical, dental, or 
psychiatric harms directly caused by their participation in research ought not 
to bear the costs of treatment for these harms all by themselves.
Moral considerations other than justice also argue for treatment or compen-
sation for treatment of research-related injuries. to the extent that human 
subjects research is biomedical and conducted by physicians, nurses, dentists, 
clinical psychologists, and other health care professionals, then professional 
ethical commitments to the principles of beneficence and non-maleficence 
also support a system of compensation for those harmed by research. One 
might argue that clinician-investigators who know that at least some indi-
viduals will inevitably be harmed by their human subjects research ought not 
to engage in such research unless they can be assured that there is a system in 
place to care for those harmed by research so that their duties of beneficence 
and non-maleficence can be fulfilled.
finally, general utility also argues for such a system. Potential human research 
subjects may be more likely to agree to serve if they know they will be taken 
care of in the event that they are harmed as a direct result of their participa-
tion. In an era in which the recruitment of adequate numbers of research 
subjects continues to be a major challenge, this could be significant. 
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further, if there is a growing commitment toward harmonization of policies 
and recognition of equivalent protections, the fact that federally sponsored 
human subjects research differs substantially in its policy towards compen-
sation for human subjects who are harmed in the course of research could 
prove a significant barrier. Domestically, private sponsors of human subjects 
research have voluntarily committed to assuring such protections to research 
subjects, and internationally, many other countries require this. Harmo-
nization and equivalent protections could be well-served were the federal 
government either to prove that such a system already exists in a rigorous 
(even if inchoate and patchwork) fashion, or to adopt a more formal and 
transparently comprehensive system of compensation. 
The Commission concludes that ethics requires that subjects harmed in the 
course of human subjects research ought not individually bear the costs of 
care required to treat qualified harms resulting directly from that research.105 
Such a conclusion does not, however, specify what an optimal system to carry 
out this ethical mandate would look like. Some serious considerations include 
the scope of any possible coverage, the delineation of qualified harms, mecha-
nisms for determination of causation and qualification, relation to the tort 
system, the need for any special public or private insurance, and how the 
current nonsystematic approach to this issue functions in practice. A distinc-
tion also needs to be made between compensation for the costs of needed care 
resulting from harms due to participation in morally justifiable research and 
reparations for unethical research.
Reparations for Unethical Research
The foregoing discussion concerns treatment or compensation to treat harms 
sustained as a result of participation in trials that are ethically justified. The 
Commission finds that it is important to distinguish this from possible repa-
rations for unethical and exploitative research.
the above discussion focused on compensation (or restitution) through 
providing medical care or the funds to remunerate participants in human 
subjects research for the direct costs of medical care for injuries that have 
proximately resulted from their participation in research. The Commission 
argues that these costs should not be borne by the subjects themselves. under 
the presumption that these injuries were the result of ethically acceptable 
research and could not reasonably have been prevented but instead resulted 
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directly from the uncertainties associated with the experimental intervention 
(and which justified undertaking the research project in the first place), the 
investigators cannot be held ethically blameworthy for such injuries.
Thus, treatment or compensation/restitution for the costs of treatment, is 
justified by distributive or corrective justice and by duties of beneficence. It 
is also justified by the primary duty of professional caregivers to do no harm. 
for example, someone who enrolls in an ethically approved and conducted 
clinical trial, who suffers from pneumonia caused by the trial drug but who 
lacks health insurance to pay for treatment, therefore could merit treatment 
or compensation for treatment costs. Likewise, someone currently enrolled 
in an ethically designed and ethically conducted u.S.-sponsored trial carried 
out overseas who develops a severe side effect and needs health care but has 
no independent means to obtain treatment, such as insurance for health care, 
could likewise merit treatment or compensation for the costs to treat the 
research-related harm.106
Reparation, by contrast, calls for acknowledgment of wrongdoing and 
contrition, along with actual or symbolic repayments for wrongdoing. The 
Commission uses the term reparation in this context to describe the expres-
sion of regret for wrongs done to victims of unethical human subjects 
research. Such individuals need not have been harmed physically or psycho-
logically, and may not even be alive. Likewise, the individual perpetrators of 
the unethical research may no longer be alive to be held directly accountable. 
However, once unethical research has come to light, the institutional spon-
sors of such unethical research bear some responsibility to make amends 
for past institutional wrongdoing or that of their former agents. As such, a 
formal apology, compensation for any identifiable living individuals harmed 
by such research, or symbolic gestures of contrition such as the establishment 
of charitable foundations or institutions related to the future prevention of 
such harms may also be appropriate in some cases.107
Compensation might be part of reparation. for example, an individual 
who was enrolled in the infamous Public Health Service’s “tuskegee Study 
of untreated Syphilis in the Negro Male” (tuskegee Syphilis Study) from 
1932-1972, and now, still alive, needs treatment for tertiary syphilis, might 
deserve compensation as part of an overall program of reparation.108 Repa-
ration, however, need not include compensation. for example, in 1997, 
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President William Jefferson Clinton apologized to the families of those who 
were enrolled in the tuskegee Syphilis Study, and the united States provided 
funds for the establishment of the tuskegee university National Center for 
Bioethics as an act of reparation.109 President Obama’s swift apology to the 
people of Guatemala for the u.S. Government’s sponsorship of the 1946-1948 
StD studies was similarly an important act of reparation, or moral repair.
Designing a System of Compensation 
the Commission recommends that the federal government undertake a 
careful assessment to address how best to satisfy the ethical obligation to 
compensate individuals who suffer research-related injuries as a result of 
volunteering in a federally funded study. The nature and extent of injury, 
the type of research in which the injury is occurring, and the costs of injury 
to subjects, investigators, and society have not been systematically studied. 
When the scope and nature of compensation for research-related injuries is 
determined, it will be possible to address adequately the practical questions 
associated with treatment and compensation.
The questions to be addressed in such an assessment include: to what extent 
do established (and emerging) public and private health insurance programs 
contribute to compensating individuals for research-related injuries? What 
types of injuries are compensated? How is it best to establish causal links 
between research protocols and medical problems? How should research 
subjects in foreign countries be compensated? Should there be limits placed 
on the time, amounts, and categories of compensation?
The Commission was informed and advised about the advantages and disad-
vantages of various means by which the current system offers treatment or 
compensation for treatment for some research subjects. These means include: 
civil tort liability, institutional self-insurance and commercial insurance, 
individual health insurance, government benefit programs like Medicare, and 
direct treatment paid or provided by agencies directly (and as a term and 
condition of a research award). As a general matter, the tort system works 
well for many types of intentional and accidentally caused injuries. Some 
alternatives that selectively pre-empt the tort system, such as the National 
Vaccine Injury Compensation Program (which the Panel proposed as a model 
for consideration), have been established to take into account the particular 
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circumstances under which compensation is due.110 The Commission, accord-
ingly, advises of the importance of carefully considering the variation among 
federally sponsored human subjects research in order to determine the 
optimal system for compensation.111
today, several federal departments and agencies provide treatment or compen-
sation for treatment when research subjects are injured. The Departments of 
Defense and Veterans Affairs both provide care for research-related injuries. 
The Department of Veterans Affairs’ regulations require that it provides care 
for all research-related injuries, even in those studies considered minimal 
risk.112 The Department of Defense provides health care services from mili-
tary treatment facilities for subjects injured in the course of research, but no 
compensation (i.e., payment) for injuries.113 The NIH Clinical Center provides 
short-term care but no long-term care or financial compensation for injury.114 
These programs essentially “self-insure” for treatment or costs of treatment.115 
Personal insurance or government programs such as Medicare also pay the 
costs for treatment for some injuries arising from research.116 (See table 3.2.)
Table 3.2 u.S. Treatment/compensation for Treatment methods
inSTiTuTion TyPE oF Policy
NIH Clinical Center Provides short-term care during the trial, but no long term care or financial 
compensation.
NASA Provides compensation for injuries arising from intramural research through its 
worker’s compensation system; directs principle investigators for extramural research 
to provide compensation through “insurance, worker’s compensation, or the like.” 
Medicare Medicare covers “reasonable and necessary items and services used to diagnose and 
treat complications arising from participation in all clinical trials.” Medicare serves as 
a secondary payer for these costs. 
University of Washington Self-insurance: no-fault program that provides up to $10,000 for out-of-pocket costs 
and write-off of care provided at University of Washington Medicine.
Private clinical trial 
insurance providers 
(e.g.: RJ Ahmann Company)
Covers a number of different types of liability, including: general liability, latent injury 
liability, and incidental medical malpractice liability.
Sources: National Institutes of Health. (2006). Sheet 6—Guidelines for Writing Informed Consent Documents, retrieved 
from http://ohsr.od.nih.gov/info/sheet6.html (accessed November 23, 2011); NASA. (2004). NASA Procedural 
Requirement 7100.1 – Protection of Human Research Subjects, secs. 9.1.4, 11.6, and Appendix B, Revalidated July 
7, 2008; Centers for Medicare and Medicaid Services. Medicare Coverage—Clinical Trials: Final National Coverage 
Decision. Retrieved from: https://www.cms.gov/clinicalTrialPolicies/Downloads/ finalnationalcoverage.pdf; Centers 
for Medicare and Medicaid Services. (2010, May 26). Clinical trials and liability insurance (including self-insurance), 
no-fault insurance, and workers’ compensation. Retrieved from: http://www.cms.gov/MandatoryInsRep/Downloads/
AlertClinicalTrailsNGHP.pdf; Moe, K.E., Director and Assistant Vice Provost For Research, University of Washington. 
(2011). University of Washington Human Subjects Assistance Program. Presentation to the PCSBI, November 17. 
Retrieved from http://bioethics.gov /cms/meeting-seven; RJ Ahmann Company. (n.d.). What You Need to Know About 
Insuring Your Clinical Trials. Retrieved from http://www.rja.com/clinical-trial-insurance-liability-minneapolis-mn/.
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Some academic centers that receive federal funds for research with human 
subjects also provide treatment and cover medical costs for research-related 
injuries. these are established through institutional self-insurance and 
commercial insurance schemes. for example, since 1972 the university of 
Washington health care system has administered a university-wide system of 
treatment and compensation for treatment of research-related injuries. This 
system, self-funded through the institution’s operating budget, provides up to 
$10,000 for out-of-pocket expenses and for treatment at university of Wash-
ington facilities.117
Sometimes component programs of federal departments and agencies 
require awardees to provide for treatment of research-related injuries or carry 
insurance to cover treatment costs. the National Aeronautics and Space 
Administration directs principal investigators seeking funding for research 
conducted outside of its facilities to provide compensation for injury “by 
means of insurance, worker’s compensation, or the like” and may fail to 
approve research because such a provision is not included in a protocol.118 The 
National Human Environmental Effects Research Laboratory (funded by the 
Environmental Protection Agency) promises to provide up to $5000 to cover 
costs for treatment of research-related injuries.119 Costs for insurance are paid 
by the government as part of research awards.120
fDA guidance directs research investigators as part of their duties to protect 
the rights, safety, and welfare of subjects and to provide both “reasonable 
medical care…for medical problems arising during participation in [a] trial 
that are, or could be, related to the study intervention,” and “reasonable 
access to needed medical care, either by the investigator or by another identi-
fied, qualified individual (e.g., when the investigator is unavailable, or when 
specialized care is needed).”121
Most industry-based clinical research sponsors carry insurance to compensate 
individuals injured in research trials. In discussion and written comments 
to the Commission, representatives from PhRMA and the Biotechnology 
Industry Organization, trade groups representing pharmaceutical and 
biotechnology companies respectively, explained that good business practice, 
as well as legal obligations, require their member companies to carry insur-
ance to cover the costs of research-related injuries.122
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No authoritative sources exist by which to determine whether all individuals 
for whom compensation for research-related injuries is warranted are both 
adequately and quickly compensated for their medical care. Consequently, 
in order to fulfill the President’s aim of ensuring that all human subjects 
are adequately protected in federally supported research, the Commission 
finds that further study into any shortfalls of the existing system and the 
utility of alternative systems of compensation is necessary. The Commis-
sion recognizes that it would be unwise to alter or supplant the country’s 
current approach to compensation for research-related injuries without first 
gauging the nature and scope of harms that remain unaddressed. A careful 
and timely study, however, will enable the government to address the prac-
tical questions associated with whether or how to develop a better overall 
system or a supplementary set of approaches to the current system that opti-
mally assures compensation.
for example, the government may decide that a study of alternative 
approaches to compensation should take into account considerations such as 
deterrence, loss spreading, and internalization of risk.123 These considerations 
raise questions about where the burden of compensation is best placed. for 
example, how much (if any) of the burden of compensation should be placed 
on research sponsors to create and sustain incentives for ensuring the highest 
possible level of protection of human research subjects consistently with 
preserving the incentives and capacity for research? Are researchers them-
selves in the best position to internalize some or all of those costs, that is, 
to price some or all of the costs of compensation—including insurance and 
administrative costs—into their research programs? Because researchers play 
an essential role in advancing biomedical research and discovery, an effective 
compensation system should not unnecessarily burden them or impede their 
ability to undertake novel research programs that advance scientific progress 
and discovery. The Commission is recommending a study to help the govern-
ment determine what constitutes a manageable cost of compensation and who 
should bear these costs.
Alternative, complementary, or supplementary models to the status quo 
that merit consideration range from case-by-case compensation by insured 
or self-insured research sponsors and institutions, to a more centralized 
governmental system of compensation for research subjects (analogous to 
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the current National Vaccine Injury Compensation program), to the creation 
of wholly new institutions or system-wide requirements (that specify what 
constitutes adequate standards of compensation). Some compensation 
programs preempt state tort remedies, while others do not. Statutes such as 
the National Childhood Vaccine Injury Act and the legislation that estab-
lished the Workers Compensation fund preempt state tort remedies.124 The 
study that the Commission recommends should explicitly consider whether 
federal preemption of state tort remedies is necessary or desirable for any 
new (or revised) compensation model, whose goal is to ensure coverage of all 
qualified research-related injuries. The study should also consider whether 
a single and predictable model of compensation is more or less burdensome 
to researchers and secure for subjects than a piecemeal approach, the over-
arching ethical goal being to ensure that research participants who are injured 
by research—whether by foreseeable or wholly unexpected injuries—receive 
adequate medical care for their injuries.
the Commission’s deliberations found that National Childhood Vaccine 
Injury Act model or other strict liability models may not be appropriate for 
human subjects research, and could be difficult to apply in a wide range of 
research settings. Many retrospective federal systems of compensation—such 
as the September 11th Victim Compensation fund—are not appropriate 
models: they have been responses to disastrous events that called for a coor-
dinated unique national response.125 The National Childhood Vaccine Injury 
Act, which is a prospective model of compensation, was also a response to 
concerns of vaccine manufacturers about the risk-benefit ratio of producing 
vaccines in light of the substantial civil liability they were then facing and 
could continue to face.126
The Commission thinks it important to recognize the limits of these models 
in the course of considering the optimal means (which are likely to be plural, 
rather than singular) of ensuring appropriate compensation for research-
related harms. A study should take into account the differences between 
the conditions of being recruited and volunteering for the kind of experi-
mental research that may later result in harm and being a subject who uses 
an approved, manufactured product that later results in harm. Similarly, 
designing a system of retrospective compensation for harms sustained by 
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many people during a single involuntary event, for example the September 
11th Victim Compensation fund, differs from designing a prospective 
program for compensating people harmed by having volunteered to assist the 
common good. 
Comparing possible clinical compensation schemes to vaccine compensa-
tion schemes may provide useful insight. for example, clinical research often 
occurs in environments where research subjects are asked to take medicines 
or other interventions outside of the clinical setting. Vaccines are admin-
istered in a clinical setting where one can be certain that the vaccine was 
administered, when it was given, and to what individual. A relatively small 
number of signature adverse events arise from vaccines, and when one of 
those adverse events occurs, the vaccine more likely than not caused the 
injury. The side effects that arise from clinical research trials may not be as 
limited or as predictable. There are a large number of research protocols and 
a wide range of medical interventions, each of which may produce a variety 
of adverse events.
Any system of compensation needs to define a standard or standards for when 
an injury would become a treatable or compensable event.127 Such standards 
could turn on the nature or the severity of the injury, and whether side effects, 
including those that follow an effective therapeutic intervention—such as 
anticipated or unanticipated side effects—should constitute a compensable 
event. Moreover, a standard or standards should articulate what is needed to 
show that the research caused the injury.
Recommendation 3: Treating and Compensating for Research-Related Injury
Because subjects harmed in the course of human research should not indi-
vidually bear the costs of care required to treat harms resulting directly 
from that research, the federal government, through the Office of Science 
and Technology Policy or the Department of Health and Human Services, 
should move expeditiously to study the issue of research-related injuries 
to determine if there is a need for a national system of compensation or 
treatment for research-related injuries. If so, the Department of Health 
and Human Services, as the primary funder of biomedical research, should 
conduct a pilot study to evaluate possible program mechanisms.
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Recommendation 4: Treating and Compensating for Research-Related Injury 
Follow Up
The Commission recognizes that previous presidentially appointed bioethics 
commissions and other duly appointed advisory bodies have made similar 
recommendations regarding compensation or treatment for research-related 
injuries; yet no clear response by the federal government has been issued. 
Therefore, the federal government, through the Office of Science and Tech-
nology Policy or the Department of Health and Human Services, should 
publicly release reasons for changing or maintaining the status quo.
3. Creating a Culture of Responsibility: Human Research Protections as 
Professional Standards
The most fundamental obligation of research involving human subjects is 
to protect the rights and welfare of individuals who offer themselves for the 
good of both science and society and, in some cases, for the hope of personal 
benefit. As persons, research subjects possess an inviolability that rules out 
treating them as mere means to the ends of others, including others who 
may be suffering from a disease or in need of medical care. But, in helping to 
advance research, human subjects sometimes place themselves in a position of 
informational asymmetry, where they must rely on the expertise and wisdom 
of researchers, reviewers, funding institutions, and, at times, their own physi-
cians to ensure that a research study in which they enroll is designed and 
deployed with their rights and welfare in mind. 
Respecting the interests of subjects is often more complicated than it might 
appear. Despite comprehensive (and what some describe as overly burden-
some) regulations, a number of competing interests may make it difficult for 
researchers to recognize or exercise objective ethical judgment in practice.128 
for example, in clinical trial design researchers may struggle with trade-offs 
between high quality science—which offers the possibility of developing 
future means to prevent, treat, or reverse disease—and the immediate best 
interests of subjects.129 So too, financial and nonfinancial conflicts of interest, 
or the appearance of these conflicts, have received increasing attention in the 
last decade. When manifest, they can lead to harm and unethical treatment 
and jeopardize participant and public trust in the research system.130
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As early as 1966, physician Henry Beecher introduced the idea that the best 
protection for subjects is the enlightened and ethically sensitive conscience of 
the investigator. In addition to the requirement of informed consent, Beecher 
described “the presence of an intelligent, informed, conscientious, compas-
sionate, responsible investigator” as offering the best protection for research 
subjects.131 In his view, a system of external regulation was unnecessary 
because properly educated and virtuous clinician-researchers would know to 
do the right thing based on their keenly honed internal compasses. In spite of 
Beecher’s preference for an enlightened conscience over the sometimes-heavy 
hand of regulation, a number of highly publicized research scandals, some 
identified by Beecher himself, in the last century demonstrated the need for 
external regulation.132
While a separate source of oversight in the form of regulations and enforce-
ment is an indispensable complement to a culture of virtuous investigators, 
the optimal system for human subjects protection is a dual system of external 
regulatory checks and internal embodiment of appropriate professional norms, 
such as respect for persons. In developing such a system, care must be taken 
to ensure that external safeguards are not so onerous as to dampen the desire 
and commitment to develop an internal ethical identity. Ideally, researchers 
should view the norms of research ethics as a legitimate and necessary part 
of their mission as scientists. In this regard, the principle of regulatory parsi-
mony, which the Commission developed more fully its report, New Directions: 
The Ethics of Synthetic Biology and Emerging Technologies, must be acknowl-
edged in concert with regulatory necessity.133 Only by balancing compulsory 
and voluntary checks can a lively personal sense of professional ethics develop.
Ethics in a professional practice should be seen as strict standards that are 
simultaneously self-imposed by the relevant profession and expected by the 
society it serves, similar to any other practice standards or standards of care. 
Rather than a matter of only regulatory compliance, professional ethics are 
an integral part of what it means to be a profession in the public service. 
Professional standards correlate with ethical duties toward subjects and with 
the privileges of office and cannot be waived or ignored for expediency, 
convenience, perceived interests of the many at the expense of the few, or 
the allegedly superior demands of science. Researchers must view compliance 
as a shared duty stemming not only, or even primarily, from regulation, but 
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instead from their collective professional responsibility to the subjects of their 
research and the public that supports their research mission.
today, many sources exist to describe useful professional norms. for example, 
PhRMA, of which many of the major pharmaceutical research and biotech-
nology companies are members, has released a code entitled PhRMA’s 
Principles on Conduct of Clinical Trials and Communication of Clinical Trial 
Results.134 The goal of this code is to uniformly assist member companies in 
the ethical conduct of clinical trials. Many member companies have also 
adopted their own code of conduct to promote professional standards.135
In order for researchers to understand, internalize, and embrace critical 
ethical requirements for research with human subjects, these obligations need 
to be seen as strict professional standards that accompany and justify the 
privileges of office. Throughout their professional training, researchers should 
learn and adopt these standards as a condition of acceptance into the profes-
sional discipline entrusted to undertake research with fellow human beings.136 
funding agencies and research institutions should commit to creative, flexible, 
and innovative educational approaches, such as case studies combined with 
rigorous ethical analysis, undergraduate and graduate level mentoring, and 
even senior researcher “coaching,” both in science and in ethical treatment 
of subjects by master researchers.137 A shift towards teamwork and away from 
individual blame in research institutions may also facilitate the discussions 
that will promote a culture of responsibility.138 
the aim should be to both intellectually 
engage researchers and instill a sense of ethical 
responsibility as an integral part of profes-
sionalism. Success in achieving this aim could 
avert the resentment of learning “modules” 
that many well-motivated researchers currently 
view as an insulting waste of time.139
As important as it is to teach rigorously 
the ethics of protecting human subjects to 
professionals, it is at least as important to 
teach the increasingly important and well-
researched subject of bioethics—including 
research ethics—at all levels, including the 
“Education regarding research 
and research participation 
is critically important for 
all stakeholders including 
institutional leadership, 
IRBs, investigators and 
research staff, policymakers, 
sponsors, research subjects 
and the general public.”
Letter from Barbara E. Bierer, Chair, 
Secretary’s Advisory Committee 
on Human Research Protections 
(SACHRP), to Kathleen Sebelius, 
Secretary of Health and Human 
Services. (August 5, 2011). Retrieved 
from http://www.hhs.gov/ohrp/
sachrp/commsec/commentspcsbi.
pdf.pdf.
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undergraduate level. Bioethics is a universally important subject, fully conso-
nant with a liberal arts and sciences education, and as such it should not be 
taught first, let alone only, at the professional-school level. Human subjects 
are drawn from the general citizenry, not only or mainly from the ranks of 
medical professionals and researchers. Citizens will benefit from knowing their 
rights as human subjects, and accountability will be better served if citizens are 
educated to hold accountable the researchers, IRBs, funders, and others in the 
research enterprise. The Commission recommends the development and expan-
sion of rigorous courses in bioethics and human subjects research tailored to 
students at different levels of education. A proven effective method of teaching 
ethics is to combine scholarship on the subject with case studies—such as the 
StD experiments in Guatemala—to engage students in deliberations about 
what they would and should do in these and analogous circumstances.140 Like 
the Panel, the Commission strongly recommends that ethics education play an 
increasingly central role in advancing research ethics.141
the Commission recommends that specific training in research ethics be 
focused not simply on the system of regulations but also on the ethical prin-
ciples animating them. Professional societies, universities, and accrediting 
organizations need to promote standards not as legal burdens relegated to 
compliance departments but as expectations enforced by the community of 
scientists as well as oversight officials. Regulators should explicate the ethical 
rationale for requirements reflecting these standards in order to foster a strong 
sense of professional responsibility. 
Accordingly, the Commission offers the following recommendations: 
Recommendation 5: Make the Ethical Underpinnings of Regulations 
More Explicit
To promote a better understanding of the context and rationale for applicable 
regulatory requirements, the Department of Health and Human Services or 
the Office of Science and Technology Policy should ensure that the ethical 
underpinnings of regulations are made explicit. This goal is also instrumental 
to the current effort to enhance protections while reducing burden through 
reform of the Common Rule and related Food and Drug Administration regu-
lations. (See Promoting Current Federal Reform Efforts below.) Following the 
principle of regulatory parsimony, regulatory provisions should be rationalized 
so that fundamental, core ethical standards are clearly articulated.
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Recommendation 6: Amend the Common Rule to Address Investigator 
Responsibilities
The Common Rule should be revised to include a section directly addressing 
the responsibilities of investigators. Doing so would bring it into harmony 
with the Food and Drug Administration regulations for clinical research 
and international standards that make the obligations of individual 
researchers more explicit, and contribute to building a stronger culture of 
responsibility among investigators. 
Recommendation 7: Expand Ethics Discourse and Education
To ensure the ethical design and conduct of human subjects research, 
universities, professional societies, licensing bodies, and journals should 
adopt more effective ways of integrating a lively understanding of personal 
responsibility into professional research practice. Rigorous courses in 
bioethics and human subjects research at the undergraduate as well as 
graduate and professional levels should be developed and expanded to 
include ongoing engagement and case reviews for investigators at all levels 
of experience.
4. Respecting Equivalent Protections
Clinical research has increasingly become a global enterprise. The number 
of privately sponsored clinical trials being conducted around the world has 
grown dramatically, as has the number of multinational and collaborative 
research projects sponsored or supported by the federal government.142 Most, 
but not all, human subjects research supported by the federal government is 
subject to the same regulatory requirements—either the Common Rule and/
or fDA regulations—regardless of where it is conducted. Research collabora-
tors and partners in other countries funded or supported by Common Rule 
agencies must file an assurance that they will comply with Common Rule 
requirements. At the same time, the regulations delineated in the Common 
Rule have long permitted u.S. departments and agencies supporting or 
conducting research to recognize and accept procedures from foreign coun-
tries that may differ from those delineated in u.S. regulations as long as they 
provide “protections that are at least equivalent” to those in the Common 
Rule. yet u.S. departments and agencies have rarely, if ever, exercised the 
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authority to accept any foreign country’s procedures as equivalent. In some 
cases u.S. procedural requirements even conflict with individual country 
requirements, and controversy remains regarding the processes or criteria to 
determine equivalence of protections.143
The Common Rule applies to “research conducted, supported, or otherwise 
subject to regulation by the federal Government outside the united States”;144 
and states that the policy “does not affect any foreign laws or regulations 
which may otherwise be applicable and which provide additional protections 
to human subjects of research.”145 The Common Rule also gives authority to 
a department or agency to approve the substitution of procedures utilized by 
foreign countries that differ from those delineated in the Common Rule if 
the department or agency determines that those procedures “afford protec-
tions that are at least equivalent” to those in the Common Rule.146 Since the 
time when u.S. federal regulations and the Common Rule were first written, 
many countries have developed their own regulations and laws regarding the 
protection of human research subjects and some have even adopted laws or 
guidelines based on the International Conference on Harmonization Good 
Clinical Practice Guidelines or on the Common Rule itself. In some cases, 
other countries’ laws and regulations are even more extensive than those 
found in the Common Rule.
One way of demonstrating respect for foreign collaborators and partners in 
research, a goal articulated by the Panel, is to develop and employ a process for 
determining when protections delineated 
in foreign laws and regulations are equiva-
lent to u.S. regulations.147 In addition, as 
noted by SACHRP, allowing recognition 
of equivalent protections could reduce the 
burden on u.S. IRBs without reducing, 
and perhaps even enhancing, human 
subject protections.148 furthermore, this 
process will facilitate ongoing international 
dialogue between u.S. and international 
bodies, the importance of which the Panel 
also highlighted in its recommendations to 
the Commission.149
“Recognizing equivalent 
protections would minimize  
the problem of U.S. insistence  
on procedural standards that  
may not offer more effective 
ethical safeguards for human 
subjects, or that may preclude 
research in countries where it 
could improve public health.”
The International Research Panel of the 
PCSBI (2011, September).  Research 
Across Borders: Proceedings of the 
International Research Panel of the 
PCSBI. Washington, D.C.: PCSBI, p. 9.
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The issue of whether and how to recognize “equivalent protections” offered 
by non-u.S. collaborators and researchers is not new. NBAC recommended 
in 2001 that the u.S. government “identify a set of procedural criteria and a 
process for determining whether the human participants protection system 
of a host country or a particular host country institution has achieved all 
the substantive ethical protections.”150 Also in 2001, the u.S. Office of the 
Inspector General, citing the increasing volume of international collaborative 
research, recommended that OHRP address how to “better assess whether 
other nations’ laws and practices afford equivalent protections to those that 
apply to human subjects participating in clinical trials in the u.S.”151
two years later, in 2003, an internal HHS working group made several useful 
recommendations and proposed a framework for developing criteria to deter-
mine equivalent protections. The first step in its framework is to articulate 
the specific protections embodied in the Common Rule. The working group 
noted that the Common Rule is primarily procedural and does not articulate 
either the ethical basis for its required procedures or the actual protections 
that its procedures provide. The working group identified seven protections 
it thought the Common Rule does afford, including that it: 1) establishes 
expectations of ethical conduct and due diligence in review and performance 
of research within the institution; 2) ensures adequate independence and 
authority of the IRB/Research Ethics Committee; 3) protects from biased and 
arbitrary decisions in research ethics review; 4) ensures sufficient quality and 
comprehensiveness of research ethics review; 5) ensures review and oversight 
are commensurate with risk and the vulnerability of the study population; 6) 
protects from unnecessary or unjustified risk throughout the study; and 7) 
ensures voluntary participation after adequate disclosure of study information. 
Importantly, the working group observed that “the protections embodied in 
the [Common Rule]…generally represent broad and complex aims, each of 
which might be satisfied in a variety of different ways through a variety of 
procedures.”152
Despite this 2003 HHS report and a 2005 Federal Register notice calling for 
public comment on the proposals,153 OHRP has not finalized or employed 
criteria or process for determining equivalent protections. In fact, a 2006 
Federal Register Notice on Interpretation of Assurance Requirements reiterated 
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the requirement that all who receive u.S. federal research funds, including 
those outside the united States, follow the exact procedures delineated in the 
Common Rule.154 united Kingdom government officials in 2007 formally 
requested a determination from HHS regarding the equivalence of protec-
tions afforded by united Kingdom procedures for human subjects protection, 
and other countries are also interested in gaining recognition of “equivalent 
protections” for their system.155 yet to date OHRP has not formally recog-
nized any country’s protections as equivalent. 
The federal government does recognize the adequacy of some foreign human 
subjects protections standards as part of its program to license new drugs 
and devices for use in the united States. fDA regulations for clinical inves-
tigations supporting new drug or device marketing applications specify 
requirements, similar to those found in the Common Rule, for informed 
consent, IRB review, and other standards to protect human subjects. fDA 
accepts data from foreign studies that comply with certain international 
standards for human subjects protection (such as those that abide by “good 
clinical practice,” the Declaration of Helsinki, or certain host country regu-
lations), rather than with fDA’s exact regulatory procedures.156 thus, the 
development of a system for recognizing equivalent protections under the 
Common Rule can draw from the experiences of fDA.157
Given this history, and the prominent way that recognizing equivalent protec-
tions demonstrates respect for communities (a safeguard discussed further 
below), the Commission recommends:
Recommendation 8: Respect Equivalent Protections
The federal government, through the Office for Human Research Protec-
tions, should adopt or revise the 2003 Health and Human Services 
Equivalent Protections Working Group’s articulation of the protections 
afforded by the specific procedural requirements of the Common Rule. It 
should use these requirements to develop a process for evaluating requests 
from foreign governments and other non-U.S. institutions to determine 
if their laws, regulations, and procedures can be recognized as providing 
equivalent protections to research subjects. 
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5. Promoting Community Engagement
The Panel directed the Commission’s attention to the value of community 
engagement and the demonstration of respect for cultural differences that are 
compatible with the ethical conduct of human subjects research. The term 
“community engagement” means many things. It includes but is not limited 
to:  community based participatory research, which is a term of art for studies 
designed to engage communities and researchers as equal partners, studying 
health issues in community settings, using communities or community enti-
ties as a unit of study or unit of randomization, engaging communities in 
defining research priorities, engaging communities in shaping a particular 
study to their needs, as well as community “consent,” community advisory 
boards, community outreach for recruitment, and community monitoring of 
study progress.158
In the united States, community advisory boards include, for example, the 
framingham Heart Study Ethics Advisory Board, which enables participants 
and community members from the town of framingham, Massachusetts, to 
advise researchers conducting the decades old NIH-funded epidemiological 
study on proposed research design and methods.159 Community advisory 
boards are required for each research site in the HIV Vaccine trials Network, 
a group of NIH-funded researchers working across the globe to find a vaccine 
for HIV led by researchers at the university of Washington.160 And recent 
guidance from the Centers for Disease Control and Prevention, the Health 
Resources and Services Administration, and NIH contains comprehensive 
discussion of how public health researchers and others can engage community 
partners in their work.161
the values underlying calls for community engagement are applicable to 
research conducted both domestically and abroad. Effective community 
engagement provides an additional layer of safeguard by providing the 
community with opportunities to more thoroughly weigh and accept or reject 
the risks and benefits of research activities, discover possible implications of 
research that might have unintended consequences to host communities, and 
independently evaluate the effectiveness of research protections.162 Interac-
tive and ongoing dialogue between the communities engaged in research and 
the research team allows for the integration of community norms, beliefs, 
customs, and cultural sensitivities with the research activities. 
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Community engagement should provide ongoing two-way communication 
between community partners with research funders, teams, and national 
regulatory authorities. As discussed by the Panel, such communication serves 
as a local mechanism of accountability for the researchers and can also create 
a mutual sense of partnership that facilitates realizing the goals of the research 
project. In the event that communication reveals conflicting ethical values 
among partners regarding how to conduct the research, the partners can 
engage in a mutually acceptable process of conflict resolution. 
Over the past few decades, there has been a growing international consensus 
on the principles underlying the ethical conduct of biomedical research. 
Although there remains some variation in their content, internationally 
recognized documents converge on several themes that are generally compat-
ible with the idea of accommodating community norms in human subjects 
research, but only to the extent that those norms do not conflict with the 
principles that are essential to protecting individual subjects and other-
wise making human subjects research ethical.163 to this point, the Panel 
recognized, however, that “researchers cannot—and should not—accept 
uncritically everything that a community recommends or requests.”164 for 
example, several international documents admit the possibility that it may be 
both necessary and desirable for researchers to use a mechanism other than a 
written document to obtain individual informed consent in some communi-
ties, but they rule out substitution of the collective consent of a community, 
community leader, or a spouse for the consent of any adult who is capable of 
giving his or her individual consent.165
Valuing community engagement during human subjects research around the 
globe is a relatively recent phenomenon. This is seen especially in interna-
tional guidance documents. Although the topic is tangentially discussed in 
the Council for International Organizations of Medical Sciences (CIOMS) 
2002 International Ethical Guidelines for Biomedical Research Involving Human 
Subjects, CIOMS focuses its guidelines on responsiveness to the health needs 
and priorities of host countries, and the ethical acceptability of the study 
for the host country requiring “a thorough understanding of a community’s 
customs and traditions.”166 The Declaration of Helsinki also includes provisions 
regarding the health needs and priorities of host countries, but no mention is 
explicitly made of community engagement standards.167
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Still, these principles are beginning to 
emerge with more force in transnational 
documents. The 2007 Joint united Nations 
Programme on HIV/AIDS uNAIDS and 
World Health Organization (WHO) guid-
ance document, Ethical Considerations in 
Biomedical HIV Preventative Trials, and 
the companion uNAIDS/AVAC Good 
Participatory Practice Guidelines168 explicitly 
include community engagement principles. 
Nor has the lack of international guidance 
stopped the incorporation of commu-
nity engagement principles in a piecemeal 
fashion by individual entities. for example, 
in addition to u.S. examples cited above, 
research ethics bodies in Australia and 
Canada have created documents outlining 
the importance of community engagement 
to ethical human subjects research, specifi-
cally focusing on aboriginal and other minority communities.169
Despite a dearth of explicit formulations for community engagement by inter-
national organizations, proposals for a common framework for community 
engagement in biomedical research have appeared in the literature over the 
past decade.170 Still, there remains a lack of sufficiently detailed and exten-
sive empirical information on the successful implementation of community 
engagement strategies for biomedical research and even less information for 
research in other spheres.171
In 2011, uNAIDS and AVAC published a new edition of their guidelines 
to provide trial funders, sponsors, and researchers with systematic guidance 
on how to effectively engage with stakeholders on the design and conduct of 
biomedical HIV prevention trials.172 This publication provides a roadmap to 
implement community engagement based on principles of respect, mutual 
understanding, integrity, transparency, accountability, and community stake-
holder autonomy. 
“Why does this matter? Well, it 
matters not just for the conduct 
of a single trial. It matters for 
the ways trials can take place 
in a long-term process with 
communities over many different 
types of research endeavors.  
It really comes down to ‘how  
do we create the trust and 
respect for the research  
process that researchers  
and clinicians have, but 
communities often don’t  
for lack of their input and 
engagement throughout  
the process.’”
Mitchell Warren, Executive Director, 
AVAC: Global Advocacy for HIV 
Prevention. (2011). Presentation to 
PCSBI, August 30. Retrieved from http://
bioethics.gov/cms/node/319.
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The uNAIDS/AVAC Good Participatory Practice Guidelines call for execu-
tion of community engagement through a set of activities, including use of 
community advisory boards, the development of community communication 
processes, discussion of post-trial access to beneficial research products or 
outcomes, and access to care for discovered medical illnesses. (See figure 3.1.) 
These guidelines, however, were developed specifically for HIV prevention 
research rather than for human subjects research more generally. They should 
be prospectively evaluated for applicability to human subjects research beyond 
HIV prevention. 
layers of biomedical HiV Prevention Trial Stakeholders
Source: UNAIDS/AVAC. (2011). Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials. UNAIDS: 
Geneva. Retrieved from http://www.avac.org/gpp (accessed November 21, 2011).
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to further develop operational guidelines for the protection and ethical treat-
ment of human subjects through the means of community engagement, the 
Commission recommends that:
Recommendation 9: Promote Community Engagement
The federal government, through the Office for Human Research Protec-
tions and authorized research funders, should support further evaluation 
and specification of the Joint United Nations Programme on HIV/AIDS and 
the AVAC Good Participatory Practice Guidelines with the aim of providing 
a standardized framework for those community engagement practices that 
would further the protection and ethical treatment of human subjects in all 
areas of research. Research should be conducted to prospectively evaluate the 
effectiveness of this framework and strengthen it after it is developed.
6. Justifying Site Selection
Careful selection of research sites is important for two sets of ethical consider-
ations. first, the ethical criteria for how subjects must be treated narrows the 
selection of sites to those that allow for the protection and ethical treatment 
of subjects. Second, site selection implicates other important considerations 
of fairness and justice. With regard to the ethical treatment of subjects, as the 
Belmont Report recognizes, “selection of research subjects needs to be scru-
tinized in order to determine whether some classes are being systematically 
selected because of their easy availability, their compromised position, or their 
manipulability, rather than for reasons directly related to the problem being 
studied.”173 With regard to the second set of ethical considerations, the report 
continued, “whenever research supported by public funds leads to the devel-
opment of therapeutic devices and procedures, justice demands that these not 
provide advantages only to those who can afford them and that such research 
should not unduly involve persons from groups unlikely to be the beneficiaries 
of subsequent applications of research.”174
Certain domestic and international settings present particular concern about 
possible exploitation of human subjects. Alan Wertheimer has observed that 
explicit concern for “exploitation” in research is pronounced in cases involving 
vulnerable populations and studies in low- and middle-income countries.175 
u.S. history contains examples of the failure to treat human subjects ethi-
cally in no small part because subjects were chosen for their vulnerability 
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rather than for the sake of potentially benefiting them or members of their 
community. One prominent example where the site and the subjects selected 
for research signaled a willingness to exploit vulnerable and poor members of 
a minority population for the purported benefit of others was the tuskegee 
Syphilis Study. In retrospect, some defenders of this research argued that 
subjects received some benefits through annual medical check-ups and minor 
health treatments otherwise unavailable to them, but indubitably these “bene-
fits,” standing alone, were far outweighed by the total neglect to treat the 
syphilis176 and by the pervasive deceptions that defined this study.177
The StD experiments funded by the Public Health Service in Guatemala 
during the 1940s are another prominent example of how sites may be chosen 
for the vulnerability of available subjects, in this case, prisoners, psychiatric 
patients, sex workers, and conscripted soldiers. The u.S. researchers exploited 
the easy availability, compromised position, and manipulability of these 
Guatemalan subjects, and they benefited 
from the willingness of some Guatemalan 
officials and researchers to cooperate with 
and support the experiments. 
Decisions about research site selection 
involve consideration of many factors related 
to scientific opportunities and possibili-
ties, as well as ethical considerations. When 
conducted according to the highest ethical 
and scientific standards, human subjects 
research across national borders can serve 
important scientific ends and yield life-saving 
and life-enhancing benefits for participating 
subjects and the communities in which they 
live.178 An expanding number of publicly and 
privately funded research projects are multi-
national, involving numerous collaborating 
researchers and institutions, and are taking 
place in hundreds of sites in multiple coun-
tries; therefore, attention to the ethics of site 
selection is more important than ever. Some 
reasons for site selection are worrisome—for 
“The Guatemala research 
targeted some of the most 
vulnerable groups in any society 
(prisoners, conscripted soldiers, 
institutionalized psychiatric 
patients, and children), and 
also was conducted in an 
underdeveloped country with 
pervasive social inequalities that 
exacerbated their vulnerabilities. 
Such populations are given 
special protections in modern 
society because of their limited 
abilities to protect their own 
interests…In the Guatemala 
experiments the most vulnerable 
populations appear to have been 
targeted specifically because 
of their inability to protect 
themselves or to have others 
represent their interests.” 
PCSBI. (2011, September). “Ethically 
Impossible” STD Research in Guatemala 
from 1946-1948. Washington, D.C.: PCSBI.
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example, choosing a site because of the availability of vulnerable, treatment 
naïve subjects, lower regulatory burdens, and limited plans for making the 
experimental treatment available to its population. Similarly, choosing domestic 
or international sites where systems for protecting human subjects are not in 
place, are insufficient or inexperienced, or allow for the conduct of research that 
would not pass scrutiny elsewhere elevate concerns about exploitation and the 
possibility of unethical treatment. 
The Commission strongly affirms that the same ethical principles that apply 
to domestic research should also be applicable on the international front. We 
should assess globally based research, including research in developing coun-
tries, by the same high ethical standards that we apply to domestic research 
and research in developed countries. Three longstanding and widely accepted 
principles relevant to the ethics of human subjects research are 1) do not treat 
people as mere means to the ends of others by doing research without their 
consent, 2) treat all individuals fairly and with respect, and 3) do not subject 
people to harm or the risk of harm, even with their consent, unless the risk is 
reasonable and there is a proportionate humanitarian benefit to be obtained.179 
These three fundamental principles do not change depending on the location 
of a study, the type of research, or the funding source. Nor are these principles 
of ethical research exclusively applicable to human subjects research in medi-
cine or health. Because the most prominent examples of past abuses are found 
in biomedical research, and scholars’ attention to site selection focuses on this 
area, the Commission directs this discussion of site selection to health-related 
research. However, the principled position staked out here can and should be 
extended beyond biomedical research.
The primary goal of biomedical research is the production of generalizable 
knowledge that will elucidate information about human health and illness 
and facilitate the design and application of preventive, diagnostic, or thera-
peutic interventions to meet the needs of future patients. Individual subjects 
of the research themselves may benefit by receiving medical attention in a 
study, and communities may benefit through the development of their health 
care infrastructures or if the fruits borne of a study are made available to 
them. Myriad risks comprise the burdens of research, including risks to phys-
ical health, mental health, privacy, confidentiality, social status, and economic 
productivity. Research that places a significant burden on subjects and/or 
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their communities can constitute ethically impermissible exploitation unless 
the risks are offset by an adequate level of benefit, including type and quantity 
of benefit. Research in low-income countries raises particular concern that 
communities with limited access to needed health care will accept the risks of 
research but derive benefits that are disproportionately low in relation to the 
risks involved—or that they will be enrolled in research to answer questions 
that will only benefit those in richer countries.180
these concerns lead to the Commission’s second set of reasons for calling 
attention to the issue of site selection: minimizing exploitation and promoting 
fairness and justice. One proposed strategy for minimizing the potential of 
exploitation when research is done in domestic or international low-income 
communities is to ensure that the proposed study is responsive to the health 
needs and priorities of the local community. Several international codes of 
ethics incorporate this broad criterion. for example, the CIOMS’ 2002 Inter-
national Ethical Guidelines for Biomedical Research Involving Human Subjects 
provide that, when conducting research in resource-limited areas, sponsors and 
investigators are responsible for responding to the “health needs and the priori-
ties” of the subject population as well as ensuring that they can benefit from 
the research.181 When research involves vulnerable or disadvantaged groups, 
the Declaration of Helsinki similarly holds that the justifiability of the research 
hinges on its responsiveness to local health needs and priorities.182
Generally speaking, responding to the health needs and offering benefits to a 
population may be an appropriate way to minimize the possibility of exploita-
tion and promote fairness. The Universal Declaration on Bioethics and Human 
Rights (uDBHR), adopted by the General Conference of uNESCO in 2005, 
also emphasizes the importance of responsiveness to host communities, stating 
that “transnational health research should be responsive to the needs of host 
countries, and the importance of research contributing to the alleviation of 
urgent global health problems should be recognized” (Article 21). NBAC 
recommended that a developing country should only be selected as a research 
site when the proposed study responds to the host country’s health needs 
(Recommendation 1.3).183 yet the concept of responsiveness is highly abstract 
and needs further specification before it can be operationalized; further, many 
more specific operational definitions that can be gleaned from the literature on 
responsiveness have been subject to strong counterarguments.184 Prevalence of 
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disease, for example, may be important in evaluating responsiveness, though 
it surely is insufficient as an indicator of burden of disease. Less common and 
even less burdensome diseases may be important health needs amenable to 
answers through good research. understanding responsiveness as requiring 
research to respond to health priorities may provide a disincentive to research 
other important health problems. In this way, it could readily, albeit uninten-
tionally, let the perfect—approving only ethically sound research that serves 
the highest health priorities of a poor community or country—become the 
enemy of the good—approving all ethically sound research that serves some 
health need.185
How to first effectively define and then implement the criterion of responsive-
ness remains an unsettled issue among scholars and practitioners.186 Who has 
the capacity and legitimate authority to define what research is adequately 
responsive to a community, and how best to prioritize that community’s 
health needs, are two critically important questions that remain in need of 
further careful examination. Precisely how any developed criteria of respon-
siveness to health needs apply to both publicly and privately funded research 
is yet a third question that cries out for further consideration. What is clear, 
however, with regard to the ethics of site selection is that all human subjects 
research should be performed in sites where the researchers are both willing 
and able to conduct their research in a way that protects human subjects from 
avoidable harm and unethical treatment. Enforcing this ethical mandate will 
also go a long way toward minimizing, even if not eliminating, the threat of 
unjustifiable exploitation. 
Another important consideration in site selection, which enables ethical 
research to be conducted in under-served communities both domestically 
and internationally, embraces the values of well-functioning collaborations 
and well-established infrastructure for conducting ethical research and 
high-quality science, as well as assurance that the site has or can obtain the 
necessary infrastructure, resources, and oversight structure to ensure that 
research subjects will be treated ethically. With ample capacity to conduct 
research, robust oversight and enforcement mechanisms, and a strong ethical 
framework for human subjects protection comes the expectation in inter-
national research that the host country is well positioned to participate in 
scientifically valid research and adequately protect subjects in that research. 
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In considering the adequacy of infrastructure and ethical oversight across 
national lines, many questions arise, including: Are potential research subjects 
available and can they be fairly selected from the local population? Does the 
design of the trial match the capabilities of the possible site, in terms of facili-
ties, staffing, and other assets to execute the study or can capacity be built to 
enable the conduct of the study without unreasonable diversion of limited 
resources? Is the site selection compatible with ensuring that protections for 
human subjects are equivalent or superior to those in the country originating 
the research, including mechanisms for evaluating and ensuring an acceptable 
balance of risks and benefits for the subjects, independent review of the trial 
design, informed consent, and fair compensation for research-related injury?
Careful examination of site selection is critical to ensuring that subjects in 
research are protected from avoidable harm or unethical treatment. The duty 
to ensure ethical site selection lies first with the researchers who conduct 
research. Generally, they are closest to the ground and able to judge condi-
tions in the host community and country. Sponsors and funders too retain 
responsibility and should not initiate or approve research in locations where 
ethical site selection cannot be assured. funders and sponsors may consider 
relying on determinations of duly constituted and independent IRBs and their 
equivalent bodies internationally. for example, a “just in time” certification, 
of the sort some agencies currently employ for institutional certification of 
IRB review could be developed to address the adequacy of site selection as 
well.187 But funders and sponsors should not allow IRB or ethics committee 
representations to override or replace their own responsibility. In many cases, 
IRBs will have little influence over site selection, as study site decisions may be 
made far in advance of IRB review. Each actor in the funding, conduct, and 
oversight of human subjects research can, and should, exercise their discretion 
and authority to consider the ethics of site selection.
Recommendation 10: Ensure Capacity to Protect Human Subjects
Funders of research should determine that researchers and the sites that 
they propose to select for their research have the capacity—or can achieve 
the capacity contemporaneously with the conduct of the research—to 
support protection of all human subjects. 
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In addition to the absolute requirement to choose research sites where human 
subjects can and will be protected and treated ethically (and the implied 
prohibition on not choosing sites that cannot ensure this protection), other 
important considerations in site selection include how responsive to the health 
needs of a larger community a research project must be once human subjects 
are assured protection and ethical treatment. this issue raises complex 
questions of distributive justice in a non-ideal world where incentives to 
do publicly or privately funded human subjects research are often not well 
aligned with the locations that have the greatest needs for such research.188 
Recognizing that some of these questions remain unsettled and knowing 
that they will benefit from further research and analysis, the Commission 
concludes that the government should lead an effort to focus on them and 
develop more concrete guidance for researchers, funders, and IRBs.
Recommendation 11: Evaluate Responsiveness to Local Needs as a Condition 
for Ethical Site Selection
The federal government, through the Off ice for Human Research 
Protections and federal funding agencies, should develop and evaluate 
justifications and operational criteria for ethical site selection, taking into 
consideration the extent to which site selection can and should respond to 
the needs of a broader community or communities. The Office for Human 
Reseach Protections should produce, and other agencies should consider 
developing, guidance for investigators.
7. Ensuring Ethical Study Design 
The scientific design of human subjects research, especially clinical research, 
becomes a subject of ethical concern when rigorous design elements (e.g., 
placebo controls, assignment to treatment arms, randomization, and blinding) 
raise the question of whether scientific advance is being placed ahead of 
human subjects protection.189 for example, when subjects are assigned to a 
particular treatment or control group to receive an intervention known or 
strongly suspected to be inferior to other treatments available in other arms 
of the study or existing outside the study altogether, critics raise doubts about 
whether the rights or well-being of these subjects are compromised. Several 
controversial cases in the last 20 years have polarized the medical community 
into sharply opposed camps on this issue.190
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Among the most discussed of these cases 
was a series of trials undertaken in the 
1990s to gauge the safety and effectiveness 
of a short course of AZt (an antiretroviral 
drug) in preventing the perinatal infec-
tion of children with HIV. The active arm 
receiving AZt was compared to a control 
arm receiving a placebo (i.e., an inactive 
agent). the proponents of these trials 
contended that a placebo control was 
necessary in order to develop efficiently a 
scientifically validated, safe, and effective 
prophylaxis against HIV infection in chil-
dren and noted that the use of the known 
effective method was not feasible in the 
test locations.191 Critics argued strenu-
ously that other designs (e.g., involving 
active controls and equivalency studies) 
were both scientifically reliable and ethi-
cally mandatory. They argued that those 
who designed, approved, and carried 
out such placebo-controlled trials were 
responsible for hundreds of preventable 
deaths.192 Similar debates arise when 
human subjects are engaged in contro-
versial procedures, for example “washout 
periods” that involve withdrawal of current medications for such serious 
conditions as depression or psychosis in order to avoid confusion with the 
effects of new drugs.193 Also controversial, “challenge studies” involve inten-
tional exposure to pharmacologic agents or circumstances to induce disease 
or symptoms for further study.194 
Regarding the ethics of placebo-controlled clinical trials, differences remain 
and disagreements continue, but consensus is emerging.195 In particular, 
Ezekiel Emanuel and franklin Miller have proposed a “middle ground” for 
ethical clinical research,196 largely supported by this report. Many ethicists 
and ethical codes have concluded that placebo-controlled trials can be ethical, 
diFFERing ViEWS
“Placebo Orthodoxy”
Comparing an experimental drug  
to a placebo ensures scientific 
validity and accurate measurements 
of drug efficacy. Thus, it is ethical 
to use placebos as controls, 
even when alternative, approved 
therapies exist.
“Active-Control Orthodoxy”
Placebos are never ethical if an 
alternative, approved therapy exists, 
and the best available alternative 
must be used as the control.
“Middle Ground”
A placebo-controlled trial can 
sometimes be considered ethical 
if certain methodological and 
ethical standards are met. If these 
standards cannot be met, then  
the use of placebos in a clinical  
trial is unethical.
Emanuel, E.J., and F.G. Miller. (2001). The 
Ethics of Placebo-Controlled Trials—A Middle 
Ground. New England Journal of Medicine 
345(12), 915-919.
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provided certain criteria are met, including (but not limited to) these condi-
tions: that withholding a proven treatment will cause only minimal harm to 
the subjects; that using an established intervention would not yield reliable 
results; and that the study is responsive to the needs of the host country. 
NBAC and CIOMS, for example, suggest giving the control arm of the trial 
the “worldwide best” treatment available as a default rule, with exceptions 
permitting a lower standard based on factors such as necessity, potential harm, 
affordability, and relevance of the research question to the host community.197 
The current Declaration of Helsinki, however, specifies that new interventions 
should be tested against the “best current proven” intervention, restricting the 
permissibility of placebo-controlled trials.198
In highlighting this emerging consensus, the Commission begins with the 
maxim that in research “good ethics begins with good science.”199 Every clin-
ical trial starts either within a context of controversy, wherein investigators 
disagree as to the relative merits of, for example, new drug A and old drug 
B; or a context of uncertainty wherein investigators do not know which drug 
is better. Clinical trials are designed specifically to help resolve such contro-
versy and uncertainty. If they are poorly designed and lack scientific rigor, 
studies cannot contribute to the resolution of such questions and the medical 
community will potentially ignore the results. Scientifically flawed studies 
have no social value, and if they have no social value there is no benefit to 
exposing subjects to any risk through participation. Ethical research must 
therefore be based upon a firm foundation of good (i.e., rigorous) science.
The unfettered demand for scientific and methodological rigor still can raise 
ethical concerns about whether subjects are being treated with sufficient defer-
ence to their status as moral agents worthy of equal concern and respect, 
persons should never be reduced to “mere means” for the benefit of others. 
for example, designing a placebo-controlled trial for a life-threatening illness 
such as HIV/AIDS might be thought to violate “clinical equipoise,”200 which 
would ethically necessitate a genuine controversy or uncertainty among the 
expert medical community about the net benefit of each intervention being 
compared (including a placebo/no treatment at all). With convincing evidence 
and consensus within the medical community that, for example, drug A is 
better than drug B, then a design giving some human subjects drug A and 
others drug B, under the principle of clinical equipoise, would be unethical.201 
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Different commentators describe the nature of this perceived ethical flaw in 
different ways.202 Some argue that researchers who knowingly withhold the 
best-proven treatment from subjects violate their “therapeutic obligation,” 
which is grounded in the physician-patient relationship.203 Others, owing at 
least in part to the fact that much human subjects research is not conducted 
by physicians (e.g., social scientists), locate the source of this duty elsewhere, 
such as in the subjects’ status as equal and inviolable moral agents.204 for 
example, critics of the perinatal AZt trials argued that a placebo-controlled 
trial exposed pregnant women and their children to an excessive risk of harm 
or death.205 they charged too that when citizens of rich and prosperous 
countries receive the best-proven treatments, but people in lower and middle 
income nations receive “short course” treatments or placebos in clinical trials, 
this creates a morally pernicious “double standard.”206 This concern becomes 
even more problematic when the research is not “responsive” to the health 
needs of the host country.207 
Towards a Middle Ground on Study Design
In the last section, the Commission discussed some ethical considerations that 
go into selecting research sites which must be considered in designing studies 
as well.208 furthermore, the Commission offers the following specific criteria 
for evaluating methods and risks of study design.
(1) Treatment Standards
As a matter of biological effectiveness and safety, treatments proven best for 
populations in the developed world are not always best for populations in 
the developing world. for example, genetic differences between population 
groups may make the best-proven treatment generally unsuitable for some, 
and variability in underlying health status may make some populations more 
vulnerable to side effects than others. Also, differences in the medical and 
logistical infrastructure of a developing host country may render the effec-
tive deployment of a best-proven intervention difficult or even impossible in 
practice. for example, the best possible comparator drug for the control arm 
might require refrigeration unavailable in a country lacking reliable electrical 
power, or the drug might need to be delivered intravenously in a country 
without the medical resources necessary for such delivery.209
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the standard of care available to subjects in a control group need not be 
the best-proven, especially when there is uncertainty about whether such a 
standard would be best for the local population under study. Thus, in spite 
of the rhetorical appeal of the “no double standards” objection, it has become 
increasingly evident that trial designs offering human subjects an intervention 
that falls short of the best-proven approach can pass moral muster without 
relying on moral relativism (which would underlie an objectionable double 
standard), provided that certain rigorous conditions are met. 
first, any application of clinical equipoise must carefully and scrupulously 
take into account local context. This does not, however, mean that the appro-
priate measure of the standard of care for determining ethical study design 
should be the level of access currently afforded to the study population. The 
so-called “local de facto” standard permits the deployment of placebos in 
control groups whenever the local “standard of care” is in fact no care at 
all.210 But to call “no treatment” due to impoverished health care budgets 
the local “standard of care” is to distort the meaning of standard of care as a 
guiding medical norm.211 
Recognizing that meaningful debate on this issue continues, the Commission 
finds that the optimal standard lies between the “best-proven” and “local de 
facto” interpretations: for example, a standard of care that would or should 
be optimal for a certain population; given their health needs and the level of 
available medical and logistical infrastructure, cultural practices, genetics, 
and economic capacity to sustain treatment into the future.
The Commission recognizes too that a rigid insistence upon a best-proven 
standard could have the unintended consequence of precluding meaningful 
research and achievable health reforms in relatively poor host countries. As 
Zulfiquer Bhutta, a well-known pediatrics expert, has noted, major progress in 
treating newborns with suspected sepsis has recently been achieved in India, 
but such progress would have been unlikely had the best-proven standard 
of care, intravenous antibiotics, been ethically required of the researchers. 
Instead, the researchers were able to compare an intervention against the local 
standard of care and conclude that the intervention was both accessible to the 
population and more effective than the local standard.212
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(2) Methodological Constraints
Second, the scientific design of a trial must be adequate to yield usable 
results. Absent this, results will not be credible and human subjects would 
have been exposed to risk unnecessarily. However, there is disagreement 
about the level of confidence required for sound science and adequate trial 
design. Some insist that a placebo-controlled, double-blinded, random-
ized trial is the gold standard for testing new interventions or treatments. 
Others regard insistence upon such a design as counter-productive, and an 
inappropriate dismissal of potential trial results that may be somewhat less 
conclusive but obtainable without the potentially unacceptable ethical costs 
of a placebo-controlled trial.213 
the Commission does not need to take sides in this debate to agree that 
the results of clinical trials must be amenable to definitive interpretation. 
As Robert temple and Susan Ellenberg, clinical trial experts from the fDA, 
have pointed out, it is highly desirable that the meaning and significance of 
studies be contained within the study itself.214 Ideally, one should not have to 
rely on results outside of a trial to interpret a single trial’s results. In placebo-
controlled trials, this additional outside evidence is not required because the 
study itself can show that the intervention being tested is better than no inter-
vention. But in some designs, for example “equivalency” designs (trying to 
show that the intervention being studied is at least as good as an intervention 
already being employed), previous studies demonstrating the effectiveness of 
the intervention already being employed in a similar population are required. 
temple and Ellenberg describe this as the problem of “assay sensitivity.” 
Absent a placebo control or independent evidence taken from outside the 
trial that the intervention already being employed is effective, researchers will 
be unable to interpret the study’s results.215 This sort of design is appealing, 
however, because it does not subject trial subjects to the medical risks of a 
placebo control. It is, however, logistically and economically more challenging 
because it requires the recruitment of more subjects for trials of longer dura-
tion and greater expense.216
Similar worries concern equivalency trials wherein the new drug is expected 
to perform less well than the established standard, as in the perinatal AZt 
trials, but there are compelling policy reasons to find an alternative to the 
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standard. In the perinatal AZt trials, the short course AZt was expected to 
be somewhat less effective than the “076 protocol” (the best-proven standard 
at the time), but also much less expensive and therefore more affordable in 
developing countries.217 Indeed, the goal of the short course trials was to find 
an affordable and implementable regimen to prevent perinatal HIV transmis-
sion in developing countries, not to find the best such intervention worldwide. 
In such a context, designing a trial that would compare the established 076 
protocol against short course regimens without a placebo control would have 
suffered from the same problem of assay sensitivity described above. If the new 
drug regimen had shown to be somewhat less effective than the best-proven 
standard, what would the researchers have learned? the intuitive answer 
is that the researchers would have learned that the new drug protocol was 
comparable to the best-proven standard and thus possibly a good candidate 
for public health funding; but without a comparator to judge how effective, 
decisions about adopting the intervention would be uninformed.
(3) Risk Minimization
Third, although study designs that do not use the best-proven therapy for a 
given condition in a given population can sometimes be justified for method-
ological reasons, such designs nonetheless can place subjects at risk of harm. 
An additional ethical constraint requires researchers to minimize the amount 
of harm to which subjects might be exposed.
Subjects receiving less than the optimal standard of care should not be 
subjected to substantially increased risk of mortality, serious morbidity, or 
severe discomfort. An example of a problematic study falling into the latter 
category was a placebo-controlled study of the anti-emetic drug, Ondan-
setron, which was being introduced as a remedy for nausea and vomiting 
associated with cancer chemotherapy.218 At the time of the study, there were 
a number of approved anti-emetic drugs that were effective and had been 
shown in previous trials to be superior to placebo, yet subjects in the placebo 
arm of the Ondansetron study experienced extreme vomiting following their 
chemotherapy. Such a study was arguably unethical because subjects in the 
control arm experienced serious side effects, even if it had methodological 
advantages over an active control design comparing Ondansetron against 
another approved anti-emetic.
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trials of psychiatric drugs in which some subjects receive less than the stan-
dard of care provide examples of increased risks of mortality and serious 
morbidity. Because depressed patients may be at risk for suicide, denying them 
effective treatment within a control group could place them at increased risk 
of death. Likewise, patients who are abruptly weaned from an anti-psychotic 
regimen during the washout phase of a new anti-psychotic trial might be 
placed at increased risk of new and possibly exacerbated psychotic episodes.
IRBs should scrutinize the elements of study design as a distinct focus of 
their review. Study designs that pose risks to subjects by departing from the 
current standard of care in control groups should be explicitly justified in the 
research protocol, and the anticipated additional risks to subjects should be 
proportional to the expected degree of individual or social benefit. Subjects 
who might be exposed to additional risks should be carefully examined for 
special vulnerabilities before trials begin, and their clinical course should be 
carefully monitored throughout the duration of the trial so that they can be 
taken off study, if necessary, to address emerging threats to their lives, health, 
or comfort.
The Commission finds, then, that some research designs in which control arm 
subjects receive less than the best-proven treatment can be ethically justified 
if the above criteria are all applied and clearly met. Importantly, contrary to 
some of the critics of the short-course perinatal HIV trials, the Commission 
has concluded that good ethical reasons can be found for permitting some 
of these trials and that one need not resort to any intellectually or morally 
questionable theory of ethical relativism in order to do so.
Recommendation 12: Ensure Ethical Study Design for Control Trials
When assessing how to reconcile the requirements of rigorous study design 
with the interests of research subjects, a nuanced approach is recom-
mended that permits subjects to receive a placebo or an active agent that 
otherwise might not represent the “best-proven” approach when the site 
selected is ethically justifiable and the following conditions are met: 
a) the “best-proven” intervention is not known to be the best for a partic-
ular population due to local infrastructural, behavioral, genetic, or other 
relevant circumstances; and b) the scientific rationale and the ethical justi-
fication for the study design have undergone careful review to ensure all of 
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the following: i) use of placebo or other comparators is of limited duration; 
ii) subjects are carefully monitored; iii) rescue measures are in place should 
serious symptoms develop; and iv) there are established withdrawal criteria 
in place for subjects who experience adverse events. 
8. Promoting Current Reform Efforts
federal efforts to reform the current human subjects research protections 
system are already underway. In July 2011, the HHS Secretary and the OStP 
Director published an ANPRM entitled Human Subjects Research Protections: 
Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, soliciting comments on possible revisions to the 
Common Rule and other provisions of the current system of protection for 
human research. Specifically, the ANPRM asks for public comment on “how 
current regulations for protecting human subjects who participate in research 
might be modernized and revised to be more effective.”219
the ANPRM includes many thoughtful proposed revisions to human 
subjects protections. The Commission generally supports the objectives of the 
ANPRM and the goal of better protecting human subjects while reducing 
burden, delay, and ambiguity for investigators.220 Several sections in the 
proposed reforms specifically are of interest to the Commission, and several 
topics are of particular relevance to the Commission’s charge from the Pres-
ident. Moreover several of the recommendations made above, such as the 
recommendation to develop specific regulatory directions for investigators, 
could be included as part of the current reform effort and the Commission 
urges the government to consider doing so.
Ensuring Risk-Based Protections
Currently under the Common Rule, review of human research studies is 
undertaken by a convened IRB for all studies involving more than minimal 
risk to subjects or more than minor changes from previously reviewed 
work.221 Studies involving no more than minimal risk or minor changes 
in previously approved research may be reviewed by a single IRB member 
through “expedited review” if the category of research appears on a published 
list of activities eligible for expedited review.222 Additionally, six categories 
of studies are “exempt” from IRB review altogether.223 OHRP guidance 
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recommends—but does not require—
that review of exempt studies be done by 
someone other than the investigator in 
order to confirm that the study has been 
appropriately classified as exempt.224
the current system has been criticized 
as “not adequately calibrating the review 
process to the risk of research.”225 further-
more, many IRBs review minimal risk 
studies at convened meetings out of concerns 
for regulatory and institutional liability, 
rather than through expedited review. 
Accordingly, many social and behavioral 
scientists have argued that their research is 
over-regulated in the current system.226
In its f irst report, New Directions: The 
Ethics of Synthetic Biology and Emerging 
Technologies, the Commission elucidated 
the principle of intellectual freedom and 
responsibility, and its corollary principle 
of regulatory parsimony. These principles 
ref lect the fact that scientific discoveries 
and advancements depend on the intellec-
tual freedom of researchers coupled with 
the responsibility of individuals and insti-
tutions to use their creative potential in 
morally responsible ways. Regulatory over-
sight must be limited to that which is truly 
necessary to ensure justice, fairness, secu-
rity, and safety while pursuing the public 
good. Consequently, the Commission supports reforming research review 
to appropriately calibrate the evaluation with the level of risk to human 
subjects. this reform also would accomplish the vital goal of allowing 
IRBs and institutions to focus their efforts and limited resources on studies 
involving higher risk. The Commission endorses the ANPRM in its goal of 
“The current regulations 
governing human subjects 
research were developed 
years ago when research was 
predominantly conducted at 
universities, colleges, and 
medical institutions, and each 
study generally took place at 
only a single site. Although  
the regulations have been 
amended over the years, they 
have not kept pace with the 
evolving human research 
enterprise, the proliferation  
of multi-site clinical trials  
and observational studies,  
the expansion of health  
services research, research 
in the social and behavioral 
sciences, and research involving 
databases, the Internet, and 
biological specimen repositories, 
and the use of advanced 
technologies, such as genomics. 
Revisions to the current human 
subjects regulations are being 
considered because OSTP and 
HHS believe these changes 
would strengthen protections  
for research subjects.”
Subjects Research Protections: 
Enhancing Protections for Research 
Subjects and Reducing Burden, Delay, 
and Ambiguity for Investigators, 76 Fed. 
Reg. 44,512 (July 26, 2011).
MOR AL SCIENCE  Protecting Participants in Human Subjects Research
98
eliminating continuing review for certain lower-risk studies and to regularly 
update the list of research categories or activities that may undergo expe-
dited review. 
Also elucidated in New Directions, the principle of public beneficence 
encourages maximizing public benefits and minimizing public harm, and 
the principle of responsible stewardship reflects a shared obligation among 
members of the domestic and global communities to act in ways that demon-
strate concern for those who are not in a position to represent their own 
interests. Both of these principles applied to human subjects research demand 
a thorough and more complete review of studies deemed to be greater than 
minimal risk to subjects. These principles also encourage a lesser regulatory 
burden on investigators conducting minimal risk research so that important 
work is not delayed through unnecessary regulatory processes and so that 
IRBs can focus their resources on reviewing higher risk protocols. 
for exempt research, expanded and called “excused” in the ANPRM, the 
Commission agrees with the proposal to adopt a registration system as a 
reasonable strategy to track this research, provided that institutions respon-
sible for this research retain the flexibility to require a higher standard of 
independent review of exempt status. Just as with determinations concerning 
independent review of minimal risk research, which the Common Rule 
currently allows to be made by expedited review,227 decisions about exemption 
should be made without full IRB review so long as they are not limited solely 
to the discretion of the individual investigator. Data from projects, such as the 
“Exempt Wizard” currently being studied through the federal Demonstration 
Partnership, will be useful in evaluating how registration protects subjects of 
exempt research.228
Streamlining IRB Review of Multi-Site Studies
While the current Common Rule regulations do not require IRB review by 
each institution involved in a multi-site study, in many—if not most—cases 
individual institutions229 and IRBs independently review research protocol 
and informed consent documents.230 This sometimes results in hundreds of 
individual reviews and, if the protocol is revised, multiple re-reviews at each 
site. This process is time consuming, logistically burdensome, and often dupli-
cative for both the IRBs as well as the investigators, and there is little evidence 
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that multiple reviews improve human subjects protections. In addition, IRBs 
do not always reach the same conclusions on important issues. 
The Commission supports reducing time consuming duplicative IRB review 
where duplication serves no purpose to improve protections. Reducing 
unnecessary burdens to research is encouraged by the principles of intellec-
tual freedom and responsibility and regulatory parsimony. Multiple reviews 
can unnecessarily delay important research, result in costly and problematic 
alterations to protocols and study designs, cause burdensome requirements to 
clear minor changes, and in some cases even jeopardize the integrity of the 
science. In addition, reducing burdens and barriers to effective IRB review 
helps speed research discoveries from the bench to the bedside and thereby 
effectuates the principle of public beneficence by improving public health 
and overall societal well-being. Although the ideal of a single IRB of record 
for such studies should be pursued as the ANPRM describes, the Commis-
sion believes it should not be mandated. In some situations, institutions and 
investigators have unresolved concerns about liability, regulatory enforcement, 
and implementation of a single Institutional Review Board of record, which 
should not be ignored.
Improving Informed Consent
the Common Rule requires legally effective informed consent from all 
research subjects in studies subject to the Rule, unless that requirement is 
waived by an IRB in accordance with pre-specified regulatory criteria.231 
However, the ANPRM notes that “consent forms may frequently fail to 
include some of the most important pieces of information that a person would 
need in order to make an ‘enlightened decision’ (to quote the Nuremberg Code) 
to enroll in a research study. Rather than presenting the information in a way 
that is most helpful to prospective subjects—such as explaining why someone 
might want to choose not to enroll—the forms often function as sales docu-
ments, instead of as genuine aids to good decision-making.”232
The principle of responsible stewardship requires citizens and their represen-
tatives to think and act collectively for the common good. The government, 
in collaboration with institutions and investigators, should refocus on the 
importance of the process of informed consent lest the procedures, ostensibly 
derived from ethical principles, serve to obscure the values they were intended 
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to implement. If both the government and institutions take a step back and 
concentrate on that which ensures actual informed consent, they may start to 
unravel the impediments to the process overall. That said, much like stream-
lining IRB review, regulating informed consent procedures must be done with 
great care and should be informed by data concerning what is and is not 
effective in achieving such consent. The Commission encourages the develop-
ment of flexible guidelines and procedures for obtaining informed consent, 
especially in social and behavioral sciences as well as in epidemiology, public 
health, and quality improvement research since the issues in these kinds of 
research are often different than those in more classic pharmaceutical trials.
Clarifying and Harmonizing Regulatory Requirements and Agency Guidance
Although the Common Rule is widely seen as a single, comprehensive stan-
dard for protecting human subjects in research across the federal government, 
departments and agencies vary in their implementation of it233 and some 
funders of research have not adopted it at all.234 The ANPRM acknowledges 
the importance of improving the consistency of guidance on the protections 
of human subjects across federal departments and agencies.235
The Panel recommended to the Commission in its Research Across Borders 
report that “continued efforts to harmonize and guide interpretation of rules 
should be made a priority over creating new rules.”236 The Panel acknowledged 
that new rules may be needed to harmonize existing u.S. rules, but any addi-
tions should be clear, sound, and streamlined. furthermore, harmonization 
would add clarity to the u.S. oversight process, particularly for international 
clinical trials.
The principle of responsible stewardship espouses the clarity, coordination, 
and accountability of regulations across the government called for both by the 
ANRPM and the Panel, and reinforces the compelling case for consistency, 
to the extent feasible, among all federal departments and agencies supporting 
human subjects research. 
Data Collection to Enhance Adverse Event Reporting
The ANPRM also discusses the standardized collection of safety data, specifi-
cally adverse events, and suggests changes to improve the real-time, prompt 
collection of such data.237 These proposed changes include using a streamlined 
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set of data elements to satisfy most agency reporting requirements and imple-
menting a prototype of a web-based, federal-wide portal, already in use by 
several agencies, to which institutions can submit safety data.238
This concept of centralized human subjects research data collection is also 
reflected in one of the Panel’s recommendations to the Commission, further 
discussed in Improving Accountability above, enumerating that “[t]o enhance 
transparency and accountability, governments should consider requiring all 
greater than minimal risk research to be registered and results reported.”239
The Commission recognizes that different agencies have different systems, 
but efforts should be made to report some common data elements in a 
unified system.
In sum, the ANPRM is an encouraging and important step forward in 
ensuring that human subjects in federally sponsored research are protected 
from harm and unethical treatment. Many of the ethical principles the 
Commission has previously articulated f ind ref lection in the current 
proposals. The Commission expressly endorses several of the specific proposals 
contained in the ANPRM.
Recommendation 13: Promoting Current Federal Reform Efforts
The Commission supports the federal government’s proposed reforms to:
a) Restructure research oversight to appropriately calibrate the level and 
intensity of the review activities with the level of risk to human subjects;
b) Eliminate continuing review for certain lower-risk studies and regularly 
update the list of research categories that may undergo expedited review;
c) Reduce unnecessary, duplicative, or redundant institutional review board 
review in multi-site studies. Regardless of the process used to review and 
approve studies, institutions should retain responsibility for ensuring that 
human subjects are protected at their location as protection of human 
subjects includes much more than institutional review board review. 
The use of a single institutional review board of record should be made 
the regulatory default unless institutions or investigators have sufficient 
justification to act otherwise;
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d) Make available standardized consent form templates with clear language 
understandable to subjects;
e) Harmonize the Common Rule and existing regulations of the Food and 
Drug Administration, and require that all federal agencies conducting 
human subjects research adopt human subjects regulations that are 
consistent with the ethical requirements of the Common Rule; and
f) Work toward developing an interoperable or compatible data collection 
system for adverse event reporting across the federal government. 
9. Following Up
The Commission recognizes that many of these recommendations have been 
made previously by presidentially appointed bioethics commissions and other 
duly appointed government advisory bodies over the past two decades, yet it 
found no clear response by the federal government to many of these recom-
mendations. A primary example concerns compensation for research-related 
injuries, which was recommended by President Clinton’s Advisory Committee 
on Human Radiation Experiments in 1995. Writing only six years later, in 
Ethical and Policy Issues in International Research: Clinical Trials in Developing 
Countries, NBAC again called for the “adequate care and compensation to 
participants for injuries directly sustained during research.” Other commis-
sions have more modestly recommended an investigation of the need for 
compensation of human subjects for injury in research trials.240 
Recommendation 14: Responding to Recommendations
The Commission recommends that the Office of Science and Technology 
Policy or another appropriate entity or entities within the government 
respond with changes to the status quo or, if no changes are proposed, 
reasons for maintaining the status quo with regard to the recommenda-
tions below. Possible departments or agencies to lead the efforts include the 
Department of Health and Human Services, the Office for Human Research 
Protections, and the National Institutes of Health, as well as other funders 
and regulators. 
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Table 3.3 Recommendation Follow-up Summary
REcommEndaTion 
numbER†
SummaRy oFFicE
1 Increase accountability through online access to basic 
human subjects research data.
OHRP/all departments and 
agencies that support human 
subjects research
2 Support the development of systematic approaches to 
assess the effectiveness of human subjects protections 
and expand support for research related to ethical and 
social consideration of human subjects protection.
OHRP/all departments and 
agencies that support human 
subjects research
3 Study research-related injuries to determine if there 
is a need for a national system of compensation or 
treatment for research-related injuries because subjects 
harmed in the course of human research should not 
individually bear the costs of care required to treat 
harms resulting directly from that research.
OSTP/HHS
4 Publicly release reasons for changing or maintaining 
the status quo regarding compensation or treatment for 
research-related injuries.
OSTP/HHS
5 Explicate the ethical underpinnings for human subjects 
protection requirements. 
HHS/OSTP
6 Add responsibilities of investigators to the Common Rule. HHS/OSTP
8 Adopt or revise the 2003 Department of Health and 
Human Services Equivalent Protections Working 
Group’s analysis and develop a process for evaluating 
requests from foreign governments and other non-U.S. 
institutions for determinations of equivalent protections.
OHRP
9 Support further evaluation of the UNAIDS/AVAC 
Guidelines to provide a standardized framework for 
community engagement practices across research fields.
OHRP
11 Support research to develop and evaluate justifications 
and operational criteria for ethical site selection.
OHRP/all departments and 
agencies that support human 
subjects research
13 Develop proposed regulations to reform the current 
Common Rule. 
OSTP/OHRP
14 Follow up. OSTP/other appropriate entity
† Listed here are recommendations directed to the federal government only.
A response need not be unduly lengthy or provided by a single department, 
agency, or division. the Commission knows that analyzing and imple-
menting (or not) the recommendations contained herein may involve work 
with multiple agencies across the government, and may also involve public 
engagement and legal processes, such as rulemaking or statutory change. 
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The Commission is asking that the public be informed whether the federal 
government intends to move forward, and if so in what way, with any or all 
of these recommendations.
The Commission’s point, simply put, is to assist all members of society to 
understand the response of those entrusted with policymaking on its behalf 
to these specific recommendations. Repeatedly during its review, Commis-
sion members, guest speakers, and members of the public asked “what will 
the next ‘Guatemala’ be?” for many, this question related to concern about 
what future generations will see as “ethically impossible” in our own prac-
tices. While it is difficult to know what future generations will think, it 
is clear that they will be aided in their assessment by clear articulation of 
what this generation, through its authorized policymakers, thinks and, most 
importantly, how it acts.
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manner most protective of the health of his or her study participants. Given the proven, 
life-saving effectiveness of other surfactants, a placebo-controlled trial could not satisfy this 
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Appendix I: Human Subjects Research Landscape Project: Scope and 
Volume of Federally Supported Human Subjects Research
Table Title
I.1 Departments/Agencies and HHS Operating Divisions
I.2 Extramural Human Subjects Projects Over time
I.3 Intramural Human Subjects Projects Over time
I.4 HHS Human Subjects Projects Over time
I.5 HHS Extramural Human Subjects Projects Over time
I.6 HHS Intramural Human Subjects Projects Over time
I.7 Location of Human Subjects Projects Over time
I.8 Location of HHS Human Subjects Projects Over time
I.9 total Extramural Award funding (Human Subjects Projects) Over 
time
I.10 total HHS Extramural Award funding (Human Subjects Projects)  
Over time
I.11 top 20 (of 117) Human Subjects Project Site Countries  
by Number of Projects, fy10
I.12 top 20 (of 68) Extramural Awardee Institution Countries  
by Number of Human Subjects Projects, fy10 
I.13 Location of unique Extramural (Human Subjects Projects) Awardee 
Institutions, fy10
I.14 Proportion of Extramural Human Subjects Projects with  
Known Award Amounts 
I.15 Proportion of Human Subjects Projects with Known Site Country 
I.16 Proportion of HHS Human Subjects Projects with Known  
Site Country 
I.17 Proportion of Human Subjects Projects with Known Subject Count
I.18 Proportion of Human Subjects Projects with Known Exempt/ 
Non-exempt Status
I.19 Proportion of Human Subjects Projects with Known Number of Sites
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Table i.1 department/agencies and HHS operating divisions
Departments and Agencies that Received Data Request
dEPaRTmEnT/agEncy abbREViaTion
Agency for International Development USAID
Central Intelligence Agency CIA
Consumer Product Safety Commission CPSC
Department of Agriculture USDA
Department of Commerce DOC
Department of Defense DOD
Department of Education ED
Department of Energy DOE
Department of Health and Human Services HHS
Department of Homeland Security DHS
Department of Housing and Urban Development HUD
Department of Justice DOJ
Department of Transportation DOT
Department of Veterans Affairs VA
Environmental Protection Agency EPA
National Aeronautics and Space Administration NASA
National Science Foundation NSF
Social Security Administration SSA
HHS Operating Divisions
uniT abbREViaTion 
Agency for Healthcare Research and Quality AHRQ
Assistant Secretary for Preparedness and Response ASPR
Centers for Disease Control and Prevention CDC
Centers for Medicare & Medicaid Services CMS
Food and Drug Administration FDA
Health Resources and Services Administration HRSA
Indian Health Service IHS
National Institutes of Health NIH
National Vaccine Program Office NVPO
Office of Adolescent Health OAH
Office of Population Affairs OPA
Substance Abuse and Mental Health Services Administration SAMHSA
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Table i.2 Extramural Human Subjects Projects over Time†
dEPaRTmEnT/
agEncy 
Fy06 Fy07 Fy08 Fy09 Fy10 mEan
HHS 21,676 21,491 20,929 22,309 22,322 21,745
DOD 2,976 2,946 2,925 1,890 2,107 2,569
NSF 1,820 2,271 2,627 2,988 3,051 2,551
ED 222 1,145 1,199 1,296 1,969 1,166
USDA 68 75 178 167 231 144
DOJ 95 107 74 125 188 118
USAID 159 157 106 64 62 110
DOE 88 70 72 60 52 68
EPA 29 29 35 17 40 30
DHS‡ N/R 19 30 23 10 22
NASA 8 15 17 23 26 18
SSA 10 18 17 14 13 14
HUD 7 11 7 18 18 12
DOT 4 8 11 18 19 12
DOC 11 8 13 10 10 10
CPSC 0 0 0 0 1 0
VA 0 0 0 0 0 0
CIA§ N/R N/R N/R N/R N/R
Total 27,173 28,370 28,240 29,022 30,119
† “Extramural” includes projects conducted solely extramurally and projects with an extramural component. 
“Projects” include awards and individual studies. “N/R” means that the data were not reported to the Commission. 
Departments/agencies that appear italicized reported that they were unable to provide complete data. See Appendix II 
for additional detail. 
‡ DHS reported that there “are no earlier data” than FY07. Mean is of reported years.
§ The CIA did not submit project-level data to the Commission’s database because these data are confidential (although 
not classified).
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Table i.3 intramural Human Subjects Projects over Time†
dEPaRTmEnT/
agEncy 
Fy06 Fy07 Fy08 Fy09 Fy10 mEan
VA 16,763 16,731 16,706 16,383 15,415 16,400
HHS 3,599 4,209 4,239 4,203 4,329 4,116
DOD 3,542 3,611 3,961 4,389 4,977 4,096
DOE 319 298 299 288 311 303
NASA 75 89 104 110 110 98
USDA 50 47 42 34 41 43
DOT 22 18 24 29 37 26
DOJ 25 11 12 15 28 18
DOC 10 18 21 17 13 16
EPA 7 12 8 4 6 7
CPSC 1 1 2 1 0 1
DHS‡ N/R 3 0 1 0 1
SSA 5 0 0 0 0 1
USAID 0 0 0 0 0 0
ED 0 0 0 0 0 0
HUD 0 0 0 0 0 0
NSF 0 0 0 0 0 0
CIA§ N/R N/R N/R N/R N/R N/R
Total 24,418 25,048 25,418 25,474 25,267
† “Projects” include awards and individual studies. “N/R” means that the data were not reported to the Commission. 
Departments/agencies that appear italicized reported that they were unable to provide complete data. See Appendix II 
for additional detail.
‡ DHS reported that there “are no earlier data” than FY07. Mean is of reported years.
§ The CIA did not submit project-level data to the Commission’s database because these data are confidential (although 
not classified).
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Table i.4 HHS Human Subjects Projects over Time†
uniT Fy06 Fy07 Fy08 Fy09 Fy10 mEan
NIH 22,396 23,210 22,709 24,028 23,891 23,247
CDC 1,739 1,387 1,380 1,334 1,317 1,431
AHRQ 668 634 598 655 898 691
IHS 254 277 238 239 251 252
FDA 90 103 122 192 200 141
HRSA 47 51 50 43 35 45
OAH‡ x x x x 31 31
NVPO 61 14 39 0 0 23
OPA 12 16 22 17 16 17
ASPR 8 8 10 4 12 8
CMS 0 0 0 0 0 0
SAMHSA 0 0 0 0 0 0
Total 25,275 25,700 25,168 26,512 26,651
† “Projects” include awards and individual studies.  See Appendix II for additional detail.
‡ OAH was established in 2010. Mean is of reported years.
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Table i.5 HHS Extramural Human Subjects Projects over Time†
uniT Fy06 Fy07 Fy08 Fy09 Fy10 mEan
NIH 20,632 20,526 19,922 21,255 21,006 20,668
AHRQ 562 550 517 574 830 607
CDC 277 251 289 310 304 286
FDA 67 66 71 93 74 74
HRSA 44 47 46 40 31 42
OAH‡ x x x x 31 31
NVPO 61 14 39 0 0 23
OPA 12 16 22 17 16 17
IHS 13 13 13 16 18 15
ASPR 8 8 10 4 12 8
CMS 0 0 0 0 0 0
SAMHSA 0 0 0 0 0 0
Total 21,676 21,491 20,929 22,309 22,322
† “Extramural” includes projects conducted solely extramurally and projects with an extramural component. 
“Projects” include awards and individual studies. See Appendix II for additional detail.
‡ OAH was established in 2010. Mean is of reported years.
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Table i.6 HHS intramural Human Subjects Projects over Time†
uniT Fy06 Fy07 Fy08 Fy09 Fy10 mEan
NIH 1,764 2,684 2,787 2,773 2,885 2,579
CDC 1,462 1,136 1,091 1,024 1,013 1,145
IHS 241 264 225 223 233 237
AHRQ 106 84 81 81 68 84
FDA 23 37 51 99 126 67
HRSA 3 4 4 3 4 4
ASPR 0 0 0 0 0 0
CMS 0 0 0 0 0 0
NVPO 0 0 0 0 0 0
OAH‡ x x x x 0 0
OPA 0 0 0 0 0 0
SAMHSA 0 0 0 0 0 0
Total 3,599 4,209 4,239 4,203 4,329
† “Projects” include awards and individual studies.  See Appendix II for additional detail.
‡ OAH was established in 2010. Mean is of reported years.
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Table i.7 location of Human Subjects Projects over Time† 
dEPaRTmEnT/
agEncy 
locaTion Fy06 Fy07 Fy08 Fy09 Fy10
CIA‡
Domestic N/R N/R N/R N/R N/R
Foreign 0 0 0 0 0
Mixed 0 0 0 0 0
Unknown 0 0 0 0 0
CPSC
Domestic 1 1 2 1 1
Foreign 0 0 0 0 0
Mixed 0 0 0 0 0
Unknown 0 0 0 0 0
DHS§
Domestic N/R 20 26 23 10
Foreign N/R 2 4 1 0
Mixed N/R 0 0 0 0
Unknown N/R 0 0 0 0
DOC
Domestic 21 26 34 27 23
Foreign 0 0 0 0 0
Mixed 0 0 0 0 0
Unknown 0 0 0 0 0
DOD
Domestic 2,451 4,904 4,775 5,082 6,787
Foreign 203 379 368 255 265
Mixed 2 6 5 8 30
Unknown 3,862 1,268 1,738 934 2
DOE
Domestic 391 356 356 334 348
Foreign 14 10 13 12 14
Mixed 2 2 2 2 1
Unknown 0 0 0 0 0
† “Projects” include awards and individual studies. “Mixed” means  projects with both domestic and foreign 
components. “N/R” means that the data were not reported to the Commission. Departments/agencies that appear 
italicized reported that they were unable to provide complete data. See Appendix II for additional detail.
‡ The CIA did not submit project-level data to the Commission’s database because these data are confidential  
(although not classified), but the agency did advise the Commission that all of its human subjects research  
takes place in the United States.
§ DHS reported that there “are no earlier data” than FY07.
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dEPaRTmEnT/
agEncy 
locaTion Fy06 Fy07 Fy08 Fy09 Fy10
DOJ
Domestic 118 118 86 140 215
Foreign 0 0 0 0 1
Mixed 0 0 0 0 0
Unknown 2 0 0 0 0
DOT
Domestic 26 26 35 47 56
Foreign 0 0 0 0 0
Mixed 0 0 0 0 0
Unknown 0 0 0 0 0
ED
Domestic 114 1,067 1,104 1,151 1,538
Foreign 0 6 30 65 115
Mixed 0 0 0 0 0
Unknown 108 72 65 80 316
EPA
Domestic 32 39 37 20 44
Foreign 4 2 6 1 2
Mixed 0 0 0 0 0
Unknown 0 0 0 0 0
HHS
Domestic 24,176 23,173 22,303 23,633 23,539
Foreign 370 401 474 503 481
Mixed 654 854 1085 1,375 1,577
Unknown 75 1,272 1,306 1,001 1,054
HUD
Domestic 7 11 7 18 18
Foreign 0 0 0 0 0
Mixed 0 0 0 0 0
Unknown 0 0 0 0 0
NASA
Domestic 74 104 120 132 133
Foreign 0 0 1 1 1
Mixed 0 0 0 0 0
Unknown 9 0 0 0 2
† “Projects” include awards and individual studies. “Mixed” means  projects with both domestic and foreign 
components. “N/R” means that the data were not reported to the Commission. Departments/agencies that appear 
italicized reported that they were unable to provide complete data. See Appendix II for additional detail.
Table i.7 location of Human Subjects Projects over Time†
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dEPaRTmEnT/
agEncy 
locaTion Fy06 Fy07 Fy08 Fy09 Fy10
NSF
Domestic 1,820 2,271 2,626 2,984 3,049
Foreign 0 0 1 4 2
Mixed 0 0 0 0 0
Unknown 0 0 0 0 0
SSA
Domestic 15 18 17 14 13
Foreign 0 0 0 0 0
Mixed 0 0 0 0 0
Unknown 0 0 0 0 0
USAID
Domestic 26 28 20 15 14
Foreign 126 121 82 44 45
Mixed 7 8 4 1 3
Unknown 0 0 0 4 0
USDA
Domestic 111 118 193 198 258
Foreign 4 3 5 2 5
Mixed 1 1 17 1 4
Unknown 2 0 5 0 5
VA¶
Domestic 0 0 0 0 0
Foreign 0 0 0 0 0
Mixed 0 1 2 4 9
Unknown 16,763 16,730 16,704 16,379 15,406
All
Domestic 29,383 32,280 31,741 33,819 36,046
Foreign 721 924 984 888 931
Mixed 666 872 1115 1391 1624
Unknown 20,821 19,342 19,818 18,398 16,785 
Total 51,591 53,418 53,658 54,496 55,386
† “Projects” include awards and individual studies. “Mixed” means  projects with both domestic and foreign 
components. “N/R” means that the data were not reported to the Commission. Departments/agencies that appear 
italicized reported that they were unable to provide complete data. See Appendix II for additional detail.
¶ Although most VA research normally takes place in the United States, VA did not have data to assure the  
Commission that all of its research for which it did not specify a site country took place domestically. 
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Table i.8 location of HHS Human Subjects Projects over Time†
uniT locaTion Fy06 Fy07 Fy08 Fy09 Fy10
AHRQ
Domestic 668 634 598 655 893
Foreign 0 0 0 0 0
Mixed 0 0 0 0 0
Unknown 0 0 0 0 5
ASPR
Domestic 2 3 4 1 4
Foreign 2 0 0 2 0
Mixed 1 2 0 0 0
Unknown 3 3 6 1 8
CDC
Domestic 1,637 1,264 1,182 1,078 1,077
Foreign 85 104 177 235 220
Mixed 16 17 21 21 20
Unknown 1 2 0 0 0
CMS
Domestic 0 0 0 0 0
Foreign 0 0 0 0 0
Mixed 0 0 0 0 0
Unknown 0 0 0 0 0
FDA
Domestic 85 102 121 191 200
Foreign 2 1 1 1 0
Mixed 0 0 0 0 0
Unknown 3 0 0 0 0
HRSA
Domestic 45 50 50 43 35
Foreign 0 0 0 0 0
Mixed 2 1 0 0 0
Unknown 0 0 0 0 0
IHS
Domestic 254 277 238 239 251
Foreign 0 0 0 0 0
Mixed 0 0 0 0 0
Unknown 0 0 0 0 0
† “Projects” include awards and individual studies. “Mixed” means projects with both domestic and foreign 
components. See Appendix II for additional detail.
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uniT locaTion Fy06 Fy07 Fy08 Fy09 Fy10
NIH
Domestic 21,473 20,827 20,088 21,409 21,033
Foreign 281 296 296 265 261
Mixed 635 834 1,064 1,354 1,557
Unknown 7 1,253 1,261 1,000 1,040
NVPO
Domestic 0 0 0 0 0
Foreign 0 0 0 0 0
Mixed 0 0 0 0 0
Unknown 61 14 39 0 0
OAH‡
Domestic x x x x 30
Foreign x x x x 0
Mixed x x x x 0
Unknown x x x x 1
OPA
Domestic 12 16 22 17 16
Foreign 0 0 0 0 0
Mixed 0 0 0 0 0
Unknown 0 0 0 0 0
SAMHSA
Domestic 0 0 0 0 0
Foreign 0 0 0 0 0
Mixed 0 0 0 0 0
Unknown 0 0 0 0 0
All
Domestic 24,176 23,173 22,303 23,633 23,539
Foreign 370 401 474 503 481
Mixed 654 854 1,085 1,375 1,577
Unknown 75 1,272 1,306 1,001 1,054 
Total 25,275 25,700 25,168 26,512 26,651
† “Projects” include awards and individual studies. “Mixed” means projects with both domestic and foreign 
components. See Appendix II for additional detail.
‡ OAH was established in 2010. 
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Table i.9 Total Extramural award Funding (Human Subjects Projects) over Time (in $)†
dEPaRTmEnT/
agEncy 
Fy06 Fy07 Fy08 Fy09‡ Fy10‡
CIA§ N/R N/R N/R N/R N/R
CPSC 0 0 0 0 612,662
DHS¶ N/R 0 0 0 0
DOC 1,575,482 819,419 1,735,902 1,609,793 3,389,309
DOD 162,285 0 0 0 0
DOE 46,865,718 52,400,201 44,218,307 46,772,089 34,528,425
DOJ 51,306,495 57,291,788 33,820,452 63,808,343 113,365,616
DOT 5,268,756 20,410,017 3,304,967 14,373,087 4,125,572
ED 151,777,538 611,483,875 705,112,958 802,093,966 1,120,977,802
EPA 27,280,526 14,764,372 43,740,633 18,018,128 22,252,025
HHS 12,140,348,243 13,025,906,747 11,727,308,402 13,543,732,524 14,172,966,147
HUD 3,863,530 7,196,379 3,570,404 10,889,720 15,503,513
NASA 2,075,000 3,100,000 3,822,000 4,858,000 6,583,124
NSF 475,612,817 639,525,864 774,954,954 998,513,105 1,013,447,119
SSA 33,676,780 31,367,788 31,078,994 23,642,888 16,039,115
USAID 39,023,094 34,526,585 36,113,044 30,310,172 32,660,180
USDA 18,859,721 25,786,633 81,409,010 58,552,343 98,614,148
VA 0 0 0 0 0
Total 12,997,695,985 14,524,579,668 13,490,190,027 15,617,174,158 16,655,064,757
† The total, de-duplicated funding amount was calculated as described in the methods. “N/R” means that the data 
were not reported to the Commission. Departments/agencies that appear italicized reported that they were unable to 
provide complete extramural funding data. See Appendix II for additional detail.
‡ FY09 and FY10 funding includes American Recovery and Reinvestment Act (ARRA) funding.
§ The CIA did not submit project-level data to the Commission’s database because these data are confidential (although 
not classified).
¶ DHS reported that there “are no earlier data” than FY07.
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Table i.10 Total HHS Extramural award Funding (Human Subjects Projects)  
over Time (in $)†
uniT Fy06 Fy07 Fy08 Fy09‡ Fy10‡
AHRQ 103,132,977 85,009,499 84,190,585 108,927,568 501,164,798
ASPR 1,295,992,119 1,333,999,855 329,190,000 254,329,277 372,039,662
CDC 0 7,213,883 7,213,883 0 840,000
CMS 0 0 0 0 0
FDA 12,840,244 16,527,562 14,048,750 13,008,554 16,947,213
HRSA 24,066,586 28,774,579 28,678,683 25,630,790 24,879,696
IHS 1,935,769 1,794,339 1,906,226 2,384,267 3,055,331
NIH 10,684,023,688 11,547,265,574 11,251,479,555 13,136,308,827 13,206,860,106
NVPO 15,994,885 2,275,174 6,320,016 0 0
OAH§ x x x x 44,018,655
OPA 2,361,975 3,046,282 4,280,704 3,143,241 3,160,686
SAMHSA 0 0 0 0 0
Total 12,140,348,243 13,025,906,747 11,727,308,402 13,543,732,524 14,172,966,147
† The total, de-duplicated funding amount was calculated as described in the methods. Departments/agencies that 
appear italicized reported that they were unable to provide complete extramural funding data. See Appendix II for 
additional detail.
‡ FY09 and FY10 funding includes American Recovery and Reinvestment Act (ARRA) funding.
§ OAH was established in 2010.
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Table i.11 Top 20 (of 117) Human Subjects Project Site countries by number of 
Projects, Fy10†
SiTE counTRy uSaid cia‡ cPSc uSda doc dod Ed doE HHS
United States 17 N/R 1 262 23 6,858 1,538 349 25,121
Canada 2 22 1 3 86
Peru 1 69 4 1 14
Kenya 8 1 10 3 53
Egypt 61 3
South Africa 13 5 2 30
United Kingdom 2 14 3 28
Uganda 12 1 28
India 8 7 25
China 1 2 10 2 21
Thailand 12 1 1 16
Australia 1 8 15
Bangladesh 4 1 19
Brazil 3 3 16
Tanzania 4 1 5 8
Malawi 5 1 11
Indonesia 1 11 1
France 5 3 4
Mexico 1 1 1 4 3
Sweden 6 2 4
Foreign 1,557
Blank or N/A¶ 5 2 316 1,054
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dHS Hud doJ doT Va EPa naSa nSF SSa ToTal
10 18 215 56 9 44 133 3,049 13 37,716
1 2 117
1 90
75
64
1 51
1 48
41
40
36
1 31
24
24
1 1 24
1 19
17
13
12
2 12
12
1,557
15,406§ 2 16,785
† “Projects” include awards and individual studies. Departments/agencies that appear italicized reported that they 
were unable to provide complete extramural funding data. See Appendix II for additional detail 
‡ “N/R” means that the data were not reported to the Commission. The CIA did not submit project-level data to the 
Commission’s database because these data are confidential (although not classified), but the agency did advise the 
Commission that all of its human subjects research takes place in the United States.
§ Although most VA research normally takes place in the United States, VA did not have data to assure the Commission 
that all of its research for which it did not specify a site country took place domestically.
¶ “Blank” and “N/A” mean that the department/agency did not report a site country. See Appendix II for additional detail.
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Table i.12 Top 20 (of 68) Extramural awardee institution countries  
by number of Human Subjects Projects, Fy10†
inSTiTuTion counTRy ToTal
United States 29,142
Canada 94
United Kingdom 34
Australia 19
China 16
South Africa 15
Bangladesh 14
Germany 11
India 11
New Zealand 11
France 10
Netherlands 10
Switzerland 10
Brazil 9
Kenya 9
Sweden 9
Israel 8
Peru 8
Uganda 7
Thailand 6
Invalid, N/A, or Unknown‡ 607
† “Projects” include awards and individual studies. See Appendix II for additional detail. 
‡ “Invalid” means that text other than an institution name was entered in the “Institution 
name” column; “N/A” means that an institution name field was left blank; and “Unknown” 
means that the location of the awardee institution could not be determined with certainty, 
e.g., if an individual was listed as the awardee.
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Table i.13 location of unique Extramural (Human Subjects Projects) awardee 
institutions, Fy10†
locaTion ToTal
United States 2,867
Foreign 189
Invalid, N/A, or Unknown‡ 60
Total 3,116
† “Projects” include awards and individual studies. See Appendix II for additional detail. 
‡ “Invalid” means that text other than an institution name was entered in the “Institution name” column; “N/A” means 
that an institution name field was left blank; and “Unknown” means that the location of the awardee institution could 
not be determined with certainty, e.g., if an individual was listed as the awardee.
Table i.14 Proportion of Extramural Human Subjects Projects with Known award amounts†
dEPaRTmEnT/agEncy Fy06 Fy07 Fy08 Fy09 Fy10
CIA‡ N/R N/R N/R N/R N/R
CPSC — — — — 1.000
DHS§ N/R 0.000 0.000 0.000 0.000
DOC 1.000 1.000 1.000 1.000 1.000
DOD 0.001 0.000 0.000 0.000 0.000
DOE 1.000 1.000 1.000 1.000 1.000
DOJ 1.000 1.000 1.000 1.000 1.000
DOT 1.000 1.000 1.000 1.000 1.000
ED 0.468 0.789 0.791 0.776 0.585
EPA 1.000 1.000 1.000 1.000 1.000
HHS 0.986 0.988 0.985 0.984 0.986
HUD 1.000 1.000 1.000 1.000 1.000
NASA 1.000 0.867 1.000 0.957 1.000
NSF 1.000 1.000 1.000 1.000 1.000
SSA 1.000 1.000 1.000 1.000 1.000
USAID 1.000 1.000 1.000 1.000 1.000
USDA 1.000 1.000 1.000 1.000 1.000
VA — — — — —
Weighted Average 0.875 0.878 0.876 0.912 0.892
† “Extramural” includes projects conducted solely extramurally and projects with an extramural component; “Projects” 
include awards and individual studies; “Known” means “Total Award $” is not N/A, NULL, or an “invalid” $0, i.e., 
a $0 indicating that the Department/Agency cannot link funding and project data. “—” means that the proportion 
is undefined because the denominator is 0. “N/R” means that the data were not reported to the Commission. See 
Appendix II for additional detail.  
‡ The CIA did not submit project-level data to the Commission’s database because these data are confidential  
(although not classified).
§ DHS reported that there “are no earlier data” than FY07.
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Table i.15 Proportion of Human Subjects Projects with Known Site country†
dEPaRTmEnT/agEncy Fy06 Fy07 Fy08 Fy09 Fy10
CIA‡ N/R N/R N/R N/R N/R
CPSC 1.000 1.000 1.000 1.000 1.000
DHS§ N/R 1.000 1.000 1.000 1.000
DOC 1.000 1.000 1.000 1.000 1.000
DOD 0.407 0.807 0.748 0.851 1.000
DOE 1.000 1.000 1.000 1.000 1.000
DOJ 0.983 1.000 1.000 1.000 1.000
DOT 1.000 1.000 1.000 1.000 1.000
ED 0.514 0.937 0.946 0.938 0.840
EPA 1.000 1.000 1.000 1.000 1.000
HHS 0.997 0.951 0.948 0.962 0.960
HUD 1.000 1.000 1.000 1.000 1.000
NASA 0.892 1.000 1.000 1.000 0.985
NSF 1.000 1.000 1.000 1.000 1.000
SSA 1.000 1.000 1.000 1.000 1.000
USAID 1.000 1.000 1.000 0.938 1.000
USDA 0.983 1.000 0.977 1.000 0.982
VA 0.000 0.000 0.000 0.000 0.001
Weighted Average 0.596 0.638 0.631 0.662 0.697
† “Projects” include awards and individual studies; “Known” means the entry in the “Site Country” field is not N/A, 
NULL, or blank. Note that a response of “Foreign” is considered “Known” in this report. “N/R” means that the data 
were not reported to the Commission. See Appendix II for additional detail.
‡ The CIA did not submit project-level data to the Commission’s database because these data are confidential (although 
not classified).
§ DHS reported that there “are no earlier data” than FY07.
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Table i.16 Proportion of HHS Human Subjects Projects with Known Site country†
uniT Fy06 Fy07 Fy08 Fy09 Fy10
AHRQ 1.000 1.000 1.000 1.000 0.994
ASPR 0.625 0.625 0.400 0.750 0.333
CDC 0.999 0.999 1.000 1.000 1.000
FDA 0.967 1.000 1.000 1.000 1.000
HRSA 1.000 1.000 1.000 1.000 1.000
IHS 1.000 1.000 1.000 1.000 1.000
NIH 1.000 0.946 0.944 0.958 0.956
NVPO 0.000 0.000 0.000 — —
OAH‡ x x x x 0.968
OPA 1.000 1.000 1.000 1.000 1.000
Weighted Average 0.997 0.951 0.948 0.962 0.960
† “Projects” include awards and individual studies; “Known” means the entry in the “Site Country” field is not N/A, 
NULL, or blank. Note that a response of “Foreign” is considered “Known” in this report. “—” means that the 
proportion is undefined because the denominator is 0. See Appendix II for additional detail.
‡ OAH was established in 2010. 
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Table i.17 Proportion of Human Subjects Projects with Known Subject count†
dEPaRTmEnT/agEncy Fy06 Fy07 Fy08 Fy09 Fy10
CIA‡ N/R N/R N/R N/R N/R
CPSC 1.000 1.000 1.000 1.000 1.000
DHS§ N/R 0.000 0.000 0.000 0.000
DOC 0.857 0.846 0.853 0.852 0.870
DOD 0.000 0.001 0.005 0.005 0.005
DOE 0.867 0.905 0.908 0.914 0.950
DOJ 0.125 0.161 0.291 0.164 0.097
DOT 0.577 0.346 0.429 0.404 0.411
ED 0.000 0.000 0.000 0.000 0.000
EPA 0.167 0.220 0.256 0.143 0.000
HHS 0.073 0.075 0.083 0.084 0.085
HUD 0.000 0.000 0.000 0.000 0.000
NASA 0.108 0.144 0.215 0.203 0.787
NSF 0.000 0.000 0.000 0.000 0.000
SSA 1.000 1.000 1.000 1.000 1.000
USAID 0.126 0.121 0.179 0.375 0.403
USDA 0.525 0.492 0.350 0.398 0.706
VA 0.000 0.000 0.000 0.000 0.000
Weighted Average 0.046 0.046 0.050 0.051 0.055
† “Projects” include awards and individual studies; “Known” means the entry in the “# Participants” field is not N/A, 
NULL, or blank. “N/R” means that the data were not reported to the Commission. See Appendix II for additional detail.
‡ The CIA did not submit project-level data to the Commission’s database because these data are confidential (although 
not classified).
§ DHS reported that there “are no earlier data” than FY07.
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Table i.18 Proportion of Human Subjects Projects with Known Exempt/ 
non-exempt Status†
dEPaRTmEnT/agEncy Fy06 Fy07 Fy08 Fy09 Fy10
CIA‡ N/R N/R N/R N/R N/R
CPSC 0.000 0.000 0.000 0.000 0.000
DHS§ N/R 1.000 1.000 1.000 1.000
DOC 1.000 1.000 1.000 1.000 1.000
DOD 0.666 0.878 0.901 0.854 0.839
DOE 1.000 1.000 1.000 1.000 1.000
DOJ 0.467 0.432 0.512 0.414 0.472
DOT 0.385 0.269 0.200 0.277 0.268
ED 0.910 0.130 0.158 0.164 0.396
EPA 1.000 1.000 1.000 1.000 1.000
HHS 0.033 0.035 0.035 0.036 0.041
HUD 0.714 0.909 0.857 0.944 0.722
NASA 1.000 1.000 1.000 1.000 1.000
NSF 1.000 1.000 1.000 1.000 1.000
SSA 1.000 0.444 1.000 1.000 1.000
USAID 0.000 0.000 0.000 0.000 0.000
USDA 0.873 0.893 0.959 0.980 0.801
VA 0.000 0.000 0.000 0.000 0.000
Weighted Average 0.154 0.184 0.201 0.190 0.213
† “Projects” include awards and individual studies; “Known” means the entry in the “Exempt or Non-Exempt” field 
is not N/A, NULL, or blank. “N/R” means that the data were not reported to the Commission. See Appendix II for 
additional detail.
‡ The CIA did not submit project-level data to the Commission’s database because these data are confidential  
(although not classified).
§ DHS reported that there “are no earlier data” than FY07.
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Table i.19 Proportion of Human Subjects Projects with Known number of Sites†
dEPaRTmEnT/agEncy Fy06 Fy07 Fy08 Fy09 Fy10
CIA‡ N/R N/R N/R N/R N/R
CPSC 1.000 1.000 1.000 1.000 0.000
DHS§ N/R 0.000 0.000 0.000 0.000
DOC 1.000 0.923 0.941 0.926 1.000
DOD 0.000 0.012 0.008 0.028 0.006
DOE 0.998 0.997 0.997 0.997 1.000
DOJ 0.200 0.203 0.337 0.214 0.241
DOT 0.500 0.308 0.371 0.404 0.482
ED 0.000 0.000 0.000 0.000 0.000
EPA 0.472 0.512 0.907 0.429 0.217
HHS 0.001 0.001 0.000 0.000 0.001
HUD 0.000 0.000 0.000 0.000 0.000
NASA 0.892 1.000 0.909 0.872 0.985
NSF 0.000 0.000 0.000 0.000 0.000
SSA 0.933 0.944 1.000 1.000 1.000
USAID 0.547 0.688 0.755 0.875 0.403
USDA 0.864 0.877 0.832 0.846 0.816
VA 0.000 0.000 0.000 0.000 0.000
Weighted Average 0.015 0.017 0.017 0.018 0.017
† “Projects” include awards and individual studies; “Known” means the entry in the “# Sites [per country]” field is not N/A, 
NULL, or blank. “N/R” means that the data were not reported to the Commission. See Appendix II for additional detail.
‡ The CIA did not submit project-level data to the Commission’s database because these data are confidential  
(although not classified).
§ DHS reported that there “are no earlier data” than FY07.
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Appendix II: Human Subjects Research Landscape Project Methods
In order to respond to President Obama’s charge, the Commission recognized 
that a critical first step would be to define and understand the landscape 
of “scientific studies supported by the federal Government.” finding no 
comprehensive publicly available source for this information, the Commis-
sion asked the 18 federal departments and agencies that have adopted the 
Common Rule—and therefore were likely to support scientific studies with 
human subjects—to provide basic project-level data for department/agency-
supported human subjects research in fiscal year 2006 to fiscal year 2010. 
These agencies are listed in table I.11 and an overview of the Human Subjects 
Research Landscape Project is displayed in figure II.1. 
Commission Chair, Dr. Amy Gutmann, wrote to department/agencies 
regarding this request in early spring 2011. An example of the letter is 
provided in figure II.2. As necessary, Commission staff clarified the data 
request with contacts at departments/agencies. The Commission asked depart-
ments/agencies to provide only data they maintained and that was readily 
available so that the Commission could respond to President Obama’s charge 
in a timely manner. A summary of responsive data received is included in 
table II.1.
Database and Electronic Data Collection Tools
The Commission engaged a contractor, SRA International, Inc. (SRA), to 
develop 1) an electronic data collection tool to assist departments/agencies 
in gathering data, 2) a website through which department/agencies could 
submit data (www.bioethics-rpd.net), and 3) a database in which to store 
these data, called the “Research Project Database” (RPD). The Commission, 
through SRA, also established a Help Desk to provide technical assistance to 
departments/agencies.
The Commission provided departments/agencies with the option to collect 
their data either in Microsoft Excel or XML format, and provided templates 
and instructions for each. (The data fields and instructions are listed in table 
II.2.) These data collection tools were equipped with built-in data validations 
so that departments/agencies could pre-screen their data prior to upload to 
the RPD. 
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Registered department/agency users could access the password-protected RPD 
website to upload, delete, or review submitted data. Department/agency users 
uploaded data in a separate file for each fiscal year. The system validated all 
data fields upon upload, for example, to confirm that each “Study ID” (i.e., 
unique study identification number) was unique in a single fiscal year (and, 
therefore, that each study was listed only once per year). If data fields were 
found to have errors, the system provided the department/agency with an 
automated report explaining the errors encountered during the data valida-
tion along with a request to resubmit the data. If a department/agency did not 
enter “Site Data” (i.e., site country, number of sites per country, and number 
of participants per country) or “Other federal funding Data” (i.e., source of 
other federal funding and other federal funder identifier, such as an award 
number), the system displayed “warnings” asking the department/agency 
to either add these data, or to confirm that these data were not maintained 
or readily available. The department/agency could then add these data and 
resubmit, or confirm that these data were not maintained or readily available 
to bypass the warnings and submit the file as-is. 
If a department/agency supported no human subjects research in a given fiscal 
year, Commission staff asked for written confirmation of that fact.2
uploaded data were stored in an SRA-hosted SQL Server database. The orig-
inal uploaded Excel and XML documents were also stored and retained on 
an SRA server. following the data collection period, SRA exported the entire 
data set from the RPD into three “comma separated values” (.csv) files. The 
export process and naming conventions are detailed in table II.3. Data were 
organized in three separate tables: (i) “study records” that provides project-
level data; (ii) “site records” that captures Site Data; and (iii) “other federal 
funding records” that captures Other federal funding Data. A unique ID 
field common to all three tables allowed for linkage among them. 
In the Human Subjects Research Landscape Project, the term “project” refers 
to a single line of data entered by a department/agency, whereas “study” 
refers to an individual human subjects research protocol or activity; and 
“award” refers to an extramural award, such as a grant or contract, which 
may fund more than one “study.” The Commission defined “project” broadly 
in order to accommodate different department/agency record-keeping 
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systems. Although study-level data were preferred, some departments and 
agencies provided award-level data for extramural human subjects research. 
Additional definitions are listed in table II.2.
Data Cleaning
Generally, if department/agency data passed the system’s validations, the 
Commission accepted these submissions as-is. Nonetheless, minimal data 
cleaning was performed to facilitate analyses, which is detailed below.
In the SQL database, SRA performed one cleaning task:
•	 Incorrect “unit” names. Departments/agencies could specify individual 
“units” for data submission. for example, NASA submitted data for four 
units: Ames Research Center, Johnson Space Center, Kennedy Space Center, 
and Langley Research Center. In total, six submitted files incorrectly omitted 
a unit designation. SRA corrected these unit names in the SQL database.
Prior to initial analysis of the data, consultant statisticians, Norman P. Ross, 
M.S., Ph.D. and Philip Kalina, M.A., ran a number of checks on the data 
tables, including making sure that:
•	 All variables were in columns and observation records were in rows;
•	 There was one unique id for each project record; and
•	 All missing data had been identified and the appropriate code had been 
inserted in missing data cells.
Once the data were screened and checked, statisticians performed a compre-
hensive data cleaning process on the analytical database to remove anomalies 
that could be detected through statistical screening; for example, looking for 
missing values and contradictions within or between records, duplicates, and 
outliers. Before final analysis, the data were further cleaned as follows: 
•	 Projects removed from the analysis dataset. Some departments/agencies 
noted in the “Other Comments” field that they were unable to delete or 
remove records from their data submissions. Based on a manual review of 
these comments, a small number of awards (eight) were moved out of the 
analysis dataset. 
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•	 Addition of data submitted af ter close of the database. HHS-ASPR 
supplemented its data submission after the database was closed. So that all 
data submitted to the Commission were accounted for in its analysis, these 
data were added to the SQL database and provided as a supplemental export 
to the statisticians to incorporate into the analysis dataset. In addition, one 
agency (Agricultural Research Service [uSDA-ARS]) inadvertently uploaded 
the same fy06 file for two different units. When brought to its attention, 
uSDA-ARS deleted the duplicate file and submitted corrected data after 
the database closed. These data were provided as a supplemental export to 
the consultant statisticians to incorporate into the analysis dataset. finally, 
although DOD submitted aggregate data before the database closed, it 
submitted project-level data to the database after it was closed. These data 
also were provided as a supplemental export to the consultant statisticians to 
incorporate into the analysis set. 
•	 Units combined. In the interest of simplifying and presenting data, some 
units were combined before analysis. The specific changes were:
•	 Within uSDA, all units starting with “ARS” were combined into one 
unit, Agricultural Research Service.
•	 Within HHS, all units starting with “IHS” were combined into one 
unit, Indian Health Service.
•	 Within HHS, all units starting with “National Institutes of Health” 
were combined into one unit, National Institutes of Health. NIH data 
were submitted in several parts due to limitations on the number of 
rows of data that could be entered into the Excel template. Because these 
divisions were arbitrary and not reflective of actual functional operating 
units, they were combined.
•	 Within DOJ, all units starting with “OJP” were combined into one unit, 
Office of Justice Programs.
•	 Within VA, all units were ignored. Like NIH, VA submitted its data 
in several parts due to limitations on the number of rows of data that 
could be entered into the Excel template. Because these divisions were 
arbitrary and not reflective of actual functional operating units, they 
were combined.
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•	 Within DOD, all units were ignored under the same reasoning.
•	 Study classification. Where not apparent from department/agency data 
submissions, Commission staff asked for clarification about whether the 
submitted data were award level (i.e., each line of data corresponded an 
award) or study level (i.e., each line of data submitted corresponded to a 
single study). An additional column, “Study or Award Level,” was added 
to the analysis dataset. Valid entries for this column were A (Award), S 
(Study), Q (Equivalent, where one award always supports a single study), u 
(unclassifiable), and I (Intramural). 
•	 Site country data. A few departments/agencies were able to state that 
all projects for which no country data were submitted took place in the 
united States.3 These records were updated, and blanks were replaced with 
“united States.”
•	 Awardee institution names. Departments/agencies submitted “Award 
Institution” names in a variety of formats (e.g., with differences in 
abbreviations, misspellings, etc.). Commission staff conducted a manual 
review of institution names and corrected obvious typographical errors and 
standardized institution names.
•	 Awardee institution countries. Awardee institution countries were manually 
added to the analysis dataset based on publicly available sources. If the 
awardee institution country could not be determined with certainty, 
the country was assigned a value of “unknown.” If a value other than 
an institution name was found in the “Award Institution” field (e.g., a 
department/agency mistakenly entered an abstract in this column), the 
country was assigned a value of “Invalid.” If “N/A” had been entered in the 
institution name column, the country was assigned a value of “N/A.”
•	 Total extramural award amount. “N/A” was not an accepted response 
in the “total Award $ in fy” field. Because some department/agencies 
indicated that, although they entered “0” in the total Award field, these 
data, in fact, were not available,4 a new column, titled ExtraAwardfundVal0 
(i.e., indicating whether “0” in the total Award field was a “valid” 0 or an 
indication that data was not available) was added to the analysis dataset, 
where acceptable values were y (yes), N (No), and u (unknown).
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•	 Extramural/intramural/both indication clarification. NSf initially classified 
all projects as “both” in the “Intramural or Extramural” field (i.e., with 
both intramural and extramural components), but later clarified that all 
reported projects are extramural. This change was made accordingly in 
the analysis dataset.5
•	 Duplicate awards. Instances appeared in the database where, for a given fiscal 
year, a department/agency submitted lines of study-level data with identical 
award IDs and total award amounts. This is not necessarily indicative of an 
error, as a single award can fund multiple studies. Commission staff checked 
the affected awards in a publicly available database, uSASpending.gov. If the 
award amount in the RPD matched the award amount in uSASpending.gov, 
it was assumed that the award amount in the database did indeed reflect the 
total award amount and should not inadvertently be counted twice when 
making overall funding calculations. Because of these concerns, extramural 
funding tabulations were run in two ways: (i) by adding all total award 
amounts; and (ii) by adding all total award amounts except those identified 
as duplicates through the above process. 
following these cleaning processes, a final dataset was ready for analysis, tabu-
lation, and statistical report generation. 
Data Analysis
following completeness and accuracy checks, the .csv files were read into 
a Microsoft Access database for analysis. The tables produced (included in 
Chapter 2 and Appendix I to this report) are based on descriptive tabulations 
and computations of relevant summary data. The descriptive summaries and 
tabulations presented provide a broad “landscape” view of the human subjects 
research activities being undertaken by participating departments/agencies 
both in the united States and in other countries. tabulations were provided 
for fiscal year 2006 to fiscal year 2010 for all departments/agencies that 
provided data. 
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Empirical Advisory Group
The Commission convened the Empirical Advisory Group (EAG) to assist the 
Commission with its empirical work, comprised of two Commission members 
and six outside experts in bioethics, statistics, clinical trials, and qualita-
tive research (listed in table II.4). The EAG met on multiple occasions to 
discuss the Human Subjects Research Landscape Project and other empirical 
approaches that might be used to inform the Commission’s response to the 
President’s charge. The EAG advised the Commission concerning analysis 
and interpretation of the Human Subjects Research Landscape Project data.
Limitations
the Human Subjects Research Landscape Project provides information 
that characterizes human subjects research projects supported by the federal 
government. While these data are extensive, they must be interpreted with 
some limitations in mind. These limitations include: 
The information was reported by departments/agencies and was not inde-
pendently audited or verified. As such the completeness of reporting cannot 
be verified.6 
Each department/agency determined what constituted “relevant” work, which 
may have contributed to reporting bias as well as difficulty in comparing 
data across departments/agencies. The Commission asked departments/agen-
cies to report all human subjects research projects, but definitions of “human 
subjects research” can vary across departments/agencies.7 
Not all departments/agencies provided all of the information requested. 
Accordingly, there may be distorted estimates of some summary statistics 
(e.g., total number of studies, funding/award information), further compli-
cating making meaningful comparison within and between departments/
agencies as well as comparisons over time. In addition, NIH provided two 
sets of intramural data retrieved from two different databases (IMPACII 
and Protrak), which have overlaps. Without looking through both sets of 
data individually, NIH could not be sure of the extent of the overlap or elim-
inate overlaps.8 Thus, NIH intramural projects may thus be over-reported in 
these analyses. 
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A single extramural award can fund multiple studies. Thus, a department/
agency’s total extramural funding, calculated by summing relevant “total 
Award $” fields, is likely an overestimate to the extent that the award funding 
reported may fund more projects than the single project listed.9 Moreover, 
because some departments/agencies submitted award-level data and others 
submitted project-level data, the number of “projects” reported in the data-
base is likely an underestimate of the total number of human subjects studies 
supported by the government because some projects may correspond to 
awards that fund more than one study.
The Human Subjects Research Landscape Project does not provide a robust 
understanding of research that was not reported because it is classified or because 
of national security concerns.10 
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1 Because HHS is the largest government supporter of human subjects research, the Human 
Subjects Research Landscape Project results are often presented in more detail for HHS 
Operating Divisions. table I.1 also lists the HHS Operating Divisions that responded to the 
Commission’s data request.
2 E-mail Correspondence: Theron Pride, DOJ, to Michelle Groman, PCSBI. (2011, August 2 
and 2011, September 13); Phillip Smith, IHS, to Michelle Groman. (2011, September 20); 
Lori Putman, DOt, to Michelle Groman, PCSBI. (2011, October 17); Mark Grabowsky, 
NVPO, to Michelle Groman, PCSBI. (2011, October 3); Jeffery Rodamar, ED, to Michelle 
Groman, PCSBI. (2011, September 6); Richard Legault, DHS, to Michelle Groman, PCSBI. 
(2011, September 15); Mala Adiga, DOJ, to Michelle Groman, PCSBI. (2011, August 9; 
2011, September 7, 2011; and 2011, September 12); MJ fiocco, DOt, to Michelle Groman, 
PCSBI. (2011, August 26); Krista fletcher, SAMHSA, to Michelle Groman, PCSBI. (2011, 
August 2); Amy farb, OAH, to Michelle Groman, PCSBI. (2011, August 5); Memorandum 
from Jacquelyn White, CMS, to Dawn Smalls, CMS, Request from the Presidential 
Commission for the Study of Bioethical Issues for Information on Human Subjects Scientific 
Research OS#071220111044, July 26, 2011.
3 E-mail Correspondence: Valerie Bonham, PCSBI, to Kevin Neary, HuD. (2011, October 
7); Alan trachtenberg, IHS, to Michelle Groman, PCSBI. (2011, September 28); Barbara 
DeCausey, CDC, to Michelle Groman, PCSBI. (2011, October 14). Preeti Kanodia, 
HRSA, to Michelle Groman, PCSBI (2011, November 8). NIH explained that for awards 
to domestic institutions, it reported “united States” in the site country field; for awards to 
foreign institutions, it reported the name of the awardee country in the site country field; and 
for awards to domestic institutions that have a foreign component; it reported “united States” 
and “foreign” in the site country field. Sarah Carr, NIH, to Michelle Groman, PCSBI. 
(2011, October 5). E-mail Correspondence. Thus, NIH projects understood as “foreign” 
(as opposed to “mixed,” or with foreign and domestic components) represent direct awards 
to foreign institutions. Where a project reported no Site Data, a placeholder site record was 
created with blank values for country, sites, and participants. In addition, duplicate site 
records were removed from the analysis dataset; a small number of almost-exact duplicates 
were removed upon agency confirmation. francis Chesley, AHRQ, to Michelle Groman, 
PCSBI. (2011, November 2). E-mail Correspondence.
4 Some departments/agencies and units indicated that they could not link some or all protocol-
level data with extramural funding data. Letter from Richard Legault, DHS, to Valerie 
Bonham, PCSBI. (September 29, 2011). E-mail Correspondence: Michelle Groman, PCSBI, 
to Patty Decot, DOD. (2011, October 27); Jeffery Rodamar, ED, to Michelle Groman, 
PCSBI. (2011, September 6); Rhondalyn Cox, fDA, to Michelle Groman, PCSBI. (2011, 
August 5 and 2011, October 14); Barbara DeCausey, CDC, to Michelle Groman, PCSBI. 
(2011, October 13); Jeffrey Hill, NASA, PCSBI. (2011, August 2).
5 Michelle Groman, PCSBI, to Myron Gutmann, NSf. (2011, October 24). E-mail 
Correspondence.
6 for example, it cannot be stated with certainty that if the same project was reported in several 
fiscal years that the award amount, number of participants, etc., listed in each fiscal year data 
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set was the amount/number specific to that fiscal year or if the totals were repeated year after 
year. Similarly, for awards where ARRA funding was indicated, it is unclear whether the 
reported award amount is entirely or partially ARRA funded.
7 Other terms may be defined differently by different agencies as well, such as “extramural” 
and “intramural.”
8 Sarah Carr, NIH, to Valerie Bonham, PCSBI. (2011, October 5). E-mail Correspondence.
9 total extramural funding was calculated by summing relevant “total Award $” fields rather 
than relevant “total Extramural Study $” fields because the mean response rate for this latter 
variable was less than 17 percent.
10 for example, the CIA did not submit project-level data to the RPD because “the application 
by the C.I.A. of certain research results may implicate intelligence sources and methods, 
and thus cannot be discussed in the public domain.” Letter from V. Sue Bromley, Associate 
Deputy Director, Central Intelligence Agency to Amy Gutmann, Ph.D., Chair, Presidential 
Commission for the Study of Bioethical Issues. (November 15, 2011). The CIA confirmed 
that all CIA-sponsored human subjects research is conducted in the united States – not 
abroad.  CIA personnel also met with Commission staff to discuss the CIA’s human subjects 
research portfolio and made records available to appropriately cleared Commission staff. In 
addition, the Department of Energy provided de-identified data about three human terrain 
mapping projects that have not been accounted for in the RPD.
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Figure ii.2 Sample letter from dr. amy gutmann to department/agency liaison
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Table ii.1 Responsive data Received†
dEPaRTmEnT/
agEncy
uniT daTa SubmiTTEd To RPd
Fy06 Fy07 Fy08 Fy09 Fy10
Agency for 
International 
Development
Y Y Y Y Y
Central Intelligence 
Agency
  N N N N N
Consumer Product 
Safety Commission
  Y Y Y Y Y
Department of 
Agriculture
Agricultural Research Service Y Y Y Y Y
Economic Research Service Y Y Y Y Y
National Institute of Food and Agriculture Y Y Y Y Y
Department of 
Commerce
  Y Y Y Y Y
Department of 
Defense
  Y Y Y Y Y
Department of 
Education
Institute for Educational Sciences Y Y Y Y Y
Office for English Language Education N-None N-None N-None N-None N-None
Office for Elementary and Secondary Education N N N N Y
Office for Innovation and Improvement N N N N Y
Office for Postsecondary Education  
(including Fulbright-Hays fellowships)
Y Y Y Y Y
Office of Planning, Evaluation &  
Policy Development
N N N N Y
Office of Safe and Drug Free Schools N N N N Y
Office for Special Education and Rehabilitative 
Services (including National Institute for 
Disability and Rehabilitation Research)
N Y Y Y Y
Office for Vocational and Adult Education N N N N N
Department of 
Energy
  Y Y Y Y Y
† “Y” indicates that the department/agency or unit submitted data to the RPD for the given fiscal year. “N-None” 
indicates that the department/agency or unit informed the Commission that it did not support human subjects research 
in the given fiscal year. “N” indicates that the department/agency or unit did not submit data to the RPD for the given 
fiscal year. The CIA did not submit project-level data to the Commission’s database because these data are confidential 
(although not classified). Letter from V. Sue Bromley, Associate Deputy Director, CIA to Amy Gutmann, Ph.D., Chair, 
PCSBI. (November 15, 2011). ED did not upload data as summarized here, but also reported that “OESE, OII, OPEPD and 
OVAE have very few studies that fall under the Common Rule.” Jeffery Rodamar, ED, to Michelle Groman, PCSBI. (2011, 
September 14). E-mail Correspondence. DHS reported that it had “no earlier data” than FY07. Richard Legault, DHS, to 
Michelle Groman, PCSBI. (2011, September 15). E-mail Correspondence.
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dEPaRTmEnT/
agEncy
uniT daTa SubmiTTEd To RPd
Fy06 Fy07 Fy08 Fy09 Fy10
Department of 
Health and Human 
Services
Agency for Healthcare Research and Quality Y Y Y Y Y
Assistant Secretary for Preparedness and 
Response
Y Y Y Y Y
Centers for Disease Control and Prevention Y Y Y Y Y
Centers for Medicare and Medicaid Services N-None N-None N-None N-None N-None
Food and Drug Administration Y Y Y Y Y
Health Resources and Services Administration Y Y Y Y Y
Indian Health Service‡ Y Y Y Y Y
National Institutes of Health Y Y Y Y Y
OASH National Vaccine Program Office Y Y Y N-None N-None
Office of Adolescent Health§ N-None N-None N-None N-None Y
Office of Population Affairs Y Y Y Y Y
Substance Abuse & Mental Health Services 
Administration
N-None N-None N-None N-None N-None
Department of 
Homeland Security
N Y Y Y Y
Department of 
Housing and Urban 
Development
Office of Healthy Homes & Lead Hazard Control Y Y Y Y Y
Office of Policy Development and Research Y Y Y Y Y
Department of 
Justice
Bureau of Prisons Y Y Y Y Y
Federal Bureau of Investigation Y Y Y Y Y
Office of Community Oriented Policing Services N-None N-None N-None N-None N-None
Office of Justice Programs¶ Y Y Y Y Y
Office on Violence Against Women N-None N-None N-None N-None N-None
‡ Within IHS, the Billings Area Office did not support human subjects research in FY09.
§ Because it is a “new” office, OAH did not have FY06-FY09 data to report. Amy Farb, OAH, to Michelle Groman, 
PCSBI. (2011, August 5). E-mail Correspondence. OAH. About the Office of Adolescent Health. Retrieved from 
http://www.hhs.gov/ash/oah/about-us/ (last accessed December 8, 2011) (“OAH was established through the 
Consolidated Appropriations Act of 2010, within the Office of the Assistant Secretary for Health.”).
¶ Within OJP, the Bureau of Justice Assistance did not support human subjects research in FY07, FY08, or FY10  
and the Office of Victims of Crime did not support human subjects research in FY06.
continued
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Table ii.1 Responsive data Received†
dEPaRTmEnT/
agEncy
uniT daTa SubmiTTEd To RPd
Fy06 Fy07 Fy08 Fy09 Fy10
Department of 
Transportation
Federal Aviation Administration Y Y Y Y Y
Federal Highway Administration Y Y Y Y Y
Federal Motor Carrier Safety Administration N-None Y Y Y Y
Federal Railroad Administration Y Y Y Y Y
Maritime Administration N-None N-None N-None N-None N-None
National Highway Traffic Safety Administration†† Y Y Y Y Y
Research and Innovative Technology 
Administration
Y N-None Y Y Y
Department of 
Veterans Affairs
Y Y Y Y Y
Environmental 
Protection Agency
Y Y Y Y Y
National 
Aeronautics 
and Space 
Administration
Ames Research Center Y Y Y Y Y
Johnson Space Center Y Y Y Y Y
Kennedy Space Center Y Y Y Y Y
Langley Research Center Y Y Y Y Y
National Science 
Foundation
Y Y Y Y Y
Social Security 
Administration
Y Y Y Y Y
† “Y” indicates that the department/agency or unit submitted data to the RPD for the given fiscal year. “N-None” 
indicates that the department/agency or unit informed the Commission that it did not support human subjects 
research in the given fiscal year. “N” indicates that the department/agency or unit did not submit data to the RPD for 
the given fiscal year. The CIA did not submit project-level data to the Commission’s database because these data are 
confidential (although not classified). Letter from V. Sue Bromley, Associate Deputy Director, CIA to Amy Gutmann, 
Ph.D., Chair, PCSBI. (November 15, 2011). ED did not upload data as summarized here, but also reported that “OESE, 
OII, OPEPD and OVAE have very few studies that fall under the Common Rule.” Jeffery Rodamar, ED, to Michelle 
Groman, PCSBI. (2011, September 14). E-mail Correspondence. DHS reported that it had “no earlier data” than FY07. 
Richard Legault, DHS, to Michelle Groman, PCSBI. (2011, September 15). E-mail Correspondence.
†† NHTSA data for FY06-FY09 does not include information about safety-related studies involving human  
subjects. Lori Putnam, DOT, to Michelle Groman, PCSBI. (2011, December 1). E-mail Correspondence.
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Table ii.2 data Fields and instructions
FiEld inSTRucTionS
1. Study ID# Enter a unique study identification number such as IRB or institute protocol number, IND number, 
or other unique identifier assigned by the Department/Agency. Note that award number is 
acceptable here but, because it is requested separately, an alternative identifier is preferred. NCT 
number is also acceptable here but, if available, should be provided in the “NCT#” field as well.
2. NCT#  
[N/A is option]
Enter NCT number, if available. For trials entered in ClinicalTrials.gov, ClinicalTrials.gov 
assigns a unique NCT identifier of the form NCTxxxxxxxx where each x is a numeric digit. 
Enter N/A if the Department/Agency does not maintain this data, or it is not readily available.
3. Title of Study Enter the title of the study, as maintained by the Department/Agency. “Title of Study” is 
intended to be as specific as possible, with protocol title preferred. Award title may be 
substituted for protocol title when necessary. It is understood that an award may support 
more than one protocol.
4. Abstract  
[N/A is option]
Enter the study or award abstract if it is readily available. Enter N/A if the Department/
Agency does not maintain this data, or it is not readily available.
5. PI(s) Enter the name or names of the study’s principal investigator(s). Names may be provided 
in any format, and can be separated by a “,” or “;”.
6. Year X of Y  
[N/A is option]
Enter the duration of the study, for example, “Year 2 of 4.” “X” should be entered in 
reference to the fiscal year for which the Department/Agency is reporting. That means, 
for example, that a study reported in FY06 as “Year 2 of 4,” would be reported in FY07 as 
“Year 3 of 4.” Enter N/A if the Department/Agency does not maintain this data, or it is not 
readily available. If the full duration of the study is unknown, enter N/A for “Y.”
7. Exempt or Non-Exempt  
[Ex/N]  
[N/A is option]
Enter Ex if the study is human subjects research “exempt” from 45 CFR 46 or applicable 
agency regulations. Enter N if the study is non-”exempt.” Enter N/A if the Department/
Agency does not maintain this data, or it is not readily available.
8. Total # Sites  
[N/A is option]
Enter the total number of locations where the study is being conducted, which may not 
correspond to where the approving IRB is located. Enter N/A if the Department/Agency 
does not maintain this data, or it is not readily available. 
9. Site Country  
[N/A is option]
Enter all countries in which the study is being conducted. Enter each country in a separate row. 
Enter N/A if the Department/Agency does not maintain this data, or it is not readily available. 
10. # Sites  
[Per Country]  
[N/A is option]
Enter the total number of locations where the study is being conducted in the listed 
country. Enter N/A if the Department/Agency does not maintain this data, or it is not 
readily available. 
11. # Participants  
[Per Country]  
[N/A is option]
Enter the total number of participants in the listed country in the relevant fiscal year. There 
is no need to list participants for each site within the country separately. Enter N/A if the 
Department/Agency does not maintain this data, or it is not readily available. 
12. ARRA Funded by 
Reporting Entity?  
[Y/N]
Enter Y if Department/Agency funding (if any) for the study is from American Recovery 
and Reinvestment Act (ARRA) funds. Enter N if Department/Agency funding (if any) for the 
study is not from American Recovery and Reinvestment Act (ARRA) funds.
13. Other Fed Funding?  
[Y/N]  
[N/A is option]
Enter Y if this study was funded in the reported fiscal year by another federal funder, in 
whole or in part. Enter N if this study was not funded in the reported fiscal year by another 
federal funder, in whole or in part. Enter N/A if the Department/Agency does not maintain 
this data, or it is not readily available.
14. Source of Other Fed 
Funding?
If this study was funded in the reported fiscal year by another federal funder, in whole or in 
part, select the Department/Agency that is the source of that federal funding. If more than 
one, enter each Department/Agency that is the source of other federal funding in a separate 
row. Select “Other” if the Department/Agency that is the source of other federal funding is 
not listed in the drop-down menu and, if known, enter its name in the “Other Comments” field. 
If this study was not funded in the reported fiscal year by another federal funder, in whole 
or in part, leave blank.
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FiEld inSTRucTionS
15. Other Fed Funder 
Identifier 
[N/A is option]
If this study was funded in the reported fiscal year by another federal funder, in whole or in 
part, enter a study identification number assigned to the study by the Department/Agency 
that is the source of other federal funding, such as award number or IRB protocol number, 
if known and readily available. Enter N/A if not known or readily available.
If this study was not funded in the reported fiscal year by another federal funder, in whole 
or in part, leave blank.
16. Other Non-Fed 
Funding?  
[Y/N]  
[N/A is option]
Enter Y if this study was funded in the reported fiscal year by another non-federal funder, in  
whole or in part. A non-federal funder could be, for example: foreign, state, or local governments  
or university, industry, non-profit, or philanthropic organizations. Enter N if this study was not 
funded in the reported fiscal year by another non-federal funder, in whole or in part. Enter N/A 
if the Department/Agency does not maintain this data, or it is not readily available.
17. Intramural or 
Extramural  
[I/E/B]
Enter I if the study is considered intramural by the Department/Agency. Enter E if the 
study is considered extramural by the Department/Agency. “Intramural,” generally, means 
internal agency research programs. “Extramural,” generally, means research supported 
by the Department/Agency through grant, cooperative agreement, contract, interagency 
agreement of any type, and “other transaction authority,” e.g., 10 U.S.C. 2371 (DOD). For 
studies funded with both intramural and extramural monies, enter B.
18. Total Intramural 
Study $ in FY from 
Reporting Entity  
[N/A is option]
If intramural, enter the Department/Agency’s intramural funding of the study in the 
reported fiscal year. Do not include funding from other federal or non-federal sources. 
This may be “0.” If the Department/Agency does not track total study funding by project, 
aggregate amounts by fiscal year are acceptable, e.g., laboratory or program. Please 
provide an explanation in the “Other Comments” field. Enter N/A if the Department/Agency 
does not maintain this data, or it is not readily available.
If extramural, leave blank.
19. Award ID# If extramural, enter unique identification number assigned to the award by the 
Department/Agency. “Award” means grant, cooperative agreement, contract, interagency 
agreement of any type, and “other transaction authority,” e.g., 10 U.S.C. 2371 (DOD).
If intramural, leave blank.
20. Award Institution If extramural, enter the name of the institution receiving the award.
If intramural, leave blank.
21. Award Title If extramural, enter the title of the award, as maintained by the Department/Agency.
If intramural, leave blank.
22. Total Award $ in FY If extramural, enter the amount of award extramural funding in the reported fiscal year.
If intramural, leave blank.
23. Total Extramural 
Study $ in FY from 
Reporting Entity  
[N/A is option]
If extramural, enter the Department/Agency’s extramural funding of the study in the reported 
fiscal year. Do not include funding from other federal or non-federal sources. This may be “0.” 
Enter N/A if the Department/Agency does not maintain this data, or it is not readily available.
If intramural, leave blank.
24. Direct Award $ in FY 
[N/A is option]
If extramural and “Total Study $” is not given, enter the amount of direct award funding in 
the reported fiscal year. Enter N/A if the Department/Agency does not maintain this data, 
or it is not readily available.
If “Total Study $” is given, leave blank. If intramural, leave blank.
25. Indirect Award $ in FY 
[N/A is option]
If extramural and “Total Study $” is not given, enter the amount of indirect award funding 
in the reported fiscal year. Enter N/A if the Department/Agency does not maintain this 
data, or it is not readily available.
If “Total Study $” is given, leave blank. If intramural, leave blank.
26. Other Comments Enter any necessary explanations, as well as any additional information that may be 
helpful to the Commission about the listed study.
If no other comments, leave blank.
Table ii.2 data Fields and instructions
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Table ii.3 SRa methodology
Values as Stored in Database
SPREadSHEET FiEld daTabaSE FiEld ValuE aS SToREd in 
daTabaSE
ValuE FoR analySiS
(inVERSE oF ValuE 
SToREd)
Study ID# StudyID As supplied As supplied
NCT # NCT As supplied As supplied
Title of Study Title As supplied As supplied
Abstract Abstract As supplied As supplied
PI(s) PI As supplied As supplied
Year X Year_X Integer => As Supplied; N/A 
=> NULL
Integer => As Supplied; 
NULL => N/A
Year Y Year_Y Integer => As Supplied; N/A 
=> NULL
Integer => As Supplied; 
NULL => N/A
Exempt or Non-Exempt Exempt Ex => 1; N => 0;  
N/A =>NULL
1 => Ex; 0 => N;  
NULL =>N/A
Total # of Sites Sites Integer => As Supplied; N/A 
=> NULL
Integer => As Supplied; 
NULL => N/A
ARRA Funded by 
Reporting
Arra Y => 1; N => 0 1 => Y; 0 => N
Other Fed Funding Other_Fed_Funding Y => 1; N => 0; N/A => 
NULL
1 => Y; 0 => N; NULL => 
N/A
Other Non-Fed Funding Other_NonFed_Funding Y => 1; N => 0; N/A => NULL 1 => Y; 0 => N; NULL => N/A
Intramural or 
Extramural
Funding_Type As Supplied As Supplied
Total Intramural Study 
$ in FY
Intramural_Funding IF FUNDING TYPE ==  
E => NULL
IF FUNDING TYPE == 
I,B {Money Value => As 
Supplied, without dollar 
formatting; N/A => NULL}
IF FUNDING TYPE ==  
E => NULL
IF FUNDING TYPE == 
I,B {Money Value => As 
Supplied; NULL => N/A}
Award ID# Award_ID IF FUNDING TYPE == I => 
NULL
IF FUNDING TYPE == E,B => 
As Supplied
IF FUNDING TYPE == I => 
NULL
IF FUNDING TYPE == E,B => 
As Supplied
Award Institution Award_Inst IF FUNDING TYPE == I => 
NULL
IF FUNDING TYPE == E,B => 
As Supplied
IF FUNDING TYPE == I => 
NULL
IF FUNDING TYPE == E,B => 
As Supplied
continued
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SPREadSHEET FiEld daTabaSE FiEld ValuE aS SToREd in 
daTabaSE
ValuE FoR analySiS
(inVERSE oF ValuE 
SToREd)
Award Title Award_Title IF FUNDING TYPE == I => 
NULL
IF FUNDING TYPE == E,B => 
As Supplied
IF FUNDING TYPE == I => 
NULL
IF FUNDING TYPE == E,B => 
As Supplied
Total Award $ in FY Total_Funding IF FUNDING TYPE == I  
=> NULL
IF FUNDING TYPE == 
E,B {Money Value => As 
Supplied, without dollar 
formatting; N/A => NULL}
IF FUNDING TYPE == I  
=> NULL
IF FUNDING TYPE == 
E,B {Money Value => As 
Supplied; NULL => N/A}
Total Extramural Study 
$ in FY from Reporting 
Entity
Extramural_Funding IF FUNDING TYPE == I  
=> NULL
IF FUNDING TYPE == 
E,B {Money Value => As 
Supplied, without dollar 
formatting; N/A => NULL}
IF FUNDING TYPE == I  
=> NULL
IF FUNDING TYPE == 
E,B {Money Value => As 
Supplied; NULL => N/A}
Direct Award $ in FY Direct_Funding IF FUNDING TYPE == I  
=> NULL
IF FUNDING TYPE == E,B 
and EXTRAMURAL_FUNDING 
== N/A => { Money Value => 
As Supplied, without dollar 
formatting; N/A => NULL}
IF FUNDING TYPE == I  
=> NULL
IF FUNDING TYPE == E,B and 
EXTRAMURAL_FUNDING == 
N/A => {Money Value => As 
Supplied; NULL => N/A}
Indirect $ in FY Indirect_Funding IF FUNDING TYPE == I  
=> NULL
IF FUNDING TYPE == E,B 
and EXTRAMURAL_FUNDING 
== N/A => {Money Value => 
As Supplied, without dollar 
formatting; N/A => NULL}
IF FUNDING TYPE == I  
=> NULL
IF FUNDING TYPE == E,B and 
EXTRAMURAL_FUNDING == 
N/A => {Money Value => As 
Supplied; N/A => NULL}
Other Comments Comments As Supplied As Supplied
Table ii.3 SRa methodology
Values as Stored in Database
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Table ii.4 Empirical advisory group
Robert M. Califf, MD
Vice Chancellor for Clinical Research
Duke university Medical Center
Director, Duke translational  
Medicine Institute
Ruth Faden, Ph.D., M.P.H.
Philip franklin Wagley Professor  
of Biomedical Ethics 
Director, Johns Hopkins Berman  
Institute of Bioethics
Professor, Department of Health Policy 
and Management
Johns Hopkins Bloomberg  
School of Public Health
Professor, Department of Medicine 
Johns Hopkins School of Medicine
Kenneth A. Getz, M.B.A.
founder and Board Chair
The Center for Information and Study  
on Clinical Research Participation 
Senior Research fellow
tufts Center for The Study of  
Drug Development
tufts university Medical School
Christine Grady, R.N., Ph.D.*
Acting Chief of the Department of Bioethics
National Institutes of Health  
Clinical Center
Philip W. Lavori, Ph.D.
Professor, Health Research and Policy
Stanford School of Medicine
Bernard Lo, M.D.
Professor of Medicine
Director, Program in Medical Ethics
university of California San francisco
National Program Director, Greenwall 
faculty Scholars Program in Bioethics
Kathleen M. MacQueen, Ph.D., M.P.H.
Senior Scientist, Behavioral &  
Social Sciences
Coordinator of Interdisciplinary  
Research Ethics
fHI 360
Daniel P. Sulmasy, M.D., Ph.D.*
Kilbride-Clinton Professor of Medicine 
and Ethics, Department of Medicine and 
Divinity School
Associate Director, The MacLean Center 
for Clinical Medical Ethics
university of Chicago
* Commission member
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Appendix III: U.S. Treatment/Compensation for Treatment Methods
department of defense
Title 32: National Defense, Part 108 
- Health Care Eligibility Under the 
Secretarial Designee Program and 
Related Special Authorities (2010)
DOD Instruction Number 6000.08 
(2007)
“Because subjects may be injured while participating in CI research, for 
research involving more than minimal risk as determined by the IRB having 
jurisdiction over the study, include in every intramural (in-house) CIP 
protocol an arrangement for treatment of any research-related injuries. 
Such arrangement in the protocol may be that all subjects are eligible DoD 
healthcare beneficiaries, that they are granted Secretarial designation as 
DoD healthcare beneficiaries under applicable Service regulations, or that 
specific obligations for such treatment have otherwise been undertaken.” 
Section 6.2.4 (2007).
department of Veterans affairs
38 CFR §17.85 (2002)
“VA medical facilities shall provide necessary medical treatment to a 
research subject injured as a result of participation in a research project 
approved by a VA Research and Development Committee and conducted 
under the supervision of one or more VA employees.” Part 17 Sec. 17.85(a).
medicare
Program Memorandum 
Intermediaries/Carriers: Claims 
Processing Instructions for Carriers, 
DMERCS, Intermediaries and Regional 
Home Health Intermediaries (RHHIs) 
for Claims Submitted for Medicare 
Beneficiaries Participating in Medicare 
Qualifying Trials (2000)
“This NCD states that Medicare covers: … 2) reasonable and necessary 
items and services used to diagnose and treat complications arising from 
participation in all clinical trials.” Background.
“Routine costs DO include (and are therefore covered): … Items and 
services that are medically necessary for the diagnosis or treatment of 
complications arising from the provision of an investigational item or 
service.” Clinical Trial Services that Qualify for Coverage Section 2.
national aeronautics and Space 
administration
NASA Procedural Requirements 
7100.1 Protection of Human Research 
Subjects (Revalidated 7/7/08)
“The PI may ensure that the subject or the subject’s beneficiaries receive 
compensation by means of insurance, worker’s compensation, or the like in 
the event that the subject suffers illness, disease, injury, loss, or death as a 
direct result of the research. The lack of this provision may serve as a basis 
for disapproval of the research. Such provisions for compensation shall be 
required for all studies performed at a NASA Center, uses NASA equipment 
or facilities, or for which a NASA employee or on-site contractor is the 
principal investigator.” Section 9.1.4.
national institutes of Health
Sheet 6 - Guidelines for Writing 
Informed Consent Documents (2006)
The Clinical Center of the NIH will provide short-term medical care for any 
injury resulting from your participation in research here. … In general, 
no long-term medical care or financial compensation for research-related 
injuries will be provided by the National Institutes of Health, the Clinical 
Center, or the Federal Government. Section 4(s).
university of california los angeles
Guidance and Procedure: Treatment 
and Compensation for Research 
Related Injury (last updated July 26, 
2011)
“The University of California will provide to any injured subject any and all 
medical treatment reasonably necessary for any injury or illness which a 
human subject suffers as a direct result of participation in an authorized 
University activity covered by University policy on the protection of 
human subjects in research or reimburse the subject for the costs of such 
treatment, except when the injury or illness is a consequence of a medical 
research procedure which is designed to benefit the subject directly. 
University of California Policy on Treatment and Compensation for Injury in 
Research 1.
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university of Washington
Human Subjects Manual, Section VII
“The University’s policy on compensation for adverse events to human 
subjects is intended primarily to provide necessary medical care to subjects 
who sustain bodily injury as a direct result of participation in a research 
project.” Section VII(G).
Wake Forest university
Research Related Injury  
Operational Policy and Procedure  
(last revised 2007)
“It is the position of the Wake Forest University School of Medicine 
(WFUSM) Institutional Review Board (IRB) that for any research study it 
approves and determines to be of greater than minimal risk, provisions 
must be made for the coverage of reasonable costs for the necessary 
treatment for illnesses, adverse events or injuries that results from 
medications, devices, interventions, procedures, or tests that the 
research study subject would not have been exposed to had he or she not 
volunteered to participate in the research study.” Research Related Injury.
“For research studies of greater than minimal risk that are industry 
sponsored, provisions must be made for the coverage of reasonable costs 
for the necessary treatment for illness, adverse events or injuries that 
results from medications, devices, interventions, procedures, or tests that 
the research study subject would not have been exposed to had he or she 
not volunteered to participate in the research study protocol.” Research 
Related Injury 2. [Bold added]
“The Wake Forest University School of Medicine maintains limited liability 
insurance coverage to provide for the treatment of research related injuries 
that occur as a result of participation in non-sponsored research (e.g. NIH 
or Departmental).” Research Related Injury 3. [Bold added]
Appendix III: u.S. treatment/Compensation for treatment Methods
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Appendix IV:  International and Transnational Requirements for 
Treatment and Compensation for Research Injuries
australia    
Note for Guidance on Good Clinical Practice 
CPMP/ICH/135/95 (2000)     
National Statement on Ethical Conduct in Human 
Research (2007)
Institutions must be satisfied that sponsors of trials have made 
the indemnity or insurance and compensation arrangements 
required by CPMP/ICH Note for Guidance on Good Clinical Practice 
[recommending that care be provided, and that compensation be 
provided in accordance with local requirements], ISO 14155 Clinical 
Investigation of Medical Devices [requiring disclosure of provisions 
made for compensation] and the TGA. Art. 3.3.24 (2007).
austria    
Austrian Drug Law (2009)    
Federal Act on Medical Devices (as amended 2011)
The sponsor must have personal injury insurance to cover any 
injuries that may be caused to life or health of the subject by the 
tests carried out in the clinical trial and for which the clinical 
investigator too would be liable if at fault. Art. 47(1) (2011). 
belgium    
Law Relating to Experimentation on Humans, 
Chapter XVII (Responsibility and Insurance) 
(2004)
Before commencing the experiment, the sponsor shall enter into 
an insurance contract which covers this liability, and the liability 
of every person intervening in the trial, irrespective of the nature 
of the affiliation between the intervening person, the sponsor and 
the subject. Art. 29.2.
bosnia/Herzegovina    
Medicinal Products and Medical Devices Act 
(2008)
Prior to commencement of the testing, the legal entity performing 
the clinical testing of the medical device and the sponsor of the 
clinical testing shall insure their liability against any possible 
damages which might be caused to the participant or participants 
in the clinical trial. Art. 116.
brazil    
Rules on Research Involving Human Subjects 
(Res. CNS 196/96 and others) (2003)
The researcher, the sponsor and the institution must assume full 
responsibility for providing comprehensive care to the research 
subjects, as regards complications and injury resulting from 
foreseen risks. Art. V.5.
bulgaria    
Law on the Medicinal Products in Human 
Medicine (2007, amended through 2011) 
The contracting authority and the principal researcher shall have 
insurance covering their liability for property or non-property 
damages to the study subjects caused in or on the occasion of 
the conduct of the clinical test. Art. 91.  
canada    
Tri-Council Policy Statement: Ethical Conduct for 
Research Involving Humans (2010)
The information generally required for informed consent includes: 
… (j) information about any payments, including incentives for 
participants, reimbursement for participation-related expenses 
and compensation for injury. Art. 3.2.
china    
Good Clinical Practice (Board Order No. 3) (2003)
The sponsor should provide insurance for the subjects 
participating in clinical trials so that injured subjects do not bear 
the cost of treatment and so they may receive corresponding 
economic compensation. Art. 43.
ciomS*     
Council for International Organizations of 
Medical Sciences (CIOMS),   International Ethical  
Guidelines for Biomedical  Research Involving  
Human Subjects (2002)
Investigators should ensure that research subjects who suffer 
injury as a result of their participation are entitled to free 
medical treatment for such injury and to such financial or other 
assistance as would compensate them equitably for any resultant 
impairment, disability or handicap. Guideline 19.
council of Europe+    
Convention for the Protection of Human Rights 
and Dignity of the Human Being with regard to the 
Application of Biology and Medicine: Convention 
on Human Rights and Biomedicine (1997)    
Additional Protocol to the Convention on Human 
Rights and Biomedicine concerning Biomedical 
Research, Article 13, CETS No. 195 (2005)
The person who has suffered damage as a result of participation 
in research shall be entitled to fair compensation according to the 
conditions and procedures prescribed by law. Art. 31 (2005).  
* International standard setting body
+ Supranational European body
V187
continued
croatia    
Clinical Trials and Good Clinical Practice (2003)
The Central Ethics Committee, in the approval process of clinical 
testing, will determine: the existence of insurance compensation 
in case of injury, death or treatment of subjects that is related to 
clinical trials. Art. 12.
declaration of Helsinki - World medical 
association*    
59th WMA General Assembly Seoul, Korea (2008)
The protocol should include information regarding … provisions 
for treating and/or compensating subjects who are harmed as a 
consequence of participation in the research study. Section B.14.
denmark    
The Danish Liability for Damages Act (2005, 
amended 2006 and 2007)    
Danish Act on the Right to Complain and Receive 
Compensation within the Health Service (2009)
Compensation shall be paid pursuant to the provisions of this Part 
to patients or the bereaved families of patients who suffer injury 
in Denmark in connection with examination, treatment or the like 
carried out... Individuals taking part in biomedical trials that do 
not form part of the diagnosis or treatment of their illness shall 
have the same status as patients. Part 3 §§19(1), (2) (2009).
Estonia    
Medicinal Products Act (2004; amended most 
recently in 2010)    
Conditions and Procedure for Conducting Clinical 
Trials of Medicinal Products, Regulation No. 23 
of the Minister of Social Affairs (2005)
The sponsor of a clinical trial of a medicinal product shall 
guarantee the trial subjects health insurance protection in the 
event of damage to health related to the trial. §90(9) (2004).   
European union+      
Directive 2001/20/EC of the European 
Parliament and of the Council (2001)
A clinical trial may be undertaken only if, in particular: …  (f) 
provision has been made for insurance or indemnity to  cover the 
liability of the investigator and sponsor. Art. 3.2(f).
Finland    
Patient Injuries Act (586/1986; amendments up 
to 1100/2005 included) (amendments through 
2005)
The Patient Injuries Board is responsible for issuing 
recommendations for decisions on individual claims at the 
request of a claimant… and for issuing, when requested by a 
court or one of the parties involved, statements on compensation 
claims which are being processed in court. Section 11a(1).
France    
Biomedical Research (Loi Huriet-Sérusclat), 
Articles L1121-1 to L1126-7 (2004)
Requires that entities both private (e.g. industry, individuals, or 
private institutions) and public (government or nongovernmental 
institutions) serving as sponsors must obtain insurance to cover 
the costs for all damages or injuries arising from the performance 
of the trial. 
germany    
Medicinal Products Act (The Drug Law) (2009) 
The clinical trial of a medicinal product may only be conducted on 
human beings if and as long as: ... 8. in the event that a person 
is killed or a person’s body or health is injured during the course 
of the clinical trial, an insurance policy which provides benefits, 
even when no one else is liable for the damage, exists .... Section 
40(1).
Hungary    
Act XCV of 2005 on Medicinal Products for 
Human Use and on the Amendment of Other 
Regulations Related to Medicinal Products 
(2005)
The sponsor of a clinical trial shall obtain sufficient liability 
insurance coverage for any damages that may occur in 
connection with the clinical trial from an insurance company 
that is established or has a branch in any Member State of the 
European Economic Area ... . The liability insurance policy shall 
afford sufficient cover for any and all potential claims for damage 
in connection with the clinical trial. Section 3(5).
* International standard setting body
+ Supranational European body
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iceland    
Regulation on Clinical Trials of Medicinal 
Products in Humans No. 443 (2004)
Subjects participating in a clinical trial of a medicinal product 
must be sufficiently insured against conceivable damage to their 
health resulting from the trial. The principal investigator or, as the 
case may be, the investigator shall be responsible for ensuring 
satisfactory insurance coverage. Art. 5.
icH Harmonised Tripartite guideline: 
guideline For good clinical Practice E6(R1)*    
International Conference on Harmonisation 
of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (1996)
During and following a subject’s participation in a trial, the 
investigator/institution should ensure that adequate medical care 
is provided to a subject for any adverse events … related to the 
trial. Art. 4.3.2.    
The sponsor’s policies and procedures should address the costs 
of treatment of trial subjects in the event of trial-related injuries 
in accordance with the applicable regulatory requirement(s).  
Art. 5.8.2.
india    
Ethical Guidelines for Biomedical Research on 
Human Participants (2006)
The sponsor whether a pharmaceutical company, a government, 
or an institution, should agree, before the research begins, in the 
a priori agreement to provide compensation for any physical or 
psychological injury   for which participants are entitled or agree 
to provide insurance coverage for an unforeseen injury whenever 
possible. Chapter III, Section VI.
institute of medicine*    
Responsible Research: A Systems Approach to 
Protecting Research Participants (2002)
Organizations conducting research should compensate 
any research participant who is injured as a direct result 
of participating in research, without regard to fault. 
Compensation should include at least the costs of medical 
care and rehabilitation, and accrediting bodies should include 
such compensation as a requirement of accreditation. 
Recommendation 6.8.
ireland    
Statutory Instruments, S.I. No. 190 of 2004, 
European Communities (Clinical Trials on 
Medicinal Products for Human Use) (2004)
In preparing its opinion, the ethics committee shall consider, 
in particular, the following matters: … (k) the provision made 
for indemnity or compensation in the event of injury or death 
attributable to the clinical trial; (l) any insurance or indemnity 
to cover the liability of the investigator and sponsor.... Part 3, 
Section 13(6).
israel    
Guidelines for Clinical Trials in Human  
Subjects (2006)
A commercial company entering into an agreement with a 
medical institution and/or Investigator to conduct a clinical trial 
shall insure its legal liability pursuant to the laws of Israel against 
claims filed by clinical trial participants and/or third-party claims 
in connection with the clinical trial, whether during the course of 
the trial or thereafter. Appendix 2.
italy    
Minimum Requirements for Insurance Policies 
to Protect the Subjects Participating in Clinical 
Trials of Medicines (2009)
The clinical trial sponsor must submit to the ethics committee a 
certificate of insurance. … The insurance policy must provide 
coverage to specific compensation for injuries. Arts. 1.1, 1.2.
Japan    
Pharmaceutical Administration and Regulations 
in Japan (2011)
Insurance coverage and other measures required for 
compensation in cases of trial-related injury must be undertaken 
beforehand. Chapter 3, page 101.
* International standard setting body
+ Supranational European body
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latvia    
Cabinet Regulation No. 289: Regulations on 
Conducting Clinical Trials and Non-Interventional 
Studies and Labeling of Investigational 
Medicinal Products, and Procedure for 
Conducting Inspections on Compliance with the 
Requirements of Good Clinical Practice (2010)
The sponsor shall ensure that provisions have been made for 
insurance and indemnity to cover the liability of the investigator 
and sponsor. The sponsor is not responsible for a deliberate or 
accidental injury to a subject caused by the investigator or other 
individuals involved in the clinical trial. Art. 22.
lithuania    
Principal Investigators and Biomedical  
Research Customers in Civil Liability Insurance 
Rules (2000)
Liability Compulsory Insurance Regulations govern the principal 
investigators and biomedical research customers’ compulsory 
insurance contract, the conditions of the contract, the parties - 
the insurer and the insured, the pre-contractual and contractual 
rights and obligations, and the insured person’s rights and 
obligations. Art. I.1.
macedonia (Republic of)    
On the Manner and the Procedure for 
Clinical Trials on Medicinal Products and the 
Documentation (2009)
The application for granting approval for the clinical trial of 
the medicinal product referred to in Paragraph 1 of this Article 
shall contain:  ...  14. evidence that the trial subjects had been 
insured by the applicant in case of occurrence of damage to 
the investigator’s health (damage or death of the trial subject). 
Section II(7), Art. 24.
netherlands    
Rules for Compulsory Insurance in Medical 
Research Involving Human Subjects (2003)
Medical Research Involving Human Subjects  
Act (WMO) (2006)
The trial shall not be conducted unless at the time of its 
commencement a contract of insurance has been entered into 
covering losses due to death or injury resulting from the trial. 
Such insurance need not cover injury which is inevitable or 
almost inevitable, given the nature of the trial. Section 7.1.
new Zealand    
Health Research Council: Guidelines on Ethics  
in Health Research (2002, revised 2005)    
Injury Prevention, Rehabilitation,  and 
Compensation Act (2001, amended 2007)
The Injury Prevention, Rehabilitation, and Compensation Act 
2001 (IPRC Act), provides cover for treatment injuries caused 
as part of a clinical trial where an accredited ethics committee 
has approved the trial and is satisfied that the trial was not to 
be conducted principally for the benefit of the manufacturer or 
distributor of the medicine or item being trialed. Art. 5.6 (2005).
Philippines
Philippine Council for Health Research 
and Development, National Guidelines for 
Biomedical/Behavioral Research (2000)     
National Ethical Guidelines for Health  
Research (2006)
The investigator shall provide the following information to the 
potential subject, using language that can be understood: ... w. 
That treatment will be provided free of charge for specified types 
of research-related injury or for complications associated with 
the research, the nature and duration of such care, the name 
of the organization or individual that will provide the treatment, 
and whether there is any uncertainty regarding funding of such 
treatment; x. In what way, and by what organization the subject 
or the subject’s family or dependents will be compensated for 
disability or death resulting from such injury (or, when indicated, 
that there are no plans to provide such compensation). Art. I.2 
(2006).
Poland
Pharmaceutical Law of 6 September 2001 
(amended through 2008)
The Bioethics Committee shall consider, in particular: … (9) the 
level of the indemnity or compensation in the event of injury or 
death attributable to participation in the clinical trial. Art. 37r(2).
Russia
On Medicinal Products, Federal Law No. 86-FZ 
(2006) 
The legal basis for conducting clinical trials of medicinal products 
consists of the following documents: 5) civil liability insurance of 
persons carrying out clinical trials of the drug. Article 38.1 
* International standard setting body
+ Supranational European body
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Singapore
Medicines (Clinical Trials) Regulations (2000)
The subject is entitled to a full and reasonable explanation of the 
following: … (j) any compensation and treatment available to 
the subject in the event of injury arising from participation in the 
clinical trial. Art. 14(1).
Slovakia
On Healthcare, Healthcare-Related Services 
and on the of Certain Laws, Act No. 576/2004 
Coll. (2004)
The instructions prior to informed approval must contain 
information on … (h) measures intended for ensuring adequate 
compensation in the case of damage of the health of the research 
participant in connection with his/her participation in this 
research. Art. 27(2).
South africa
Guidelines on Ethics for Medical Research: 
General Principles (2002)
In the event of significant injury, the participant should be entitled 
to receive compensation regardless of whether or not there was 
negligence or legal liability on any other basis. Art. 10.6.2.2.
South Korea
Guideline for Korean Good Clinical Practice 
(2000)
If required by the applicable regulatory requirement(s), the 
sponsor shall provide insurance or shall indemnify (legal and 
financial coverage) the investigator/the institution against 
claims arising from the trial, except for claims that arise from 
malpractice and/or negligence. Art. 32.
Spain
Royal Decree 223/2004 of 6 February Regulating 
Clinical Trials with Medicinal Products (2004)
Law 14/2007, of 3 July, on Biomedical Research 
(2007)
A clinical trial with investigational medicinal products may only 
be undertaken if insurance or other financial cover has previously 
been taken out to include any trial-related injury or loss occurring 
to the person in whom it is to be conducted... . Art. 8(1) (2004).
Switzerland
SR 812.214.2 Ordinance on Clinical Trials of 
Therapeutic Products (2010)
The developer is liable for injuries to a research subject in the 
context of a clinical trial through insurance to cover liability. Arts. 
7(1), 7(2).
Taiwan
Human Research Ethics Policy Guidelines (2007) 
Medical Care Act (2009)
In the case that violation by juridical persons in medical care 
results in damage or injury, the offender shall be responsible for 
compensation. Art. 112 (2009).
uganda
National Guidelines for Research Involving 
Humans as Research Participants - Uganda 
National Council for Science and Technology 
(2007)
Research participants shall be entitled to compensation when 
the injury is classified as ‘Probably’ or ‘Definitely’ related 
to their participation in the research project. Sponsors shall 
ensure that research participants who suffer injury as a result 
of their participation in the research project are entitled to free 
medical treatment for such injury and to such financial or other 
assistance as would compensate them equitably for any resultant 
impairment, disability or handicap. Art. 7.5.
ukraine
On Medicines, No. 3323-VI (2011)
The sponsor of the clinical trial shall, prior to its performance, 
make an Agreement on Insurance of Health and Life of the 
Patient (the Volunteer), according to the procedure envisaged by 
the legislation. Art. 8.
united Kingdom
The Medicines for Human Use (Clinical Trials) 
Regulations, 2004 No. 1031 (2004)
In preparing its opinion, the committee shall consider, in 
particular, the following matters… (i) provision for indemnity or 
compensation in the event of injury or death attributable to the 
clinical trial. Art. 15(5)(i).
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